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Non-viral gene therapy formulation development often relies on a rational design approach, where 
vector components are selected based on individual characteristics known to favour transfection 
efficiency. However, these mixtures do not necessarily result in additive or even synergistic effects on 
efficiency, leaving the vast majority of non-viral formulations limited by poor transfection. The 
development of successful non-viral gene therapy carriers is stunted by unpredictable results, even in 
vitro, and often poor correlations to external physical characterizations such as particle size, shape, and 
zeta potential to aid in effective screening of potential formulations.1 This creates reliance on trial and 
error experiments that are not feasible long-term.2 Current gene therapy studies fail to consider the 
internal mixing interactions involved in self-assembled systems and the effect of the presence of the 
intended active pharmaceutical ingredient (API), nucleic acids in this case. These factors have an 
irrefutable impact on transfection; hence, this work aimed to address this knowledge gap by exploring 
the interactions between the components of a self-assembled Pluronic/gemini surfactant-based 
nanocarrier for plasmid DNA delivery, and presents a link to transfection efficiency that may inform 
more effective vector design and screening for future formulation development. 
In an effort to improve the transfection efficiency of gemini surfactant-based vectors for non-viral 
gene therapy, the addition of neutral block copolymers known as poloxamers (or commonly by their 
former commercial name, Pluronics, BASF Corp.) to the N,N’-bis(dimethylhexadecyl)-1,3-
propanediammonium dibromide (16-3-16) gemini surfactant have recently been under investigation. 
Although preliminary studies of such formulations have shown limited transfection in vitro, the 
transfection efficiencies appear related to the nature and strength of mixed micelle formation in these 
systems, which may aid the optimization of these Pluronic/16-3-16, and related, systems in the future. 
To study the plasmid DNA-loaded Pluronic and 16-3-16 gemini surfactant mixed micellization, the 
full formulations were treated as binary mixtures in water where the 16-3-16/pDNA condensate or 
complex (prepared at charge ratio N+/P− 10:1) was treated as a single component. A critical aggregate 
concentration (CAC) of the 16-3-16/pDNA complex in water was determined by surface tension, 
conductivity, and dynamic light scattering measurements over a range of 16-3-16/pDNA 
concentrations. Based on these studies, it was also proposed that the gemini surfactant molecules only 




electrostatically-bound 16-3-16/pDNA complex. At concentrations beyond the 16-3-16/pDNA CAC, 
the complex returns to a more condensed form. 
A series of Pluronic block copolymers (F87, P84, L121, F127, P103, and L44) was used to study the 
effects of the Pluronic composition on its mixing behaviour with the 16-3-16/pDNA condensates. CAC 
values determined by tensiometry and application of Rubingh’s mixed micelle theory indicated that 
Pluronic and 16-3-16/pDNA mixed micellization is generally synergistic in nature but the strength of 
this synergism decreases with increasing PPO block length. The non-ideal mixing behaviours were 
attributed to a greater presence of the 16-3-16/pDNA component in the mixed aggregates involving the 
larger PPO blocks (60 PO units and above), as opposed to Pluronic-rich aggregates for polymers with 
lower PO content.  Presumably, micellization is hindered by the bulkiness of larger PPO blocks.  
Transfection efficiency was evaluated by expression of enhanced green fluorescence protein (eGFP) 
as a reporter gene for plasmid expression in COS-7 cells in vitro, and cytotoxicity was determined by 
propidium iodide staining. Transfection varied with the Pluronic composition and Pluronic mole 
fraction in the formulation, but there was no significant decrease in the cell viability compared to non-
treated cells. The Pluronic/16-3-16/pDNA formulations produced self-assembled nanoparticles with 
sizes generally below 250 nm and positive zeta potentials that appeared to decrease linearly with 
increasing Pluronic PEO chain lengths. Although there was no clear relationship between the 
transfection efficiency and the particle size and zeta potentials, higher transfection was associated with 
stronger synergism and aggregates enriched with the Pluronic-component. These findings could be used 
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This chapter provides a detailed review of the background literature relevant to the work presented in 
this thesis. While each body chapter also includes a short introduction to provide some context to the 
results and a relationship to current knowledge in a particular field, this chapter provides a more 
comprehensive summary of the topics. 
1.1 Surface Active Agents Form Micelles 
Surface active agents, also known as surfactants, are materials that preferentially adsorb at the boundary 
(interface) between two immiscible phases, which alters the surface or interfacial properties of the 
system.3 Surfactants are amphiphilic, possessing both hydrophilic and hydrophobic regions within their 
molecular structure, which allows for this surface/interfacial activity. (Note the term “surface” is used 
in reference to systems where one phase is a gas. In this work, “surface” and “surface tension” 
refer to that between air and water.)  
Due to their “split nature”, surfactants must reorganize themselves in solution in order to reduce the 
occurrence of energetically unfavourable hydrocarbon-water interactions. For example, when a 
surfactant is dissolved in water, there is a distortion of the solvent structure, which increases the overall 
free energy of the system.3 Since the hydrophobic chains of the surfactant molecules are unable to 
hydrogen bond with water, water molecules of the bulk phase form a cage structure around the 
hydrophobic groups.4 These cavities in the bulk water structure result in more order and in a significant 
entropy decrease.4 Therefore, the surfactant molecules concentrate at the surface where they orient in 
such a way that the lyophobic groups are directed away from the bulk solvent, thus minimizing the free 
energy of the system.3  
Once a sufficient amount of surfactant is added to the system and the surface is saturated, the free 
energy of the system must be minimized in other ways. Phase separation from solution could also 
eliminate the unfavourable hydrocarbon-water interactions, but this would also involve removal of the 
hydrophilic portions of the surfactant structures, which would not be energetically favourable. 
Aggregation of the surfactant molecules into clusters known as micelles offers a feasible means of 
minimizing the free energy of the systems.5 Micellization allows the hydrophobic groups to be removed 
from the water and combine into a hydrophobic core, while the surfactants’ hydrophilic groups face 




making up the highly ordered cavities to the normal hydrogen-bonding environment of the bulk water 
results in an entropy increase which drives the micellization process.4 Therefore, the driving force for 
micellization comes from a gain in entropy; however, when all factors are considered, the occurrence 
of micelle formation and the concentration at which micellization takes place is governed by a balance 
of forces that either favour or oppose this aggregation process.4. For example, a loss of freedom 
experienced by the surfactant molecule in being transferred from solution to confined to a micelle, and 
electrostatic repulsion between ionic surfactant head groups result in increased free energy.3,5 
Additional considerations in the head group region include the tendency for head groups to crowd 
together to minimize water contact with the micelle core, but also electrostatic, steric, and hydration 
considerations that create a tendency for head groups to spread apart.6 Nonetheless, micellization still 
occurs when the gain in entropy for the bulk solvent is greater and leads to an overall minimization of 
free energy for the system as a whole.  
Although micelles are typically depicted as spherical, the micellar structure depends on the relative 
shape and space occupied by the headgroup and hydrophobic groups (Figure 1.1-1). An approximation 
of the micelle structure in aqueous solution is given by the critical packing parameter, calculated 
according to the equation 𝑃 =
𝑣
𝑎0𝑙𝑐
, where v is the volume of the hydrophobic portion, 𝑎0 is the area 
occupied by the headgroup, and 𝑙𝑐 is the maximum length the hydrocarbon tail can stretch according to 
factors such as the molecular structure and environment.3 The critical packing parameter for some 









General Surfactant Structure Aggregate Structure 
< 0.33 Single chain and relatively large 
headgroup 
Spherical micelles 
0.33 – 0.5 Relatively small headgroup, or ionic 
surfactant in presence of excess 
electrolyte 
Cylindrical micelles 
0.5 – 1.0 Double chains (flexible)  with large 
headgroup 
Vesicles and flexible bilayer  
1.0 Double chain with small headgroup or 
immobile chains 
Planar bilayer structure 
>1.0 Double chain with small headgroup, bulky 
hydrophobic groups 
Inverted micelles 
Figure 1.1-1  Idealized sequence of surfactant aggregate structures as a function of surfactant 
concentration, critical packing parameter (Ps) and preferred surfactant membrane curvature (c0).  





These micellar structures may be considered the simplest forms of surfactant aggregates, which 
generally consist of 30-100 surfactant monomers (depending on their molecular structure), and occur 
at low concentrations.7 As the surfactant concentration is increased, the micelles grow in size, adopt 
other shapes, and eventually form higher order liquid crystalline phases. While the micellar solutions 
show little structure beyond the micellar aggregate, these lyotropic mesophases are referred to as liquid 
crystal since they are highly ordered, at least in one dimension, but are not truly crystalline.3 As 
surfactant concentration increases, and the amount of solvent available between micelles in solution 
decreases, there is an increase in the interactions between adjacent micellar structures until coalescence 
occurs.3 Typically, spherical or ellipsoidal micelles become rod-shaped, and as the concentration 
increases, a hexagonal array of close-packed cylindrical aggregates appears, referred to as the “normal 
hexagonal” or hexagonal phase (Figure 1.1-1)3 With further increase in concentration, it may become 
energetically favourable to form a bilayer structure known as the lamellar phase through coalescence 
of parallel cylinders with solvent separating the bilayers.3 Eventually, a reversed or inverted hexagonal 
phase may occur, which consists of a hexagonal array of cylindrical aggregates of surfactant molecules 
in an inverse orientation (with the aqueous phase and surfactant head groups making up the aggregate 
interior).3 Another type of liquid crystalline structure known as the cubic phase has also been reported, 
typically in the transition regions.3,7 This cubic phases consists of either a cubic arrangement of globular 
micelles or a cubic bicontinuous phase.3,7 The formation of these phases is dependent on the solvent 
properties as well as the surfactant structure; for example, greater charge repulsion between adjacent 
surfactant molecules tends to result in a delay in the formation of the liquid crystalline phases.3 
The concentration at which micelle formation begins is called the critical micelle concentration 
(CMC), which is characteristic of a given surfactant and is accompanied by dramatic changes in the 
physical properties of the solution3,5. The micellization process and estimation of the CMC can be 
experimentally detected by a number of methods – surface tensiometry, conductivity, light scattering, 
rheology, and isothermal titration calorimetry to name a few.  
Since the majority of the work presented here relies on CMC measurements obtained through surface 
tension studies conducted in water, a brief description of this phenomenon is described here. The 
interfacial tension occurring at the interface between two immiscible phases reflects the net 




difference in forces of attraction acting on the molecules at the interface/surface.3 Molecules in the 
bulk water phase experience attractive forces of equal strength to neighbouring molecules in all 
three dimensions, resulting in a net force of zero.3 On the other hand, surface molecules typically 
have a stronger attraction to identical units in their respective bulk phase rather than the “foreign” 
units in the adjacent phase; this imbalance of forces creates the apparent force of tension (a net 
downward pull) and higher potential energy of these molecules at the surface.3,8 Since surface 
tension is determined by the energy of the surface molecules, displacement of these molecules by 
adsorption of solute molecules at the surface affects the measured surface tension. As surfactant is 
progressively added to a volume of water, the surface tension will gradually decrease until the 
surface is saturated with surfactant and the surface has effectively changed from a water surface to 
a hydrocarbon surface.8 Surfactant adsorption to the air-water interface introduces more favourable 
air-surfactant tail and water-surfactant headgroup interactions. At this point, the surface tension 
reaches a minimum, which signifies the CMC (as depicted in Figure 1.1-2), and remains relatively 
constant even with added surfactant.  





In the du Nouy ring method, the force required to remove a wire ring/loop from the interface is 
measured.9 To a first approximation, the detachment force is equal to the surface tension multiplied by 
the perimeter of the ring (the perimeter of the detached surface), represented by F = W + 4πrγ, where 
W is the weight of the ring, r is ring’s radius, and γ is the surface tension.9 
In order to describe the energetic basis of the micellization process, there are two generally accepted 
models that can be used. The phase separation model (also called the pseudo-phase separation model) 
treats micelles as a separate phase, where the CMC is the saturation concentration of surfactant 
monomers in solution and the micelles form a separate but soluble phase (a pseudo-phase).3,9 Above 
the CMC, the monomer surfactant activity is assumed to remain constant (as might be observed by the 
near-constant surface tension value in surface tension measurements for some but not for all systems).6,9 
Another criticism of this model is that a sharp break point or discontinuity should be observed in the 
physical properties (e.g. surface tension, turbidity) of a surfactant solution at the CMC, however this is 
not always observed experimentally.9 Mixed micellization theories based on the pseudo-phase 
separation model will be discussed later on. On the other hand, the mass action model provides a more 
appropriate description of micellization as it assumes the surfactant monomers and the micelles are in 
a dissociation-association equilibrium.3 Therefore, an equilibrium constant can be used to calculate the 
free energy of micellization per monomer.9 
In general, either approach produces similar results in describing the energy change associated with 
micelle formation. For nonionic surfactants, or an ionic surfactant with counterion-bound micelles, the 
standard free energy of micellization is given by Equation 1.1-1, where R is the gas constant, T is the 
solution temperature.  
∆Gm
° =RTln(CMC)   Equation 1.1-1 
For ionic surfactants, the degree of counterion association with the micelles also needs to be 
considered since a portion of the counterions will transfer into the micellar phase.3 For a typical 1:1 
ionic surfactant micelle with the degree of micelle ionization represented by α, the Gibbs energy 
change of micellization is given by Equation 1.1-2.3  
∆Gm




Also note, for a surfactant with two charged head groups and monovalent counterions, such as the 
gemini surfactants discussed later, which dissociate into 3 ionic species, the (2-α) becomes (3-2α).6 
1.1.1 Surfactant Structure and Solution Conditions Influence Surfactant Self-assembly 
Ultimately, a surfactant’s chemical composition controls the micellization process because the 
magnitudes of the forces favouring or retarding micellization are determined by the chemical structure 
(with all other factors such as temperature, pressure, solvent kept constant).3 The major determining 
factor of a surfactant’s CMC is the hydrophobicity of the surfactant molecule. The CMC decreases 
logarithmically as the number of carbons in the alkyl chain of a hydrocarbon surfactant increases.3 
Changes to the hydrophilic group (for a series of surfactants having the same hydrophobic chain) can 
also impact the CMC, although this effect is much smaller than that achieved by changes to the 
hydrophobic component.3 For ionic surfactants, the free energy of micellization is also influenced by 
the interaction between the head groups and solvent, which will depend on the degree of counterion 
binding.3 Since counterions reduce the electrostatic repulsion between charged head groups, the CMC 
decreases with an increasing degree of counterion binding, which depends on the ion’s radius of 
hydration and valency.3 The larger the radius of hydration of the ion, the greater the decrease in the 
CMC.3 Accordingly, the addition of salt reduces the CMC of an ionic surfactant also due to a reduction 
in electrostatic repulsion between head groups.3 For nonionic surfactants, increasing the hydrophilicity 
of the head group, for example an increase in ethylene oxide content, tends to increase the CMC.3  
Solution properties such as ionic strength (i.e. added salt), pH, and temperature can also affect 
micellization in water. Salt effects are much smaller for nonionic surfactant systems, and can produce 
either an increase or decrease in the CMC depending on the electrolyte’s effect on the water structure.3 
Ions that strongly interact with water will induce greater hydrogen bonding and increase the 
organization of water, which would require more work to accommodate the surfactant monomer, 
leading to a “salting out” effect that lowers the CMC of the surfactant. For structure-breakers, which 
disrupt the water organization, less work is required so the surfactant is “salted in” and the CMC will 
increase. 
Surfactants containing ionizable groups will demonstrate significant changes in the CMC as a result 
of changes in the electrostatic interactions between head groups.3 Temperature can also have a complex 
effect on micellization, which differs between ionic and non-ionic surfactants.3 In general, higher 




of the surfactant molecule.3 Conversely, increased temperatures disrupt the water structure surrounding 
the hydrophobic group, essentially increasing its solubility in water and making micellization less 
favourable due to decreases in the magnitude of the free energy attributed to the hydrophobic effect.3 
Therefore, the overall temperature effect will depend on the relative magnitudes of these two effects.3 
For non-ionic surfactants, which generally rely on hydrogen bonding between water and ethylene oxide 
groups in the surfactant head group region, there is an inverse temperature-solubility relationship.3 In 
this case, the CMC decreases with increasing temperature, and increasing the temperature beyond the 
surfactant’s cloud point leads to phase separation.3 At this point, there is no longer sufficient solubility 
for effective surfactant action and a second phase dominated by surfactant is formed and its domains 
are significantly larger than typical micelles.3 
1.1.2 Surfactant Aggregates Solubilize Additives  
Most applications of surfactants involve their combination with additives such as salts, organic 
materials, polymers, drugs, and even additional surfactants (to improve the properties of a surfactant 
product). Therefore, it is also important to consider the effect of additives (other than electrolytes, which 
was already briefly discussed) on the micellization process, and the location of the solubilized 
molecules within the surfactant micelle/aggregate structure, which is determined by the molecular 
structures of the additive and the surfactant. 
The spontaneous process of solubilization produces thermodynamically stable, isotropic solutions of 
a substance/additive that is typically insoluble or has limited solubility in a particular solvent through 
the addition of amphiphilic compounds at or above the CMC.3 For example, as seen in Figure 1.1-3, in 
an aqueous solution the hydrophobic region of a surfactant micelle provides a compatible 
microenvironment for nonpolar additives (e.g. hydrocarbons, or aromatics) which would therefore 
associate with the hydrophobic core of the micelle (and result in a decreased CMC).3 The extent of 
solubilization will depend on the size of the hydrophobic chain lengths, with solubilization increasing 
with increasing alkyl tail lengths and in the following order: anionic < cationic < non-ionic headgroups 
for the same tail length.9 Further, solubilization power (molar ratio of solubilizate to surfactant) 
generally increases with increasing polyoxyethylene (PEO) groups, due to decreasing aggregation 
number which results in a greater number of micelles per mole of surfactant.9 Reverse micelle formation 
in non-polar solvent systems provide an opportunity to solubilize polar additives within the core, made 




In addition, additives may locate in the palisade region of non-ionic surfactant micelles or on the 
surface of ionic micelles (at the micelle-solvent interface).3,10 The palisade layer is the transition zone 
between the hydrophobic and hydrophilic regions of the micelle, and accounts for a large portion of the 
micellar volume for non-ionic surfactants, especially those with PEO headgroups.3 Due to the bulky 
nature of the PEO chains, steric crowding leaves little room for hydration water near the core. This 
creates a polyether chemical environment in the deeper regions of the palisade layer of these micelles; 
therefore, materials that are soluble in such environments will reside in that region of the micelle.3 For 
example, as a polarizable additive, benzene can adsorb to cationic micelle surfaces or between the PEO 
chains of PEO non-ionics.10 
Alternatively, slightly polar additives such as fatty acids or alcohols are usually located in the core-
palisade boundary and expected to have a radial orientation with the carbon tail closely associated with 
the micellar core, and polar group oriented toward the surfactant headgroups.3,10 As the carbon chain 
length of the alcohol additive increases, especially for four carbons and greater, there is a more rapid 
change in the surfactant solution properties and generally a decrease in the CMC, which is attributed to 
these materials having inherent surface activity, resulting in mixed micelle formation, where the alcohol 
acts as a second surfactant species in the micelle.3 Mixed micelles will be discussed further in Section 
1.5.  
As seen with the effect of temperature, the net effect on the CMC depends on the magnitudes of these 
opposing effects.3 Organic materials that are water-miscible such as short-chain alcohols, acetone, 
glycol, and polar organic solvents, can act as co-solvents when present at high concentrations, which 
reduces the dielectric constant of the bulk solvent, resulting in decreased electrostatic repulsions 
between ionic surfactant head groups and lower surfactant solubility, ultimately lowering the CMC.3 




As discussed later on in this chapter, surfactant micelles (and other aggregate structures) can be 
applied in pharmaceutical formulations as a way of improving the overall delivery of drugs (and genetic 
material, as discussed in the next section). Surfactant self-assembly can be exploited to improve 
solubility of otherwise poorly soluble drugs in biocompatible solutions through micellar solubilization, 
or protect degradable APIs (e.g. protect deoxyribonucleic acid, DNA, from nucleases) and improve 
circulation through solubilization or encapsulation.  
1.2 Gene Therapy Utilizes Genes as Medicine 
The term gene therapy generally refers to the transfer of nucleic acids into target cells in order to 
produce a therapeutic effect.11 This approach can involve introducing a correct copy of a missing or 
non-functional gene, silencing the expression of a non-functional or over-expressed gene (e.g. gene 
knockdown by ribonucleic acid, RNA, interference), or repairing a mutation (through gene editing).12,13 
Figure 1.1-3  Solubilization of additives in different regions of a micelle: a) hydrophobic micelle 
core; b) core-palisade interface/mixed micelle formation; c) surface or palisade region of nonionic 




Gene therapy holds potential for treating monogenic disorders (e.g. cystic fibrosis, haemophilia, 
lipoprotein lipase deficiency) as well as for treating cancer, by addressing the root cause of these 
diseases. With recent successes in clinical trials and licensing in Europe and North America, the 
capacity of gene therapy to revolutionize human disease treatments is becoming a reality. The majority 
(66.6%) of gene therapy clinical trials in 2018 addressed cancer treatment, while monogenic diseases 
also accounted for a large portion (11.5%) of the indications addressed, followed by infectious diseases 
and cardiovascular diseases that accounted for 6.3% and 6.2%, respectively.14 
Gene delivery techniques consist of vector-assisted delivery or physical methods like electroporation, 
sonoporation, microinjection, or particle bombardment via a gene gun.15 Vector-assisted gene delivery 
consists of two major categories; viral and non-viral. The viral vector method exploits the natural ability 
of viruses to introduce their genetic load to target cells, but first requires replacement of essential genes 
for viral replication, assembly, or infection with the expression cassette encoding the therapeutic gene 
to be delivered.16,17 Viral vectors have many advantages for gene therapy, including high transfection 
efficiency, persistent gene transfer, and the ability to infect dividing and non-diving cells, including 
many cell types considered difficult to transfect.18 However, multiple patient deaths in earlier gene 
therapy clinical trials highlighted safety risks associated with viral delivery systems. For example, in 
1999 18-year old Jesse Gelsinger died of an inflammatory reaction to the adenovirus-based vector used 
in a Phase I gene therapy clinical trial to treat ornithine transcarbamylase deficiency.14 Another 
occurrence involved the development of a leukemia-like condition in 2002 in two children enrolled in 
a trial to treat X-linked severe combined immunodeficiency, and development of a similar condition in 
a third child when trials restarted with a revised protocol in 2005.14 This condition was caused by 
retroviral vector integration near an oncogene promoter.14 Although these events were largely seen as 
setbacks for gene therapy, continued basic and clinical research have led to improvements. In the case 
of adenoviral vectors, there has been wide use of these vectors in various clinical applications, and safer 
dosing and routes of administration have been established.18 In fact, current approved gene therapy 
products, as well as the majority of ongoing gene therapy clinical trials, use recombinant viral vectors 
to achieve delivery (approximately 67% in September 2019).14,19 In 2012, Glybera® (uniQure, 
Amsterdam, Netherlands) was approved by the European Marketing Association (EMA) for lipoprotein 
lipase deficiency treatment, which used a recombinant adeno-associated virus to deliver the therapeutic 
gene. This was followed by Strimvelis™ (GlaxoSmithKline, Middlesex, United Kingdom) in 2016 to 




stem cells extracted from the patient.13 In 2017, the United States Food and Drug Administration (FDA) 
approved Kymriah (Novartis Pharmaceuticals, Basel, Switzerland), the first chimeric antigen receptor 
T-cell (CAR-T) cell therapy product (for acute lymphoblastic leukemia), and shortly after in the same 
year, approval for Yescarta (Kite Pharma, Santa Monica, USA) for B-cell lymphoma followed.13 CAR-
T therapies generally rely on retroviral transduction or electroporation to introduce the CAR gene into 
patient T-cells ex vivo.20 Luxturna, developed by Spark Therapeutics (Philadelphia, USA) also received 
approval by the FDA in 2017 for retinal dystrophy (also utilizing an adeno-associated virus).13  
Despite the recent success of viral vectors, safety concerns and the relatively small capacity for 
therapeutic nucleic acids still motivate interest in non-viral vectors.13 Non-viral vectors generally use 
synthetic materials to protect and deliver the therapeutic nucleic acids to the cells of interest, and 
generally offer advantages such as low immunogenicity, unrestricted plasmid size, low production 
costs, and can be produced on a large scale.21 In spite of these advantages over viral vectors, the use of 
non-viral methods is typically impeded by poor efficiency.13,21 Therefore, research endeavors to 
develop non-viral methods have not only focused on the use and development of different materials to 
achieve this goal, but also establishing structure-transfection relationships, which will be discussed in 
more detail in the following sections. Successful improvements in the efficiency of non-viral gene 
delivery have been made with the application of nanotechnology in the design of these vectors. Gene 
therapy nanoparticles can consist of inorganic materials such as silica, quantum dots, iron oxide, carbon, 
or gold, which are either directly conjugated to the therapeutic nucleic acids through an environment-
sensitive linker, or are modified with cationic molecules for nucleic acid complexation.21 Alternatively, 
“soft” nanoparticles made of lipids or polymers are used to complex with or encapsulate the nucleic 
acid cargo. Lipid nanoparticle formulations for drug delivery (e.g. polyethylene glycol-modified 
liposomal doxorubicin, Doxil®) offered reduced toxicity and/or increased efficacy (compared to the 
free drug), and the understanding of the requirements for successful delivery of these systems has been 
extended to the application of similar vehicles for gene delivery.22 A recent breakthrough and proof-of-
concept is Onpattro (Alnylam Pharmaceuticals, Cambridge, USA), which uses a lipid nanoparticle to 
deliver therapeutic small interfering RNA to the liver to treat peripheral nerve disease caused by 
hereditary amyloidosis received approval by the FDA and EMA in 201823; demonstrating gene therapy 




The following section will discuss important features of nanoparticle design (mainly “soft” 
nanoparticles) for achieving successful gene delivery and transgene expression (known as transfection). 
 
1.2.1 Non-Viral Vectors Require Rational Design to Overcome Barriers to Transfection 
Transfection, the process by which nucleic acids are delivered to cells, can be hindered by a number of 
barriers that can limit the overall efficiency of the process. At the cellular level, these barriers include 
cellular internalization of the vector, escape from the endosome/lysosome before acidification of the 
compartment occurs, intracellular trafficking, dissociation of the nucleic acid-vector complex, and 
nuclear entry of the nucleic acid cargo (as illustrated in Figure 1.2-1).1,24 In addition, extracellular 
barriers to transfection (following intravenous, i.v., injection) include vector instability due to 
components within the blood, adhesion to non-target tissues, clearance of the vector by the reticulo-
endothelial system, and degradation by endonucleases in the blood and extracellular space.25,26 The key 
to successful gene therapy is to protect the therapeutic nucleic acids (herein referred to as DNA, but 
Figure 1.2-1  Schematic representation of extracellular and intracellular barriers to gene delivery. 





generally applies to other nucleic acid forms unless specified) from degradation and assist the 
therapeutic load in overcoming these barriers so that it can reach its intracellular target of the 
appropriate cells for treatment. Although viruses naturally overcome many of these obstacles, efficient 
transfection by non-viral vectors remains stalled by such factors; therefore, non-viral gene delivery 
systems often require a rational design approach.  
 
1.2.1.1 Nucleic Acid Cargo Requires Compaction and Protection 
Traditionally, non-viral gene delivery vectors generally require a component to bind and condense the 
DNA, usually with a cationic component, and usually some additional components are added to help 
evade or overcome the rest of the barriers mentioned above. The following discussion will cover the 
major barriers in more detail accompanied by typical strategies for addressing them in the context of 
non-viral vector design.  
The most common vectors are those consisting of cationic lipids (which form “lipoplexes” with 
nucleic acids) or cationic polymers (forming “polyplexes”), which bind DNA through electrostatic and 
hydrophobic interactions.27 This cationic component is important for: 1) neutralizing the negative 
charge of the nucleic acid phosphate backbone, 2) condensing the DNA size to enable cellular 
internalization, 3) when used in enough excess, providing a positive charge to facilitate interactions 
with the cellular membrane via electrostatic attraction and cellular uptake, and 4) protecting the DNA 
cargo from both extra- and intracellular degradation.28 Some cationic materials that have been 
investigated for compacting and delivering nucleic acids include: spermine, cationic surfactants 
(CTAB, gemini surfactants), cationic lipids (DOTMA, DODAB, DOTAP), cationic cholesterol 
derivatives (Dc-Chol), chitosan, polyethyleneimine (PEI), polypropyleneimine, poly(L-lysine).1,28 
Poly(lactic-co-glycolic acid) (PLGA) has also been used to encapsulate DNA/RNA through a double-
emulsion solvent evaporation technique rather than electrostatic interactions, and shows stability and 
an ability to protect the nucleic acid cargo in vivo.25 Nontheless, novel materials, including polymers 
modified with a cationic component or other cationic polymer (e.g. chitosan-modified PLGA) continue 
to be developed for gene delivery purposes.25 
The hollow compartments of liposomal structures also offer an opportunity to encapsulate DNA in 




through fusion with biological membranes. Liposomes are also said to offer more stability upon dilution 
in the circulation following i.v. administration versus micelles that can disassemble once diluted below 
the CMC. However, there are some drawbacks to the use of liposomal structures and their preparation 
processes. For example, in the classical thin film hydration method, there is generally poor loading 
efficiency of hydrophilic molecules since the volume of hydration is larger on the outside of the 
liposomes rather than the aqueous core.29 Additionally, the conventional methods for liposome 
formation are not easily applicable for industrial scale production due to inconsistent encapsulation 
efficiencies, and broad size distributions. In order to overcome these problems, more sophisticated 
methods, such as microfluidics technology, are required.29 Furthermore, for temperatures above the  
phase transition temperatures of the particular lipids used, liposomes can also be leaky at body 
temperature (37°C) and the encapsulated contents may be released in circulation prior to reaching the 
target tissue. However, this might be reduced by choosing lipids with gel states under physiological 
conditions, or adding cholesterol to stabilize the lipid bilayer. Similarly, micellar delivery systems made 
from materials with a low CMC (e.g. polymers) would also be less affected by dilution, and has the 
advantage of simple preparation through self-assembly.30 
1.2.1.2 Circulation and Clearance Are Influenced by Nanoparticle Size and Surface 
Characteristics 
Although useful at the cellular level, the positive charge of many lipoplex and polyplex systems often 
results in interactions with serum components, leading to clearance by the immune system, which 
renders the delivery vector ineffective.23,31,32 Foreign organisms or materials, such as gene or drug 
nanoparticle carriers, become covered with opsonin proteins in the blood serum, which makes the 
nanoparticle more visible to macrophages of the mononuclear phagocytic system (MPS, also known as 
the reticuloendothelial system, RES).32 Following this process (known as opsonization), the 
nanoparticle is phagocytosed (engulfed) by the macrophage and digested in order to remove the foreign 
material from the bloodstream.32 This can occur within seconds of i.v. injection.32 Any nanoparticles 
that cannot be cleared by macrophages (typically polymeric nanoparticles) are sequestered in the liver 
and spleen.23,32 Due to increased adsorption of serum proteins, hydrophobic particles reportedly 
undergo opsonization quicker than hydrophilic particles; while charged particles are opsonized faster 
than particles with a neutral charge.23 Therefore, vectors often include “stealth groups”, such as 




provide stability, reduce non-specific interactions, and prolong circulation times in vivo.23,25 Although 
PEG and the PEG-containing polysorbate, poloxamine, and poloxamer (discussed later) are the most 
effective, numerous other polymers have also been used as shielding/stealth groups, including 
polysaccharides, polyacrylamide, poly(vinyl alcohol), and poly(N-vinyl-2-pyrrolidone).23  
Even neutral nanoparticles can benefit from “PEGylation” since they too form large aggregates in 
physiological salt concentrations, which can adsorb to serum proteins.25 PEG introduces an aqueous 
layer at the liposome surface, which confers colloidal stability and steric hindrance, leading to inhibition 
of adsorption of proteins and less recognition by macrophages.33 As a result, sterically stabilized (e.g. 
PEGylated) delivery vehicles can have significantly longer blood circulation times after i.v. 
administration (which is also observed with the addition of PEG to drug delivery liposomes; for 
example, higher levels of accumulation in tumors with PEGylated liposomal doxorubicin versus free 
doxorubicin).33 The thickness, charge, surface density, and conformation of the PEG layer can also 
impact the interaction with opsonins; therefore, optimization of the PEGylation is also required.32 
Nevertheless, it has been found that this “stealth method” works better in vitro than in vivo, where 
aggregation is still known to occur with these complexes.  
Prolonged circulation is also desirable because it can result in enhanced accumulation in pathological 
sites such as solid tumors through the enhanced permeability and retention (EPR) effect, allowing for 
passive targeting.33 In theory, this exploits the leaky vasculature of tumor tissue (which has a 
discontinuous or absent basement membrane due to rapid angiogenesis) and lack of lymphatic drainage, 
which allows small and even large macromolecules or nanoparticles to accumulate in the interstitial 
tumor space.33 However, it is also important to keep in mind that the PEG layer on the surface of gene 
carriers has been known to reduce interactions with the cell surface and the increased stability 
introduced by PEG results in poor membrane fusion for endosomal escape33; therefore, additional 
strategies (e.g. ligands for cellular uptake, cleavable PEG systems, and endosomal fusogenic peptides) 
are required to compensate for these drawbacks.33 
Furthermore, in regard to the EPR effect, early nanomedicine approaches to overcome the low 
specificity of traditional chemotherapeutics relied on the EPR effect as the major underlying 
mechanism to achieve drug accumulation in the tumor tissue while reducing side effects.34 Naturally, 
anti-cancer gene therapy nanomedicines also adopted this approach, generally leading researchers to 




to avoid renal clearance in vivo (which removes particles smaller than 30 nm from circulation), 
contributing to longer blood circulation times, the idea is also that these particle sizes would achieve 
passive targeting to tumor tissues by extravasation through the discontinuous, hyperpermeable tumor 
vasculature that allow passage of particles of 10-500 nm (but not through normal vasculature, which 
requires 2-4 nm sizes).34–36 However, a few caveats exist with this approach. First, although smaller 
particles would accumulate faster and diffuse deeper into the tumor compared to larger particles, a 
smaller size also allows for more rapid diffusion back to the vascular compartments; this of course, 
reduces its accumulation in the tissues.37 Second, large tumors show pathophysiological heterogeneity; 
in particular, the central region of metastatic tumors does not exhibit the EPR effect, also leading to 
less nanoparticle accumulation throughout the tumor tissue.38 Third, loss of effective dose within 
tumours may also occur due to the tumour core having a higher interstitial pressure than the periphery, 
allowing the nanoparticles to flow outward.38 Similarly, a negative pressure gradient of the tumor 
interstitium may also limit movement of nanoparticles from the intravascular to extravascular space.38 
As a result, the EPR effect is better documented in small animal models, but fails to translate in the 
clinic.34 Therefore, use of the EPR effect in the rationale of nanoparticle designs is likely only 
appropriate for some tumors known to show a strong EPR effect (e.g. Kaposi sarcoma and head and 
neck tumors), and other approaches that exploit the tumor microenvironment instead may be more 
promising. Although outside the scope of this work, some methods include stimuli-responsive 
nanoparticles to take advantage of gradients in the tumor regions such as pH, or hypoxia.34 
Opsonization and phagocytosis form the main clearance mechanism for removing undesired 
elements from the blood when they are larger than the renal threshold.32 Hence size can also play a role 
in whether a gene delivery vector remains in the body long enough to achieve its desired benefit, even 
for PEGylated/stealth nanoparticles.32 In general, for nanoparticles that cannot be cleared by the renal 
system, nanoparticles with a hydrodynamic size over 200 nm are typically cleared faster than those 
under 200 nm.23 Taking PEGylation into consideration, poloxamer-coated nanoparticles smaller than 
150 nm showed increased uptake in the bone marrow of rabbits versus the liver and spleen (the major 
sites of clearance for 250 nm particles), which may be due to the steric barrier having greater 
effectiveness on the smaller particles despite having a lower concentration of adsorbed polymer (as 
opposed to a more crowded arrangement and lower mobility of the polymer chains on larger particles 
with a smaller surface curvature).39  Furthermore, in most systems, size also affects the ability to 




consistent across systems. Gene delivery particles can range from “small”, ≤100 nm, to “giant”, ≥1000 
nm.1 Small particles have shown high transfection efficiency in vivo due to their ability to cross 
capillary networks, for example in the spleen, lungs, liver, and kidney.1 On the other hand, once at the 
cellular level, larger lipoplexes may be capable of releasing their contents into cells through fusion with 
the cellular membrane, which by-passes the barriers associated with cellular entry through endocytosis 
pathways (discussed later).1  
1.2.1.3 Gene Delivery Vectors Achieve Internalization 
The first obstacle encountered by the delivery complex at the cellular level is the plasma membrane.  
Passive diffusion into the cell is not possible due to the size restrictions of transmembrane pores and 
channels; therefore cellular uptake strategies take advantage of the natural cellular mechanisms used to 
internalize macromolecules, specifically, the process of endocytosis.28 Cellular internalization of the 
complex can occur through non-specific uptake following ionic interactions with negatively charged 
membrane-bound proteoglycans, receptor-ligand binding at the cell surface, lipophilic interactions 
between lipophilic residues in the delivery vector and cellular membrane phospholipids, or through the 
use of cell-penetrating peptides originally derived from cationic, amphipathic viral proteins capable of 
membrane translocation.28 The mechanism by which cellular internalization occurs can determine the 
intracellular pathway and fate of the delivery vector and DNA cargo; therefore, it is important to 
consider and can contribute to more rational design.  
Similar to many macromolecules and solutes that are unable to permeate the plasma membrane, gene 
delivery vectors are most commonly internalized/engulfed through clathrin-mediated, caveolae-
mediated, or micropinocytosis pathways.40 These pathways differ in the composition of the structures 
or coat (if any), size of the vesicle, and the fate of the particles that are internalized.41 Firstly, clathrin-
mediated endocytosis is triggered by binding of a ligand to its high-affinity transmembrane receptor, 
which triggers clustering of these ligand-receptor complexes into membrane structures known as 
clathrin-coated pits.40–42 These pits then invaginate and are pinched off from the plasma membrane, 
forming intracellular clathrin-coated vesicles that reportedly have a cargo size upper limit of 150-200 
nm in diameter.42,43 Depolymerization of the vesicle’s clathrin coat then results in an early endosome 
and acidification in the lumen to pH 5.9-6, which dissociates the ligand from the receptor.41 The early 
endosomes fuse with each other or with other pre-existing endosomes, forming a late endosome that 




DNA needs to escape the endosome and avoid degradation by the lysosome in order to be effective. 
Strategies for endosomal escape will be discussed in the following section. 
Caveolae-mediated uptake occurs through small, hydrophobic domains in the plasma membrane that 
are rich in cholesterol and glycosphingolipids.41,42 Unlike the clathrin-mediated pathway, the 
caveosome does not follow an acidic or digestive route.44 Therefore, the pathogens and particles taken 
up by this route will be transported directly to the Golgi apparatus or endoplasmic reticulum without 
undergoing degradation.44 For gene therapy purposes, caveolae-mediated uptake could be advantageous 
if internalization by this route (e.g. through exploitation of specific receptors) can be increased; 
however, it is also important to keep in mind that internalization of caveolae is generally slower and 
their size is more appropriate for 50-80 nm vehicles.43 
Finally, in micropinocytosis a large volume of extracellular medium is non-selectively internalized 
by membrane protrusions that collapse and fuse with the plasma membrane.42,43 Contrary to the other 
mechanisms mentioned, this process is not directly driven by receptors or by the cargo, but can be 
induced by mitogenic factors.41,44 The resulting vesicles, known as macropinosomes, can vary in size 
up from 0.5 to 10 μm.43 The fate of macropinosomes remains unclear but appears to be cell type 
dependent, where some fuse with lysosomes, and others do not mature beyond the early endosome 
stage.44 Although not covered in this discussion, other endocytosis pathways include: phagocytosis; 
which occurs in specialized cells such as macrophages, neutrophils, and monocytes; and caveolae- and 
clathrin-independent, which are not very well characterized.40 
Manifestly, the fate of the DNA cargo depends on the size of the gene delivery nanoparticle and 
endocytosis pathway. Furthermore, when administered intravenously, the non-viral delivery vector 
likely has a negative charge following interactions with serum components; therefore, there may not be 
much electrostatic interaction with cell membranes to rely on.45,46 However, while lipoprotein particles 
inhibit uptake, adsorption of fibrinogen on the surface of lipoplexes stimulates uptake through 
interaction with specific cell surface receptors.45,46  
Cellular uptake can also be improved through receptor targeting and receptor-mediated 
endocytosis.28 This generally results in faster internalization compared to non-specific uptake (without 
a ligand) and accumulation of the DNA cargo inside the cell (which is expected to decrease the amount 
of cargo required to achieve efficient transfection due to greater accumulation of the DNA within the 




are exploited to enhance internalization and transfection activity by coupling targeting molecules 
(ligands) to gene delivery vectors.27 These ligands bind surface markers exclusively present or up-
regulated on specific cells, and facilitate receptor-mediated endocytosis into the intended cells. 
Additionally, the ligand-receptor binding should be particularly strong in order to be effective.25 
Incorporating targeting molecules in transfection formulations is also thought to decrease the non-
specific delivery to normal cells outside of the target tissue that can often lead to toxicity of the gene 
therapy in in vivo applications, contributing to a safer and more efficient therapeutic.11,47 Some common 
ligands include transferrin (recognized by transferrin receptors upregulated in many cancer cells), 
arginine-glycine-aspartic acid (RGD) peptides (recognized by tumor vasculature integrins), lactose 
(recognized by hepatocytes), mannose (recognized by macrophages and dendritic cells), folate 
(recognized by certain tumor cells), as well as receptor-targeting antibodies (e.g. an anti-transferrin 
receptor single chain antibody fragment, which was incorporated in a cationic liposome currently under 
phase II trials for targeted p53 gene therapy for metastatic pancreatic cancer, in combination with nab-
paclitaxel).25,27 The choice of ligand can also be used to target the caveolin-dependent versus clathrin-
dependent pathway. While the clathrin pathway is receptor-mediated, this does not mean all ligand-
receptor binding results in cellular uptake through this pathway. Rather, the internalization pathway 
depends on the cell type and receptor. For example, transferrin receptor binding triggers clathrin-
mediated endocytosis, whereas folic acid uptake occurs through caveolae.  
Cell-lipoplex fusion is thought to be a secondary pathway for internalization of lipid-based vector 
contents into cells, but accounts for only a small fraction of internalization events.1 The surface of gene 
therapy nanocarriers can also be decorated with cell-penetrating peptides to accelerate cellular entry, 
such as that derived from the HIV-1 TAT protein which enters cells by interacting with negatively 
charged components of the cell membrane.25,48 These peptides consist of 5-30 amino acids, and are 
cationic and/or amphipathic.48 Cationic peptides interact with anionic/acidic motifs on the cell 
membrane, whereas amphipathic peptides adsorb to the cell membrane.48 Depending on the features of 
the peptide, the conjugated cargo, cell type, and the lipid composition of the membrane, the cell-
penetrating peptides can increase uptake through direct translocation (conjugated to small cargo) or 




1.2.1.4 Endosomal Escape Must Occur to Avoid Degradation 
If internalized through endocytosis, the next intracellular hurdle to be conquered is escape from the 
endosome before the encapsulated delivery vector is either recycled back to the cell surface, shuttled to 
an acidic lysosome (pH decreases to approximately 5), or delivered to other organelles such as Golgi 
apparatus or endoplasmic reticulum.28 In any case, release from the endosome is vital in order to avoid 
degradation and for the DNA to make its way to the nucleus. Some methods that facilitate endo-
lysosomal escape are to incorporate endosomal release peptides (peptides that adopt a membrane-
disrupting conformation with decreases in pH), protonatable groups with a pKa generally between 5 – 
7 (known as the proton sponge effect), or encourage interaction of hydrophobic alkyl chains able to 
interact with the endosomal membrane.28  
Endosomal release peptides undergo a conformational change at low pH, which leads to interaction 
and disruption of the endosomal membrane.28 The protonatable carboxyl groups and alkyl chains of 
these peptides are suspected to be responsible for this function, which has been mimicked in synthetic 
pH-sensitive polymers.28  
With the proton sponge effect, as the endo-lysosomal vesicle acidifies, functional groups, such as 
secondary and tertiary amines or imidazole, of the delivery vector become protonated, acting as a 
“proton sponge”, and prevents the desired pH from being reached inside the vesicle.28 As protons 
continue to enter the endosome, water follows; this eventually causes the endo-lysosomal vesicle to 
osmotically swell, rupture, and release its contents into the cell cytoplasm.28,49 PEI is a notable example 
of a gene delivery material capable of inducing this proton sponge effect under the acidic conditions of 
the endosome, which has been credited, in part, with the high transfection efficiency achieved by PEI 
gene delivery systems, including the commercially available reagents jetPEI and ExGen500.50 Some 
other chemicals capable of this effect are ammonium chloride, chloroquine, methylamine, poly-L-
histidine, polyamidoamines, and polypropylacrylic acid.51  
Lipid-based vectors can also disrupt the endosomal membrane by interacting with the membrane 
lipids; however, the mechanism of this process remains unclear. It has been hypothesized that cationic 
lipoplex interaction with endosomal membranes induces reorganization of the phospholipids where 
lipids from the cytoplasmic-facing layer of the membrane flip inward, neutralize the cationic lipids in 
the vector, and results in dissociation of the DNA and its release into the cytoplasm.52 Alternatively, 




and subsequent DNA release from the vector occurs in the cytoplasm following interactions with lipids 
of other organelles in the cytoplasm.45  
Furthermore, addition of lipids such as dioleylphosphatidylethanolamine (DOPE), known as helper 
lipids, to cationic lipid transfection complexes aids in forming stable, liposomes that are fusogenic and 
initiate endosomal escape and tissue penetration.1 The transfection efficiency achieved by such lipid 
carriers has been correlated to the structural transformation of the lipoplexes accompanied by their 
interaction with the anionic lipids of cellular membranes, for example, bilayer-to-micelle transitions or 
the lamellar-to-inverted hexagonal phase transition achieved by DOPE-containing bilayers.1,53 
Koynova et al. suggested that lipoplexes with a lamellar phase, but close to a lamellar-nonlamellar 
phase boundary would optimally protect the DNA and subsequently release it upon mixing with 
membrane lipids; otherwise, lamellar lipoplexes would likely maintain their structure after contact and 
may not release the DNA.53 Comparatively, formulations that form phases with a highly negative 
interfacial curvature (such as inverted micellar cubic or inverted hexagonal) would be the most effective 
carriers.53 The commercially available transfection reagent Lipofectamine (consisting of DOPE and 
DOSPA) is also expected to have a pH-dependent transition due to the polyamine region of DOSPA.54 
Increased transfection can also be achieved upon conjugation of whole, inactivated virus particles 
(e.g. adenovirus55) to a synthetic gene carrier, possibly due to virus-mediated endosomal escape; 
however, the virus’ presence raised safety concerns, which is also an important consideration in vector 
design.45,51 Likewise, it is also important to consider excessive damage to lysosomes can reduce the 
safety of the method despite its efficiency.45,51 
1.2.1.5 Nuclear Entry is Essential for Plasmid DNA Transfection 
Depending on the vector composition, the DNA may dissociate from the vector at the endosomal-stage 
or within the cytoplasm following interaction or fusion with the cytosolic membrane network (i.e. the 
endoplasmic reticulum, Golgi, mitochondria, or nuclear membrane).45 However, cytoskeletal elements 
such as microtubules, intermediate filaments, and microfilaments within the cell cytosol greatly hinder 
diffusion of the DNA or the DNA/vector complex, and carrier-mediated gene delivery is unable to take 
part in microtubule-mediated transport as some viruses do.28,50 Cationic vectors that compact the DNA 
into small enough particles could aid in nuclear localization and protection of the nucleic acid cargo 
from degradation by endonucleases in the cytoplasm; meanwhile, diffusion of naked DNA through the 




Once localized at the cell nucleus, passage of the DNA into the nucleus must occur rapidly before 
the unbound, de-condensed DNA is degraded by cytoplasmic DNA nucleases.1 A double membrane 
surrounds the nucleus.45 Transport structures known as nuclear pores regulate passage across the 
nuclear membrane, and the size threshold for molecules to freely pass through the nuclear pore complex 
is approximately 9-11 nm in diameter.50 Plasmid DNA, commonly used for transfection, is typically 
too large to enter the nucleus unassisted and is therefore thought to either i) enter during mitosis when 
the nuclear membrane structure disappears in dividing cells, or ii) be imported through an ATP-
dependent pathway.50  
These energy-dependent modes of nuclear transport can occur through a DNA sequence-dependent 
transport or through addition of peptides carrying a nuclear localization signal (NLS).45 The presence 
of protein-binding sequences in the plasmid DNA, for example sequences derived from the SV40 viral 
genome such as the SV40 origin of replication or early and late promoters, bind to cytoplasmic proteins 
(e.g. transcription factors) that contain NLSs. These proteins then couple the plasmid DNA to the NLS 
import machinery.45 As such, nuclear import, and therefore transfection, can be increased by strategic 
selection of sequences in the therapeutic DNA molecule that can be recognized by transcription factors 
expressed in the cells of interest.45 Another strategy involves coupling NLS peptides to the DNA or the 
chemical vector.45 For example, coupling an SV40-derived NLS-containing peptide resulted in an 
eight-fold increase in PEI-mediated plasmid transfection.45,56 Alternatively, some pharmaceutical 
excipients, such as Pluronics, can activate certain cellular signaling pathways that enhance nuclear 
transport of plasmid DNA (pDNA) containing specific sequences without additional modification of 
the DNA (discussed later on).57 
It is also worth acknowledging that there are a number of other important elements in the pDNA 
structure that generally impact transfection. Briefly, and specifically relating to pDNA transfection, the 
plasmid is composed of a bacterial backbone and a eukaryotic expression cassette.58,59 The bacterial 
backbone consists of an origin of replication for pDNA replication in bacteria, and a drug resistance 
gene, such as kanamycin or ampicillin resistance, which allows for the selection of plasmid-transformed 
bacteria.58,59 The eukaryotic expression cassette consists of everything necessary for successful gene 
expression in the transfected cells.  Firstly, there is a promoter, which contains a DNA sequence capable 
of recruiting RNA polymerase II for the transcription of the pDNA.59  This promoter may also contain 




RNA polymerase II.59  The expression cassette is also comprised of a 5ꞌ untranslated region, including 
at least one intron (to ensure the pre-mRNA is processed into a mature mRNA, and exported into the 
cytoplasm) and a Kozak sequence (that provides the ribosome with a signal to start translation); the 
open reading frame, which encodes the gene to be expressed; and a 3’ untranslated region with a 
polyadenylation sequence.59  Polyadenylation promotes nuclear export and translation of the mRNA 
and inhibits its degradation.59  
While this work focuses on pDNA delivery, a significant number of gene therapy efforts involve 
RNA interference methods where small interfering RNA, microRNA, or antisense oligonucleotides are 
used for the post-transcriptional regulation of a gene of interest. In this case, only delivery to the cytosol 
is required – eliminating the need to overcome the challenges to nuclear entry. 
1.2.1.6 Safety Must Also Be Considered 
Although non-viral vectors are generally considered safer than viral vectors due to lower 
immunogenicity, the safety of these vectors must still be considered and characterized along with their 
efficacy. Factors such as the chemical composition of the materials used, particle size, nanoparticle 
surface properties, and shape also contribute to the safety profile of gene therapy nanoparticles. For 
instance, the cationic charge often necessary for efficient transfection (as discussed above) is often a 
double-edged sword, where delivery vehicles carrying a higher cationic surface charge are generally 
more cytotoxic, which has been attributed to interactions with critical enzymes such as protein kinase 
C and substantial cell membrane permeabilization.60,61 Administration of highly cationic materials such 
as PEI in the circulatory system can also cause toxicity by adhering to and destabilizing the plasma 
membrane of red blood cells (hemolysis).60 The presence of particles carrying a high cationic surface 
charge also have the potential to induce platelet aggregation in the blood.35 Similarly, lipid materials 
containing ether linker bonds have been shown to produce greater transfection in vitro, but these bonds 
are generally too stable for biodegradation, which can also pose a toxicity risk.60 Non-degradable 
materials can accumulate in organs such as the liver and spleen, which leads to toxicity.23 On the other 
hand, amide and ester linkers are associated with less cytotoxicity since they are more biodegradable 
but these gene carrier materials would also be more susceptible to decomposition in systemic 
circulation.60 In terms of particle size, formulations administered intravenously should not possess 
particle sizes larger than 0.5 μm and should have a maximum aggregation limit of 5 μm in order to 




As previously mentioned, the incorporation of materials such as PEG could mitigate some of these 
challenges; however, although PEG is generally well-tolerated by the body (due its hydrophilicity), 
these molecules may turn out to be immunogenic considering anti-PEG antibodies having been 
identified in approximately 25% of patients following administration of PEG conjugates.23 
 
All in all, an ideal non-viral vector would be able to overcome all of the above mentioned barriers.  Of 
course this is where rational design and structure-activity approaches play a role and plenty of effort 
towards optimization is required, since a component incorporated to overcome one barrier could hinder 
the system’s ability to overcome another.1,28,50 For example, as discussed above, a delivery complex 
with an overall positive charge allows for favourable interactions with the cell surface; however, excess 
positive charge can lead to serum instability or toxicity. 
1.3 Cationic Gemini Surfactants Can Act as Non-Viral Transfection Vehicles 
A number of cationic lipids and surfactants have been investigated for non-viral DNA delivery, 
including: monocationic lipids with ammonium head groups, cationic cholesterol derivatives, 
dicationic lipids and surfactants, polycationic lipids, and cationic lipid hybrids (containing sugar, 
peptide or polymer residues).1 Of particular interest for the work present here, is the application of a 
family of dimeric cationic surfactants commonly referred to as “gemini” surfactants. The general 
structure of gemini surfactants consist of two amphiphilic monomers covalently linked at or near their 
positively charged head group by a spacer.62 The most commonly studied series of gemini surfactants 
is the dicationic N,N’-bis(dimethylalkyl)-alkane-diammoniumdibromide series, or “m-s-m” type 
(where m in this notation refers to the number of carbon atoms in the alkyl tails, while s denotes the 
number of atoms in the spacer group connecting two quaternary ammonium head groups).62 The 





Figure 1.3-1 Structure of the m-s-m gemini surfactant known as 16-3-16 
As a group, gemini surfactants display unique solution properties compared to conventional 
surfactants; making them attractive for building gene delivery carriers. These properties include CMC 
values that are at least one order of magnitude lower than that of comparable monomeric surfactants, 
and the ability to form a wide variety of aggregate morphologies in solution through manipulation of 
the molecular structure.62 The unique structure of gemini surfactants also offers advantages like CMC 
control which is important when designing transfection vectors.  For example, a high CMC is important 
in order to have a sufficiently high monomer concentration to form DNA complexes with an overall 
positive charge; meanwhile, a low CMC can increase micelle stability and keep the delivery complex 
together during the delivery process.63 Since the CMC of a gemini surfactant is more sensitive to 
changes in alkyl tail length than variations in the spacer size, its properties can be fine-tuned by 
manipulating the spacer, without affecting the CMC.62  
1.3.1 DNA Binding and Transfection Efficiency Depend on Gemini Surfactant 
Structure and Aggregation Properties 
In regard to gene therapy application, cationic gemini surfactants are known to bind nucleic acid 
molecules, leading to compaction and protection against enzymatic degradation and ultimately 
successful delivery to cells. Atomic force microscopy studies of gemini surfactant-plasmid DNA 
complex formation showed 16-3-16 binds to naked plasmid DNA and compacts the large loop structure 
of the plasmids within 30 seconds, and more compact particles form within 15 minutes.64 The process 
of surfactant-mediated DNA compaction is discussed in more detail in Section 1.5.3. 
Gemini surfactants, either alone or in combination with helper lipids have exhibited transfection 




condense DNA has been associated with the spacer length, where the most condensed DNA form is 
achieved with surfactants having spacers shorter than 4 carbons or longer than 10 carbons, for a given 
series of constant alkyl tail length.62 Intermediate lengths of s = 5 – 10 are generally less efficient.62  
Similar correlations are seen between spacer length and transfection efficiency (highest transfection 
efficiencies are achieved with s ≤ 4 or s > 12). These effects are attributed to the distance between the 
cationic nitrogen centres in the surfactant headgroups; the shorter spacer lengths create optimal spacing 
for the amine groups to interact with adjacent phosphates on the DNA backbone.62 The increased 
transfection with long spacer groups may be due to the spacer bending into a U-shape, which 
subsequently decreases the headgroup distance that allows for improved DNA binding, or membrane 
disruption via folding of the spacer into the alkyl tail region of biological membranes.62,63 
Binding of gemini surfactant micelles to DNA is entropy-driven, which is attributed to the release of 
counterions from the micelles and the DNA upon binding; therefore, changes in the counterions 
associated with the gemini surfactant headgroups are reported to alter the concentration at which gemini 
micelles begin to form along the DNA molecule.65 For example, one of the most effective decreases in 
this concentration is achieved by replacing the bromide ions with a divalent sulfate.65 Differences in 
transfection efficiencies have also been observed with variations in the associated counterions.66 
Transfection efficiency has also been associated with gemini surfactant CMCs, where transgene 
expression increases with decreasing surfactant CMC.63 This trend has been attributed to the ability of 
the surfactant/DNA complex to hold together due to micellar aggregation, providing stability during 
the delivery process.7,63 However, this trend may be more complicated depending on the surfactant 
series; for 12-s-12 geminis with s = 3-10, lower CMC values were associated with lower in vitro 
transfection efficiency, but transfection increased with decreasing CMC for spacer lengths 12-16.63  
The ability of the carrier to adopt various morphologies has also been correlated to increased 
transfection efficiencies, owing to greater endosomal escape.62 In particular, the ability to form an 
inverted hexagonal or cubic phase facilitates DNA release when the lipoplex interacts with anionic 
membrane lipids.67 Gemini surfactant-based delivery systems with polymorphic phases (not necessarily 
inverse hexagonal) generally produce greater transfection efficiency than those systems that show a 
particle-like morphology and lack long-range order.64 Gemini surfactants that form vesicle structures 
in aqueous solution have also been associated with better transfection efficiencies than those with 




instance, lamellar lipoplexes can bind anionic lipids of cellular membranes, which increases the packing 
parameter of the cationic surfactant and allows the formation of inverted hexagonal or cubic structures 
because the electrostatic attraction between the positive and negative head groups results in the total 
volume of hydrophobic tails of the molecules increasing faster than that of the head group areas; v 
increases faster than 𝑎0 in the packing parameter equation.
67 Although these non-lamellar structures are 
not favourable for binding DNA, they are favourable for releasing DNA once the lipoplex is within, or 
after it leaves, the endosome; a key factor in vector-assisted DNA delivery.67 Correspondingly, a neutral 
helper lipid such as 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolyamine (DOPE) is often added to 
gemini surfactant-based gene delivery formulations in order to enhance transfection.67 Addition of 
DOPE creates mixed aggregates and increases the packing parameter of the systems; shifting micelle 
systems towards vesicles or inverted hexagonal structures, and vesicle systems toward the inverted 
hexagonal or a cubic phases.67 DOPE is also believed to contribute to increased transfection efficiency 
by increasing the fluidity of cellular membranes and aid in destabilization of the endosomal 
membrane.67 In fact, DOPE is required for transfection depending on the structure of the surfactant 
molecule. For example, the 12-s-12 series does not show transfection without the addition of DOPE, 
but longer alkyl tails such as those of 16-3-16 or 18:1-3-18:1 can transfect in the presence or absence 
(albeit with lower efficiency) of helper lipid.68 
Early efforts to optimize pDNA/gemini surfactant/DOPE formulations for in vitro transfection to 
PAM 212 murine keratinocytes based on transfection efficiency and cell viability simultaneously 
revealed an optimal plasmid/gemini charge ratio of 1:10 for the 16-3-16 surfactant (2.4% cells 
transfected vs. 5.9% by Lipofectamine Plus reagent).63 Although a 1:40 charge ratio produced the 
highest percentage of transfected cells (3.1%), the cell viability was significantly reduced to 20%.63 It 
was also reported that gemini surfactant-DNA complexes must be allowed to form first, followed by 
addition of pre-formed DOPE vesicles.63 Otherwise, combining the gemini surfactant with DOPE and 
then adding plasmid does not form complexes that are appropriate for transfection.63 Cationic 16-3-16 
delivery formulations have also shown significant increases in transgene expression in the intact skin 
and lymph nodes of mice treated topically with a total of 75 µg pDNA over three daily treatments 
compared to the naked DNA and a liposomal 3β-[N-(Dimethylaminoethane)carbamoyl]cholesterol 
formulation known to deliver plasmid DNA to various tissues in vivo.63 This work demonstrated that 




Progress in understanding gemini surfactant structure-transfection activity relationships has also led 
to modification of the gemini surfactant structure in an effort to achieve more favourable effects both 
in vitro and in vivo. For example, functional groups have been added in the spacer region in order to 
influence transfection. Incorporation of secondary or tertiary amines in the spacer resulted in increased 
transfection efficiencies; most notably, with a 9-fold increase in vitro (resulting in levels comparable 
to the Lipofectamine Plus commercial control) achieved by 12-7NH-12/DNA/DOPE complexes 
compared to complexes containing the corresponding unsubstituted 12-3-12 structure.54 In particular, 
the improvements achieved by 12-7N-12 and 12-7NH-12 (structures shown in Figure 1.3-2) are likely 
due to the spacing between the nitrogen groups in these structures which allows for more favourable 
interactions with adjacent phosphate groups of the DNA.54 Meanwhile, the 3-fold improvement of 12-
7NH-12 over 12-7N-12 may be related to less steric hindrance and increased pH activity from the 
secondary versus the tertiary substitution.54 12-7NH-12/pDNA/DOPE nanoparticles show transitions 
in size and zeta potential at pH 5.5, and show the presence of multiple phases that make the gemini-
DNA-lipid complexes more amenable to endosomal membrane fusion.54 Addition of a hydroxyl 
functional group in the spacer also increased transfection over the unsubstituted structures, which is 
thought to be due to enhanced interactions with the DNA through hydrogen bonding.62 However, 
addition of a second hydroxyl group or addition of one to three ethylene oxide substitutions in the 
spacer did not produce significant increases in transfection (Figure 1.3-2).62 More recently, amino acid 
moieties have been introduced at the N-position of the 12-7NH-12 spacer to improve 
biocompatibility.69 Grafting of the amino acids or short peptides provided significant enhancements to 
transfection efficiency in epithelial cell lines compared to the 12-7NH-12 parent compound, without 




particular, glycyl-lysine substitution was credited with an increased buffering capacity that allows the 
nanoparticles to escape endosomes.42  
Compaction of the DNA through electrostatic binding of cationic gemini surfactants inhibits 
intercalation of ethidium bromide (EtBr) between DNA base pairs (indicated by a loss of fluorescence 
emission).70 Therefore, strong binding results in greater loss of fluorescence, which is associated with 
greater transfection efficiency for the first generation of geminis (having alkyl spacers).70 However, 
this correlation is not necessarily true for all gemini surfactant series. For example, the amino acid-
substituted gemini derivatives showed the highest EtBr-DNA binding (less compaction) but were 
associated with greater transfection efficiency.70 This effect is thought to be an indication of balanced 
binding, where there is sufficient protection of the DNA against degradation while allowing 
intracellular release of the DNA cargo, which is necessary for gene expression.70 The introduction of 
van der Waals forces and hydrogen bonding accompanied by the amino acid-substitution may play a 
role, and increased hydration due to an increased number of amine groups may result in greater DNA 
and cell surface interactions.70 The terminal amine groups may also act as polycations at physiological 
or acidic pH and encourage membrane fusion that leads to cellular uptake or endosomal escape, or 
improve endosomal escape through the proton sponge effect.70 However, lysyl-lysine-substituted 
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Figure 1.3-2  Chemical structures of 12-s-12 substituted analogues. A) secondary amine substitution 
(12-7NH-12); B) tertiary amine substitution (12-7N-12); C) monohydroxyl substitution (12-4(OH)-





gemini surfactants having three terminal amine groups resulted in the smallest mean particle diameter, 
but the lowest transfection efficiency of all the amino acid derivatives.70  
Furthermore, the gemini-DNA binding may also influence the cytotoxicity of the formulation. For 
example, the weaker binding and more efficient release of DNA encapsulated by the glycyl-lysine 
substituted gemini 16-7N(GK)-16 (compared to 16-3-16 or the pyridine head group surfactant 16(Py)-
S-2-S-16(Py)) is thought to contribute to the reduced cytotoxicity of these lipoplexes since earlier 
release of the DNA allows translocation of free DNA to the nucleus, whereas stronger binding (by 16-
3-16 or 16(Py)-S-2-S-16(Py)) may result in greater accumulation of the intact lipoplex at the nucleus.71 
Although localization at the nucleus is important for gene expression, it was hypothesized that nuclear 
accumulation of gemini surfactants may contribute to higher toxicity since the surfactants could impact 
the membrane integrity and function of the nucleus.71 This could explain the observed correlation 
between nuclear accumulation and cytotoxicity, again emphasizing a need for balance.71 
Clathrin- and caveolae-mediated endocytosis are the most common cellular uptake pathways for 
gemini surfactants.71 Interestingly, pDNA/gemini/DOPE nanoparticles of either the 12-7NH-12 or its 
glycyl-lysine-substituted derivative, recruit both clathrin-mediated and caveolae-mediated uptake, but 
micropinocytosis does not appear to play a major role in uptake (based on comparison of gene 
expression following transfection in the prescence of various uptake pathway inhibitors).42  
Considering the interest and notable success of using gemini surfactant/DOPE mixed systems for 
gene therapy, an evaluation of the interaction properties between a series of gemini surfactants and 
DOPE was previously completed. Based on CMC determinations of gemini surfactant/DOPE mixtures, 
the tendency toward mixed aggregate formation between these two amphiphiles was found to be 
antagonistic, meaning the net interactions in the mixture are repulsive in nature.72 This was thought to 
be due to the two amphiphiles having different preferred aggregate structures (based on their packing 
parameters) and, as seen with other mixed systems, may be an indication that mixed gemini/DOPE 
aggregates would dissociate into separate gemini-rich and DOPE-rich aggregates over time.72 However, 
the strength of this antagonistic interaction (repulsion) was dependent on the gemini’s spacer group, 
with 16-3-16 showing the strongest antagonism, followed by 16-7NH-16, then 16-7-16.72 DNase 
sensitivity assays also indicated that the lipoplex’s membrane integrity degrades over time, with nearly 
complete degradation of the incorporated DNA after 4 weeks (or increased storage temperature).72 




this delivery vehicle, the relationships between mixing behavior and transfection efficiency remain 
unknown. 
While numerous alterations to the gemini surfactant structure have been evaluated in the context of 
transfection, only a few notable examples were mentioned here. Structural modifications and 
elucidation of structure-activity relationships continue to fill this research space. Likewise, other 
approaches to improve the transfection efficiency of gemini surfactants have been dedicated to 
incorporating alternative components to the gemini/DNA or gemini/DNA/helper lipid complexes to 
enhance the formulation properties to favour transfection. One such effort involved the addition of 
neutral tri-block copolymers known as poloxamers or Pluronics® (BASF Corp.) to 16-3-16/pDNA 
complexes in the presence and absence of DOPE (as discussed in Section 2.1).73 Accordingly, the work 
presented in this thesis examined the aggregation tendencies and transfection efficiencies of pDNA-
loaded 16-3-16/Pluronic nanoparticle systems. 
1.4 Pluronic Block Copolymers Enhance Drug and Gene Delivery 
There are a variety of polymers that have been investigated for use as non-viral gene delivery vectors, 
including: polyethyleneimine (and derivatives), poly(L-lysine), polymethacrylate, poly(amido-amine), 
poly(D,L-lactide-co-glycolide), and carbohydrate-based polymers (e.g. chitosan, dextran, β-
cyclodextrin).50,74 In addition, a class of water-soluble, non-ionic block copolymers known as 
Pluronics®, Synperonic®, or under the non-propriety name poloxamer (shown in Figure 1.4-1), have 
been used in gene delivery applications. Herein, these polymers will be referred to as Pluronics.  
Pluronic block copolymers have the general structure: PEOx– PPOy – PEOx, where a hydrophobic 
poly(propylene oxide), PPO (also known as polypropyleneglycol), block is flanked by two hydrophilic 
poly(ethylene oxide), PEO (also known as polyethyleneglycol) chains. The number of EO (ethylene 
oxide) and PO (propylene oxide) repeating units, represented by x and y, respectively, can be varied in 







order to alter the water-solubility and physicochemical properties of the copolymer. The nomenclature 
used by the Pluronic manufacturer BASF Corp. (Parsippany, NJ, USA) begins with a letter indicating 
its physical state under ambient conditions (F = flake, P = paste, L = liquid) followed by a two or three-
digit code referring to the chemical structure75,76. The last digit represents the weight fraction of the EO 
content, while the first two or three numbers approximate the molecular mass of the PPO block (in Da) 
when multiplied by 30075,76.  For example, Pluronic F127 is present as a flake and consists of a PPO 
block of approximately 3600 Da and approximately 70% wt. EO.   
Due to the block copolymer structure, which imparts an amphiphilic nature, the Pluronics act as 
surface active agents. Individual copolymer molecules, referred to as unimers, self-assemble into 
micelles in selective solvents (a good solvent for one type of block and a poor solvent for the other 
type) at concentrations at or above the CMC.75 In aqueous solution, the micellization is driven by the 
hydrophobic interaction between unimer PPO blocks, which segregate into the micelle core, and leaves 
the hydrated PEO chains to form the outer, hydrophilic shell, or corona.75 As expected, increases in the 
PPO block length (with constant PEO) favours micellization and results in a decreased CMC, while 
increased PEO lengths increase the CMC (albeit to a lesser extent than PPO, on a per unit basis).77 This 
is thought to be due to increased probability of the EO units to interact with the PO units within the 
micellar core, which decreases the hydrophobicity of the core and destabilizes the micelle.78 Similarly, 
Pluronics show a strong temperature dependence and have a characteristic critical micelle temperature 
(CMT) at which micelle formation occurs for a given Pluronic concentration due to temperature-
dependent differences in hydration of the PEO and PPO blocks.79 At low temperatures, Pluronics are 
present as unimers (even for high concentrations) and increases in temperature cause dehydration of 
the PPO block, leading to micellization.80 Therefore, micelle formation can be achieved by two 
approaches – either by exploiting the influence of concentration or influence of temperature.80 In fact, 
an increase in temperature as small as 10°C can reduce the CMC by a factor of about 10-100.80 PPO 
and PEO chain lengths also influence the CMT in the same way they do the CMC. Total molecular 
weight can also play a role; at constant PPO/PEO ratio, an increase in molecular weight produces a 
decrease in the both the CMC and CMT.77 This effect is greater with lower relative PEO content, so for 
the same change in CMC, a 50 EO-unit change is required for 80% EO Pluronics versus only about 10 
EO units for 40% EO Pluronics.77 Further, in aqueous solution, the micellization process is endothermic 





Pluronic unimers generally have a hydrodynamic radius of approximately 1 nm, while micelles are 
approximately 10 nm in size.75 Dynamic light scattering studies also show the co-existence of unimers, 
micelles, and aggregates at higher concentrations.75 Interestingly, the micelle size typically remains 
constant with increased temperature even though the aggregation number increases.75 This effect is 
attributed to dehydration of nonionic unimers which results in a greater tendency to separate from the 
solvent, as well as dehydration of micelles at higher temperatures.75  
The diverse compositions of the Pluronic series also allow for a variety of structures to be reached. 
Depending on the Pluronic structure, the concentration and temperature, Pluronics can form the various 
mesophases that are typically observed with normal hydrocarbon surfactants. For example, between 0 
to 50°C, increasing the concentration of an aqueous P104 solution results in transitions from spherical 
micelles to a cubic phase, then hexagonal phase, and eventually lamellar phase, with two-phase 
transition regions in between.80,81 Likewise, some liquid crystalline mesophases can be reached with 
increasing temperature at a fixed concentration, since the polymers become more lipophilic at higher 
temperatures.80,81 In particular, this sequence of mesophases occurs for EO/PO molar ratios of 0.5 or 
greater.80 Meanwhile, the hexagonal phase is the first mesophase (cubic phase disappears) for more 
hydrophobic Pluronics having an EO/PO ratio of 0.25 and the lamellar phase appears first for ratios of 
approximately 0.15.80 Furthermore, Pluronic micelles are typically spherical in shape for those 
polymers with 40% PEO content and above82; meanwhile, Pluronics with approximately 30% PEO 
form cylindrical/rod-like aggregates.82 Those polymers containing up to 20% PEO, or having a low 
cloud point form bilayers or lamellar aggregates.80,82 Spherical micelles can also transition to cylindrical 
micelles at increased temperatures, even at dilute concentrations (for example, P85 forms cylindrical 
micelles at 70-85°C for concentrations less than 1% w/w/).80 Finally, another important characteristic 
of aqueous Pluronic solutions for pharmaceutical applications is the ability to form gels at appropriate 
concentrations and temperatures. However, this only applies to Pluronics with a PPO molar mass of at 
least 1750.80 The crystalline mesophase regions have generally coincided with the gel formation regions 
of Pluronics in water.80 
Water-insoluble compounds, for example drugs, can be solubilized into the PPO core of Pluronic 
aggregates in order to increase the solubility, metabolic stability, and circulation time of the compound. 
Therefore, Pluronics have been under investigation as drug delivery carriers and formulation aids for 




Currently, five Pluronics (listed as poloxamers) are listed in the FDA Inactive Ingredient Database: 
Pluronic L44 (poloxamer 124), F68 (poloxamer 188), L101 (poloxamer 331), F127 (poloxamer 407), 
and L62 (poloxamer 182).86 Overall, Pluronic block copolymers are generally regarded as non-toxic 
for all routes of administration except intravenous injection.87 Early metabolic studies using a single 
intravenous injection of F38 in rats showed 94% was excreted in the urine and 6% in feces within 3 
days, with no breakdown of the polymer, as indicated by the presence of only the parent compound in 
the urine.88 In addition, longer retention in organs was observed after intravenous administration for 
more hydrophobic Pluronics with longer PPO blocks, and Pluronic plasma concentrations remained 
high for dozens of hours, which suggests recirculation of the copolymer in blood and organs.89 Despite 
a lack of metabolic change to the material, histologic lesions were observed in liver, lungs, and kidneys, 
which are generally attributed to the surface activity of the polymer.87 Nonetheless, Pluronic F68 
currently appears in intravenous injection formulations approved by the FDA.86 Although Pluronic 
toxicity by other routes of administration have been assessed, this discussion was limited to a brief 
summary of studies using the intravenous route. The reader is referred to an early discussion presented 
by Rodriguez and Singer, which includes summaries of acute toxicity studies conducted by the 
manufacturers of various polymers.87 
Pluronics are also known to act as biological response modifiers in both drug and gene therapy 
applications, capable of overcoming multidrug resistance in cancer cells and altering cellular membrane 
integrity, nuclear transport, and transcription (discussed in Section 1.4.1). While Pluronic micelles have 
proved useful as drug carriers, the presence of Pluronic unimers is also important since they show 
notable activity at the cellular level. 
1.4.1 Pluronic Properties Contribute to Improved Transfection 
The addition of Pluronic to various gene delivery systems (both viral and non-viral methods) has been 
associated with significant increases in transgene expression both in vitro and in vivo, examples of 
which will be discussed in further detail throughout this section.  For now, it is worthwhile noting that 
unlike cationic polymers and lipids traditionally used for gene delivery, Pluronics do not bind and 
condense the nucleic acid cargo. This was demonstrated by a lack of observable attractive forces in 
small angle neutron scattering studies of a DNA-L64 Pluronic mixture.90 Additionally, fluorescence 
produced by the intercalation of EtBr with free DNA, and the DNA electrophoretic mobility remain 




presence of Pluronic P85 also did not impede DNA digestion by DNase I.91 Therefore, Pluronics 
generally improve transfection through other modes of action. 
Addition of LentiBOOST reagent (containing Pluronic F108 as the active component) to lentiviral 
transduction of human mesenchymal stem cells produced a significant increase in transduction (gene 
transfer by a virus) to rates greater than 80% gene expression, while cell viability remained high and 
transduced cells maintained their ability to differentiate into hematopoietic lineages.92 It is thought that 
use of the reagent below the CMC increases fusion between the vector and cell membranes.92 Further, 
this improvement was achieved with the use of low amounts of viral vector, which could improve the 
cost of production and overall safety of this method.92 
The temperature sensitivity and ability of some Pluronics to form gels, have also been exploited to 
enhance the physical properties of gene delivery formulations. For example, adenoviral vectors used 
for gene delivery in vascular smooth muscle cells showed increased transfection efficiencies owing to 
the formation of a Pluronic gel under the conditions of the transfection experiment which acts as a 
reservoir for the virus, leading to high vector concentrations in the area surrounding the cells and the 
opportunity for reduced incubation times.93  This combination also had the added advantages of vector 
specificity (which remained unchanged with the introduction of Pluronic), and no specific tissue 
toxicity even with concentrations of copolymer as high as 20% w/v.93 More recently, F127 was added 
to a non-viral, gemini surfactant/lipid formulation as a gelling agent for noninvasive pDNA delivery in 
the vaginal cavity of rabbits.94 The thermogelling properties introduced by F127 allowed for easy 
handling and administration at room temperature and reduced leakage from the vaginal cavity for 
increased the residence time of the pDNA-loaded nanoparticles.94 
1.4.1.1 Pluronics Provide Formulation Stability and Stealth  
Owing to the presence of PEG (or PEO) chains in the Pluronic structure, addition of Pluronics to 
gene delivery formulations can enhance vector stability in solution and under physiological conditions.  
For example, conjugation of P85 to cationic poly{N-[N-(2 -aminoethyl)-2-aminoethyl] aspartamide 
(P85-b-P[Asp(DET)]) produced samples that did not show any aggregation, even for those with close-
to-neutral zeta potentials and had low polydispersity in dynamic light scattering measurements taken 
over 12 hours at physiological salt concentration.95 Also, addition of F68, as an alternative stabilizer to 




nanoparticles created smaller diameters and more narrow size distributions.74 These F68-containing 
nanoparticles showed greater internalization and transgene expression than those containing Tween 80 
(possibly due to F68 interactions with the cell membrane, as discussed later).74 
In the presence of 10 – 50% fetal bovine serum, addition of Pluronic to PEI-DNA complexes showed 
a notable increase in the in vitro transfection efficiency of the complexes, which was considered to be 
due to the steric barrier introduced by the Pluronics.96 This serum-stabilization was associated with 
Pluronics that have a high hydrophilic-lipophilic balance (HLB) value, such as F127 (HLB = 22), F68 
(HLB = 29), and P105 (HLB = 15).96 Similarly, addition of Pluronic P123 to a pDNA delivery vector 
consisting of Pluronic L92 conjugated to poly[2-(dimethylamino)ethyl methacrylate] (L92-
pDMAEMA) resulted in increased transfection and a reduction in the serum-mediated inhibition of 
transfection, even at P123 concentrations as low as 0.005%.97 Hemolysis measurements also showed 
F127-PEI had better blood compatibility than PEI, which is also promising for in vivo stability.98 
Even the encapsulation of a recombinant adeno-associated viral gene carrier in Pluronic F68 micelles 
prevented neutralization by a viral capsid-specific antibody and potentially allowed for more interaction 
with cell membranes by shielding of the negatively charged rAAV surface by the PEO chains.99 
1.4.1.2 Pluronics Interact with Lipid Membranes 
As previously mentioned, PEGylation of vectors is known to enhance colloidal stability and reduces 
recognition by the reticuloendothelial system; however, this method presents a dilemma as the PEG 
layer can reduce interactions with cells and hinder cellular uptake and the improved stability of these 
nanoparticles can reduce opportunities for membrane fusion that are necessary for endosomal escape.33 
While the PEG chains of the Pluronic structure can provide some of the benefits of PEGylation, the 
Pluronic’s amphiphilic nature offers an advantage for cellular uptake via PPO-cell membrane 
interactions. This was demonstrated by higher transfection efficiencies of P85-b-P[Asp(DET)] 
(mentioned above) compared to the PEG conjugate (PEG-b-P[Asp(DET)]) in both the MDA-MB-231 
human breast cancer cell line and A549 human lung cancer cell line, which was attributed to greater 
cell membrane interactions (within 30 minutes) and more efficient cellular uptake and accumulation 
within 24 hours.95  
Several reports have suggested Pluronics contribute to enhanced transfection efficiency 




plasma membrane which enhances uptake of the nucleic acid, or through surfactant activity in the 
endosome which allows for escape from degradation. Electrical measurements with model lipid 
membranes showed Pluronic L64 induces formation of ionic channels with discrete conductance levels 
similar to that of biological channels, and these structures are transiently stable in the open state for 
several seconds.90 Interestingly, pore formation was also observed for low L64 concentrations (less than 
10 µg/mL).90 It is hypothesized that once a threshold polymer concentration is reached at the membrane 
surface, a change in the local membrane curvature is induced, and small-angle X-ray scattering suggests 
the Pluronics fold so that the hydrophobic PPO region is anchored in the lipid bilayer and the 
hydrophilic PEO chains protrude out from the membrane (on the same side of the bilayer).90,100  
However, these Pluronic effects appear to be structure-dependent as well as dependent on cell type.101 
PPO chain lengths that approximate that of the acyl chain region of the bilayer (requires approximately 
39 PO units) create strong anchoring of the polymer to the membrane with the PPO block spanning the 
length of the bilayer and the PEO chains normal to the membrane surface; whereas shorter PPO blocks 
have poorer integration and create the more flat PEO chain orientation previously described for L64.100  
According to molecular dynamics simulations, long PEO chains in the Pluronic structure anchor to the 
polar head group region of the lipid bilayer of dipalmitoylphosphatidylcholine (DPPC) model 
membranes, and provide temporary stabilization to the membrane structure through interactions with 
several lipid molecules.102 In contrast, short PEO chains quickly pull the lipid head groups internally, 
causing membrane instability, leading to bending of the membrane and increased permeability, which 
is consistent with erythrocyte haemolysis assays that show hemoglobin release occurs earlier for 
Pluronics with short PEO chains.102 Hydrophobic interactions between the lipid acyl tails and the central 
PPO block of the Pluronic structure are said to stabilize the membrane structure and keep the two 
leaflets together.102 The oxygen atom in the PO units can also interact with the polar head groups of the 
lipids of the other leaflet (the leaflet not in direct contact with the PEO), which can also contribute to 
membrane bending.102 These computational simulations are also consistent with observations of the 
Pluronic influence on lipid flip-flop activity of liposomes where decreases in the PEO chain length (of 
Pluronics with equal PPO lengths) increased lipid flip-flop between the liposome inner and outer 
leaflets, whereas flip-flop activity increased with growth of the central hydrophobic PPO block.103  
In addition to the PPO length, the overall HLB of the Pluronics also influences membrane 
permeability. In bovine brain microvessel endothelial cells, hydrophilic polymers with HLB > 20 (e.g. 




solidification, showed limited cellular internalization and intracellular accumulation that was limited to 
endocytic compartments.104 Conversely, Pluronics with PPO blocks of intermediate length and an HLB 
< 20 (L64, P85, L81, and P105) fluidized cell membranes by incorporating into them. This group of 
polymers also spread into the cytoplasm, even reaching the nucleus in some cases, and also fluidized 
mitochondrial membranes.104 Hydrophobic polymers with a short PPO block (e.g. L35 and L43), 
adhered to cell membranes, spread into the cytoplasm easily and reached the nucleus, but did not appear 
to impact the mitochondria.104 Meanwhile, owing to a large PPO block and short PEO chains, 
hydrophobic Pluronics such as L121 and L101 caused the highest plasma membrane fluidization.104,105 
However, these polymers tend to anchor into the plasma membrane and remain localized in endocytic 
compartments, which suggests an ability to fluidize plasma membranes but not intracellular 
membranes.104 It is also important to note that the relationships between Pluronic structure and 
membrane binding and fluidization can also influence cell viability; cytotoxicity in Caco-2 and HMEC-
I cell lines was related to the polymer’s ability to form ion traversable pores in cell membranes.105 
Pluronic interactions with cell membranes also vary depending on the cell type, which has been 
attributed to differences in membrane composition. For example, mouse myeloma cells show a greater 
accumulation of Pluronic and decrease in membrane microviscosity compared to splenocytes and 
erythrocytes which adsorb most of the polymers to their surface and show an increase in membrane 
microviscosity.101 Tumor cells are known to have less cholesterol content and a larger amount of 
unsaturated fatty acids, which both increase membrane fluidity (decrease membrane microviscosity), 
and may account for the variations in Pluronic interaction with different cells types.106 Addition of 
phosphatidic acid to phosphotidylcholine liposomes led to a decrease in the microviscosity of the 
bilayer, which favoured the incorporation of Pluronic L61 and subsequent membrane destabilization 
by the polymer.106 Correspondingly, increases in membrane microviscosity by addition of cholesterol, 
ganglioside GM1, or phosphatidylethanolamine (to a lesser extent) reduced Pluronic binding and 
suppressed the Pluronic-induced acceleration of lipid flip-flop and reduced membrane permeability.106 
In another example, treatment of cells with Pluronic L64 two hours after transfection with PEI/pDNA 
did not influence cellular uptake but demonstrated increased survival of the internalized pDNA by 
accelerated escape from the endosome.51 Based on co-localization of fluorescently labeled lysosomes, 




pathways (clathrin-mediated and caveolin-mediated endocytosis), it was concluded that L64 increased 
the permeability of the endosome/lysosomes, which facilitated the escape of PEI and DNA.51 
1.4.1.3 Pluronics Act as Biological Response Modifiers 
Pluronic binding to cell membranes not only influences cellular uptake and distribution, but has also 
been shown to improve transfection through activation of cell signaling pathways involved in cellular 
uptake and nuclear transport of DNA containing specific elements.  
Co-administration of pDNA with Pluronic P85 or a L61/F127 mixture (known as SP1017) by 
intramuscular injection in mice increased transgene expression up to 20-fold (with the P85 formulation, 
1-day post-injection) compared to injection of the naked pDNA.91 P85-formulation of the pDNA also 
resulted in prolonged transgene expression.91 However, there was no evidence of binding and 
condensing the pDNA, nor did the Pluronic protect the DNA against degradation.91 Instead, the ability 
of P85 to enhance gene expression depended on the type of promoter controlling the gene of interest.91 
Most notably, a cytomegalovirus (CMV) promoter, or a basic promoter element (TATA-box) and an 
inducible cis-enhancer element responding to either NF-κB or p53 transcription factors produced a 20-
, 8-, and 21-fold increase in gene expression 24 hours after injection, respectively.91 Conversely, other 
promoters (e.g. SV40), which lack an NF-κB binding site, did not produce a statistically significant 
increase in expression.91 A similar selectivity toward promoters containing stress response elements 
(e.g. CMV promoter) causing upregulated transgene expression was also observed with i.m. injection 
of pDNA formulated with SP1017 (a mixture of 0.25% Pluronic L61 and 2% Pluronic F127)91, as well 
as in vitro with stably transfected mouse myoblasts treated with either P85 or L64107, or administration 
of P123 following polyethyleneimine-based polyplex transfection.57 The promoter-selectivity, along 
with a lack of response to Pluronic in athymic nude mice91, and evidence of IκB-α phosphorylation in 
treated cells suggest Pluronics act as biological response modifiers in transfection through activation of 
the NF-κB signaling pathway.57,91,107 NF-κB is known as a key regulator in inflammation, and a range 
of inflammatory diseases, where it is essential in transcriptional activation of pro-inflammatory 
cytokines, cell proliferation, and cell survival, and has also been shown to participate in oncogenesis 
and regulation of programmed cell death. 108,109 Hence, targeting and exploiting NF-κB has emerged in 
a number of gene therapy approaches.108 
The Pluronic is thought to interact with the cell plasma membrane which leads to the rapid 




binding site in the cytosol, and transport it to the nucleus through the nuclear import machinery.57,91 
Following transport into the nucleus, activation of the NF-κB signaling pathway by Pluronics is also 
thought to increase transcription.57 Furthermore, NF-κB’s nuclear localization signal has been shown 
to import DNA into the cytoplasm across the cell membrane, which may also account for the enhanced 
transfection efficiency.91 Interestingly, confocal microscopy studies showed Pluronics were not 
transported along with the DNA, but co-localizes with caveolin-1, which may be evidence that NF-κB 
activation by Pluronics occurs through disruption of caveolae.57 
As mentioned, p53 binding sites can also produce an increase in transgene expression in the presence 
of Pluronic P85. Therefore, it is also possible Pluronics activate both transcription factors.91 It is 
noteworthy that despite both transcription factors being involved in inflammatory events, the 
inflammatory responses to Pluronic are reportedly mild and generally no cytotoxic effects are observed 
in cell lines.57  
Although Pluronics have generally displayed transfection-enhancing effects as biological response 
modifiers, it is also important to note that the opposite effect can occur under certain conditions. For 
example, P85 is known to have an ATP-depletion effect, which may inhibit DNA uptake by 
endocytosis, a process which requires energy through ATP.91 
In summary, previous investigations show that Pluronics, or at least those with the appropriate 
structural properties, are capable of increasing transfection efficiencies by creating pores in the cellular 
membrane, activating signaling pathways within the cell to enhance DNA internalization, trafficking, 
and expression within the cell, and/or possibly by acting as a surfactant within the endosome to induce 
membrane disruption and DNA release. 
1.5 Mixed Surfactant Systems Provide Opportunities for Optimized 
Performance 
As previously mentioned, surfactant systems consisting of two (or more) surfactants in solution can 
introduce new properties that would not be possible for either component on its own; it essentially 
provides an opportunity to optimize the surfactant performance in a particular application. For example, 
introduction of an ionic surfactant to a non-ionic surfactant system results in an increase in (or complete 
elimination of) the cloud point of the nonionic component, as a result of mixed micelle formation.3 This 




solvent conditions (e.g. added electrolytes and high temperature) in which neither component would be 
effective alone.3 
1.5.1 Mixed Micelle Theories Characterize Surfactant Mixing Behaviours 
Mixtures containing two or more surfactants in solution can result in mixed micelle formation; 
however, the nature of the final mixed aggregates depends on the surfactants present and the 
interactions occurring between them. The stability of mixed micelles has been estimated by a number 
of different models, which typically take a molecular thermodynamics approach, a phenomenological 
approach, or a combination of both.110,111 Thermodynamic characterizations based on the pseudo-phase 
separation model (which considers micelles as separate but soluble phase that appears when the 
surfactant concentration reaches the CMC, and is in equilibrium with monomers in the bulk) requires 
experimental determination of the mixed micelle composition. However, in some cases this parameter 
cannot be directly measured.110,111 Therefore, phenomenological models of micellization (also based on 
the pseudo-phase separation model) can be applied, which will be the focus of the discussion from this 
point on. 
In an “ideal” mixed micelle scenario, there is no net interaction between the surfactant molecules, 
which usually occurs with nonionic surfactants or in the case of both surfactants possessing the same 
polar head group but have different hydrophobic chain lengths.9,112 The concentration (CMCideal) 
corresponding to mixed micelle formation of a surfactant mixture (at particular mole fractions of each 
surfactant) is reflected by the average of the CMC values of the individual components, as seen in 
Equation 1.5-1 where α1 is the mole fraction of surfactant 1 in the solution (often referred to as Clint’s 
model).9 According to Motomura et al., the mixed micelle composition of the ideal systems would be 













  Equation 1.5-2 
The greater the difference in the CMCs of the two surfactants, the more dramatic the changes in the 
CMC of the mixture and the mixed micelle composition as the solution composition is varied.  
In real systems (as opposed to ideal), mixtures consisting of different surfactant types tend to have 




repulsion, counterion binding, and steric interactions.112 For example, mixtures of a cationic and an 
anionic surfactant are expected to have strong electrostatic attraction between the oppositely charged 
head groups.9 In the case of ionic and nonionic surfactant mixtures, the presence of the nonionic 
surfactant within a mixed micelle is thought to reduce the repulsion between ionic surfactant head 
groups, which would also contribute to an overall net interaction between the two components.9 
Therefore, activity coefficients (fi) of each component, i, in the micelle are introduced to Equation 1.5-3 









  Equation 1.5-3 
 
According to Rubingh’s mixed micelle theory (based on regular solution theory, RST), the activity 
coefficients can be related to an interaction parameter, β, as represented in Equation 1.5-4 and Equation 
1.5-5.113 
𝑙𝑛𝑓1 = 𝛽(𝑋2)
2 = 𝛽(1 − 𝑋1)
2 Equation 1.5-4 
𝑙𝑛𝑓2 = 𝛽(𝑋1)
2   Equation 1.5-5 
X1 and X2 in the above equations are the mole fractions of surfactants 1 and 2, respectively, within the 
resulting mixed micelles at the CMC of the mixed system. Rubingh’s interaction parameter (β), 
characterizes a mixed micellar system’s deviation from ideal (zero net interactions) mixing, or in 
other words quantifies the nature and strength of the molecular interactions between surfactants 





   Equation 1.5-6 
 
where w11 and w22 are the interaction energies between the surfactant molecules of the same kind within 
the pure surfactant micelles, w12 is the interaction energy between the unlike surfactant molecules 
within in the mixed micelles.112,113 NA is Avogadro’s number, R is the gas constant, and T is temperature 
in the above equation.  
In order to allow one to calculate the interaction parameter from experimental CMC data of mixed 










2    Equation 1.5-7 
A negative β value indicates a net attraction (synergism) between the surfactants; meanwhile, a 
positive β value means there is net repulsion (antagonism). For true synergism, |β| > |ln(C1/C2)|.10 A 
value of zero indicates no net interactions. The magnitude of β signifies the strength of the interaction, 
where a larger magnitude indicates stronger interactions. Therefore, as seen from Equation 1.5-6, a 
large negative β value suggests the interaction between the two different surfactants in the mixed 
micelles is stronger than the interaction within the pure micelles, and the mixed micelles are 
stabilized.112  
Once the actual CMC of the mixture is known (determined experimentally), X1 is calculated through 











= 1  Equation 1.5-8 
The X1 value can then be compared to the calculated Xideal to give further description of the mixed 
micelles in comparison to the ideal mixing state. For X1 < Xideal, the mixed micelles are said to be 
enriched with component 2 (poor in component 1); meanwhile, X1 > Xideal indicates the mixed 
micelles are enriched with component 1. Contrary to the ideal systems, as the CMCs of the individual 
surfactants get less similar, the micellar composition becomes less sensitive to variations in the 
interaction parameter.9 
Using the X1 value, the excess free energy of micellization can then be calculated according to 
Equation 1.5-9. 
∆𝐺𝑒𝑥 = 𝑅𝑇[𝑋1𝑙𝑛𝑓1 + (1 − 𝑋1)𝑙𝑛𝑓2]  Equation 1.5-9 
In turn, the above calculated parameters can also be used to estimate the monomer concentration in 
the bulk (C1
m and C2
m) and the mixed micelle composition (X1) at a surfactant concentration above the 








   Equation 1.5-10 
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   Equation 1.5-12 
where ∆ =  𝑓2𝐶𝑀𝐶2 − 𝑓1𝐶𝑀𝐶1 and C is the total surfactant concentration of the mixture. At high 
concentrations above the CMC, the mixed micelle composition approaches that of the bulk mixture.  
Typically, the largest experimentally determined β magnitude is found with mixtures of an anionic 
and cationic surfactant, giving β values of -20 or less.114 Mixtures of a monovalent ionic surfactant with 
a nonionic surfactant are usually much smaller, between -1 to -5, and mixtures of two non-ionic 
surfactants are usually quite small (-1 < β < 0).114 Synergism can also be reduced (β becomes less 
negative) by steric effects due to either an increase in the size of the hydrophilic head group (or 
branching near the head group) or due to branching in the hydrophobic group.10 Examples of 
antagonistic mixing (i.e. greater repulsion or small attractions between the two components after mixing 
than before mixing) include i) anionic-anionic surfactant mixtures, or ii) mixtures of hydrocarbon-chain 
surfactants with perfluorocarbon-chain surfactants having the same charge type.10  
It is important to note there have been some criticisms of applying regular solution theory to describe 
non-ideal mixed micelles, therefore these approaches should only be considered as useful empirical 
models.112 For example, RST assumes the excess entropy of mixing is zero, but for some mixtures, β 
has been found to vary depending on the solution composition. In this case, the assumption of zero 
excess entropy of mixing is invalid.2 The theoretical development of Rubingh’s non-ideal mixed 
micelle model also did not include the effect of counterion binding in surfactant mixtures involving 
ionic surfactants.113 However, some ionic-nonionic surfactant mixtures show agreement between the 
predicted the experimental CMC data, which implies the deviation from ideality caused by the effect 
of counterion binding is either small, or is accounted for in the activity coefficients.113  
Additionally, in the absence of salt or combination of ionic surfactants, the interaction parameter, β, 
determined by Rubingh’s RST approach is dependent on the micelle composition, and only considers 
long-range electric interactions.115 For high ionic strength solutions, the electrostatic interactions are 
short-range since there is sufficient shielding of the electrostatic repulsions around each charged site; 
therefore, β is assumed to be independent of micelle composition.115 However, with medium ionic 
strength long-range electric interactions are no longer negligible (although the solution’s ionic strength 
is independent of micelle composition), and for low ionic strength solutions, the ionic strength varies 
significantly with the micelle composition.115 More recently, Maeda described the thermodynamic 




surfactant mole fraction within the mixed micelle (XION). As seen below, Maeda’s theory (Equation 
1.5-13), takes both the hydrophobic chain-chain and electrostatic interactions into account.116  Once B2 
is determined through the relationship B2 = -β, where β is Rubingh’s interaction parameter, Maeda’s 
B1 parameter can be calculated as shown below. B1 represents the free energy change associated with 
the replacement of a non-ionic monomer within a non-ionic micelle with an ionic monomer, which 
involves short-range interactions between the hydrophobic chains and between the head groups.116 
Negative values of 𝐵1 indicate an important contribution by the hydrophobic chain interactions, which 
is typically seen with hydrocarbon tail dissimilarity between the components.116  
∆𝐺𝑀𝑎𝑒𝑑𝑎 =  𝑅𝑇(𝐵0  +  𝐵1𝑋𝐼𝑂𝑁  +  𝐵2𝑋𝐼𝑂𝑁
2 )  Equation 1.5-13 
B0 = 𝑙𝑛 𝐶𝑀𝐶𝐼𝑂𝑁 
𝐵2 = -β, where β is the interaction parameter from Rubingh’s theory 
𝐵1 = 𝑙𝑛 (
𝐶𝑀𝐶𝑁𝑂𝑁
𝐶𝑀𝐶𝐼𝑂𝑁
) + 𝐵2 
 
Despite their limitations, the above theories and equations continue to be applied as tools to help 
describe and quantify the non-ideal mixing behaviours of mixed surfactant systems in the literature. In 
particular, the β value provides a quantitative description of mixed micelle systems, and a way to 
compare different surfactant pairs.2 For example, as discussed in Section 1.3.1, characterizations of 
gemini surfactant/DOPE mixtures previously reported by the Wettig lab used Clint’s, Motomura’s and 
Rubingh’s mixed micelle theories.72 Likewise, descriptions of gemini surfactant and Pluronic mixed 
micelle systems using these models will be summarized in Section 1.5.4 and the non-ideal mixing 
behaviour of pDNA/16-3-16/Pluronic systems investigated in this work will also be described 
according to Rubingh’s and Maeda’s theories in Chapter 3. 
1.5.2 Surfactant-Polymer Interactions 
Similar to mixed surfactant systems, surfactant-polymer mixtures also have the potential to improve 
the properties of a formulation compared to what either component would achieve when used alone.117 
Consequently, many surfactant-based formulations, for example in pharmaceutical, cosmetic, and 
detergency applications, also include a water-soluble polymer.117 Therefore, it is important to 




such mixtures as it can provide valuable insights into how these systems work and may be helpful in 
designing mixtures to achieve more desirable properties.117 Accordingly, understanding the self-
assembled Pluronic/16-3-16/pDNA transfection nanoparticles discussed in this work requires 
consideration of the interactions occurring within these mixtures. Existing literature describing the 
interactions between the dicationic gemini surfactants interactions with plasmid DNA, and gemini 
surfactant interactions with Pluronic block copolymers are discussed later on in this section. 
The same forces controlling the solution and interfacial properties of single-amphiphile systems are 
also responsible for surfactant-polymer interactions, and the nature of the polymer and surfactant will 
determine the relative importance of each interaction type (i.e. van der Waals forces, dipolar 
interactions, electrostatic interactions, and hydrophobic effect).3 The interactions are further 
complicated by the aggregation properties of the polymer and order of addition (for example, addition 
of the polymer into a micellar surfactant solution).  
Surfactant-polymer interactions can occur as complexes formed between the polymer chain and a 
surfactant micelle or other aggregate structure (e.g. pre-micellar aggregates, liquid crystals, or 
bicontinuous phases) or between individual surfactant molecules and the polymer resulting in direct 
formation of micelles along the polymer chain.3 Typically, the addition of surfactant to a solution of 
free polymer chains in water results in surfactant micellization below the surfactant’s CMC.3 This 
concentration is often referred to as the critical aggregate concentration (CAC), which is the surfactant 
concentration corresponding to the onset of surfactant molecules binding to the polymer.3,4 Depending 
on the nature of the polymer and surfactant, the CAC can be lower than the CMC by a factor of 10 to 
1000 in some cases.3 This significant difference in CAC vs. CMC values can be attributed to 
stabilization of the aggregates provided by the polymer.3 Upon addition of polymer to a surfactant 
solution already containing micelles or other aggregate structures, polymer adsorption onto or into the 
aggregates may be expected.3 
Anionic surfactant interactions with nonionic polymers such as polyvinyl pyrrolidone or 
polyethylene glycol, are expected to rely on van der Waals forces and hydrophobic interactions. Of 
course, the hydrophobic effect would depend on the polymer’s ability to undergo hydrogen bonding 
with water, as well as the availability of nonpolar sites along the polymer chain.3 When hydrophobic 
interactions are the primary mechanism, these would occur between the surfactant tail and the polymer 




between ionic surfactant head groups and the resulting polymer-surfactant aggregates resemble a string 
of pearls.3 This complex acts similar to a polyelectrolyte in solution, where addition of a salt would 
neutralize the electrostatic repulsions and allow the chain to collapse or contract.3  
Not surprisingly, interactions between surfactants and polymers of the same charge are usually 
minimal (due to electrostatic repulsions that would inhibit any non-electrostatic attractions), especially 
for polymers with a relatively uniform charge distribution along the chain.3 Nevertheless, if the charges 
happen to be concentrated in specific regions along the chain, there may still be an opportunity for 
hydrophobic interactions in the non-ionized regions.3 
Interactions between surfactants and polymers of opposite charge occur predominantly through 
electrostatic attraction, and are considered co-operative due to hydrophobic interactions between the 
surfactant molecules.3,118 Initially, the surfactants “coat” the charged sites of the polymer chain through 
electrostatic interaction with the surfactant headgroup, creating a “hairy worm” appearance.3 With the 
hydrophobic chains projecting outward and free to interact, seed regions along the chain can form and 
the addition of more surfactant molecules leads to polymer-associated micelles.3 The initial electrostatic 
binding also leads to collapse of the ionic polymer coil (as seen in Figure 1.5-1) and a decrease in 
solubility and eventually precipitation due to charge neutralization.3 With high surfactant binding, both 
the surfactant’s charged head group and hydrophobic tail are involved in binding.3 Eventually, a 






1.5.3 Surfactant-DNA Interactions  
Surfactant-DNA complexes often exist in aqueous solution (which is the focus of this work), but can 
also be prepared as thermotropic liquid crystals, and bulk films.119 Aside from their application in gene 
delivery, surfactant-DNA complexes can also be exploited for a large number of purposes such as: drug 
delivery vehicles or depots in vivo, scaffolds for DNA-templated reactions and functionalization of 
nucleic acids, scaffolds for fluorescence resonance energy transfer, prevention of concentration 
Figure 1.5-1  Expanded and collapsed coil configurations of a charged polymer (e.g. protein) 




quenching of fluorescent dyes, or even incorporation into optoelectronic devices like OLEDs and solar 
cells.119  
Cationic surfactant interactions with DNA are similar to polyelectrolyte-oppositely charged 
surfactant systems, where the DNA can be considered as an amphiphilic polyanion. These interactions 
result in compaction of DNA and reduction of its charge, which is important for non-viral gene therapy 
applications (as discussed above). 
Early studies found that a single DNA molecule undergoes a discrete transition between an elongated 
coil state and compacted globule state (plus a coexistence region) with the addition of 
cetyltrimethylammonium bromide (CTAB) in solution.120 Binding of the surfactants to the DNA 
molecule is primarily through electrostatic attraction, occurring below the CMC of the surfactant.118   
This is supported by findings that addition of salt increases the CAC of DNA-cationic surfactant 
systems in solution.118 In addition, 23Na NMR showed displacement of sodium with surfactant binding, 
which implies the cationic surfactants replace sodium as the DNA counterions, and likewise, DNA 
replaces the anionic counterions of the cationic surfactants.118  
DNA-cationic surfactant interactions are highly co-operative, according to binding isotherms that 
show a sigmoidal shape.118 The binding mechanism is similar to that described in surfactant-polymer 
systems (above). Following individual surfactant binding to DNA through electrostatic interactions, the 
complex becomes stabilized through hydrophobic interactions118,120. Formation of DNA-associated 
surfactant micelles through hydrophobic interactions between surfactant molecules occurs once a 
sufficient surfactant concentration is reached.118 These micelles then act as multivalent ions and induce 
compaction through electrostatic attraction to different areas of the DNA chain.118  
1.5.3.1 Surfactant structure influences interactions with DNA 
Surfactants with a larger alkyl chain length induce DNA compaction at a much lower concentration 
compared to those with a shorter alkyl chain (e.g. 8.0 vs. 80 μM for CTAB versus dodecyl-
trimethylammonium bromide (DTAB), respectively).118 Further, according to force-measuring optical 
tweezer studies, short-chain surfactants, such as octyl-trimethylammonium bromide (OTAB) do not 
induce condensation, likely due to an ability to “lie down” on the DNA surface and interact directly 




aliphatic tail length, for example DTAB, promote DNA condensation through inter-molecular 
interactions between hydrophobic tails, which likely orient away from the DNA surface.121  
In addition to hydrophobic chain lengths, alterations in the surfactant head groups can also impact 
the compaction efficiency. For instance, modification of the head group region that increases the 
hydrophobicity of the surfactant (e.g. addition of an aromatic ring between the head group and tail) will 
increase the surfactant’s efficiency in compacting DNA. This effect is similar to that seen with 
increasing the hydrophobic tail of the surfactant, resulting in decreases in both the CMC and CAC.118 
Increased valency of a surfactant’s polar head group also increase compaction efficiency.118,122 
Alternatively, increasing the surfactant hydrophilicity, for example by introduction of hydroxyl 
substituents in the CTAB headgroup, preserved the EtBr access to the DNA to a significantly larger 
extent.118 This result is thought to be due to surfactant packing effects that increase the curvature of the 
aggregates, on account of the increased effective size of the polar headgroup (based on presence of 
bulkier groups and also due to increased hydration of a more polar group), producing smaller and more 
globular micelles on the surfactant-DNA complex as opposed to the typical rod-like CTAB micelles.118 
This increased curvature of surfactant aggregates likely produce less efficient, patch-like coverage of 
the DNA, which allows for EtBr binding.118  
DNA compaction efficiency can also be enhanced by use of cationic gemini surfactants. Introduction 
of a second alkyl tail improves the hydrophobic tail interactions that are important for compaction. In 
fluorescence microscopy studies of bacteriophage T4 DNA interaction with gemini surfactants of 
varying architecture, DNA globules were detected at a much lower surfactant concentration (almost 
two orders of magnitude) with the 12-3-12 gemini surfactant compared to its divalent, single-tail 
equivalent 12-3-1.122 As previously discussed, spacer length also influences compaction efficiency with 
either short (s < 4) or long (s > 10) spacers showing the highest DNA compaction efficiency.122 This 
trend also appears to correspond to the trends in the observed CMCs of the 12-s-12 series studied, where 
the minimum in DNA compaction corresponds to the maximum CMC value in this gemini surfactant 
series.118,122 This effect is thought to be due to greater flexibility as the spacer length increases, and 
presumably the conformation is restricted upon interaction with the DNA, which leads to a loss of 
entropy.118,122 However, with further increases beyond s=10, the spacer becomes long enough to 




to decreases in the CMC values and increases in the surfactant’s DNA compaction efficiency once 
again.118,122 
In general, the structure of surfactant and oppositely charged polyelectrolyte complexes is dictated 
by that of the pure surfactant aggregates in solution, given that the polymer is sufficiently flexible to 
adapt to the surfactant’s structure.118 However, in the case of DNA as the polyelectrolyte, this may not 
be possible – although the surfactant aggregate structure does not necessarily need to deviate 
significantly from the structures they form on their own.118 Hence, the rod-like structures of CTAB 
aggregates are slightly distorted in order to match with the phosphate groups on the DNA.118 Overall, 
the CTAB/DNA complex shows a hexagonal structure (HI), which can be described as hexagonally-
arranged cylindrical micelles surrounded by DNA rods.118,123,124 As the surfactant alkyl tail length 
decreases (for example, in DTAB), the aggregates, and therefore the DNA-surfactant complexes, 
become more spherical and less ordered.118 For surfactants that form lamellar structures, the DNA will 
reside in the water region between two lamellar bilayers.118  
Since surfactant-mediated DNA compaction relies on surfactant self-assembly, the compaction can 
be controlled or reversed.118 Decompaction/decondensation can be induced with the addition of non-
ionic or anionic surfactants, liposomes, polymers, or salts.52,118,125,126 The interaction between the 
surfactants is more favourable than the surfactant-DNA interactions.118 The addition of cylcodextrins 
can also decondense the surfactant-DNA complex through formation of inclusion complexes with the 
surfactant hydrophobic chains and increase steric hindrance inside the complex.125 However, unlike 
addition of an anionic surfactant such as sodium dodecyl sulfate, this mechanism does not result in 
complete release of the surfactant from the DNA.125  
Important for the work presented here, Pluronics have also demonstrated the ability to dissociate 
gemini surfactant/DNA complexes.127 Similar to other anionic or non-ionic surfactant-mediated DNA 
decompaction, the 12-3-12 gemini surfactant shows preferential interaction with Pluronic P123 
micelles.127 As the gemini surfactant is added into a Pluronic/DNA solution (note these two components 
don’t show any significant interaction), EtBr binding to the DNA appears uninterrupted.127 Gemini-
DNA complex formation is hindered until the Pluronic/gemini aggregates are saturated with gemini 
surfactant.127 Further addition of the gemini surfactant then leads to gemini-DNA binding, and a 
reduction in the EtBr-DNA intercalation.127 With the addition of Pluronic to gemini surfactant/DNA 




first results in Pluronic binding of free gemini surfactant in the bulk, which disrupts the thermodynamic 
equilibrium between DNA-bound and free surfactant in solution, leading to release of surfactant from 
the DNA into the bulk.127 As more Pluronic is added, more 12-3-12/P123 complexes are formed and 
the DNA is eventually decondensed.127 
1.5.4 Gemini Surfactants and Pluronics Show Non-Ideal Mixing Behaviour 
In terms of surfactant-Pluronic interactions specifically, there are many studies in the literature 
reporting the interaction between Pluronic block copolymers and ionic surfactants (either traditional or 
gemini structures), as well as how changes to either molecular structure influences the interactions. For 
the purposes of relating to the work presented in this thesis, the following discussion focuses only on 
quaternary ammonium surfactants. 
Early studies of the monomeric cationic quaternary ammonium surfactant (essentially half a gemini 
surfactant), tetradecyltrimethylammonium bromide, TTAB, with Pluronic F127 showed the 
interactions between the surfactant and polymer somewhat vary according to the aggregation state of 
the polymer. In the presence of unassociated F127 monomers in solution, the TTAB molecules bind to 
the polymer and form micelle-like aggregates which grow during a co-operative binding process.79 This 
is the result of hydrophobic interaction where the methyl group of the PO units are in direct contact 
with the surfactant micelle palisade layer where the hydrophobic groups are in contact with water, 
which is thought to remove water from the micellar surface and also possibly from the hydrated parts 
of the polymer.79 In the presence of F127 micelles, the surfactant initially binds to the micelles, forming 
F127/TTAB mixed aggregates (which are relatively stable according to constant light scattering 
intensities).79 However, these mixed aggregates eventually break down into smaller mixed aggregates 
as F127 monomers are released into solution and the aggregates become richer in TTAB content.79 This 
effect is likely due to destabilization of the mixed aggregate by electrostatic repulsions between TTAB 
headgroups.79 Just before all the F127 micelles are dissociated into monomers, the added TTAB 
simultaneously begins binding to the F127 monomers in solution.79 This continues until all F127 
micelles are dissociated and the F127 monomers become saturated with TTAB.79 At this point, further 
addition of TTAB will form free TTAB micelles.79 Differential scanning calorimetry studies also 
revealed that small amounts of TTAB reduce the CMT of F127, as a result of F127-rich mixed micelle 





CTAB and TTAB have also demonstrated synergistic interactions (according Rubingh’s theory) with 
Pluronic-like triblock copolymers having the structures (EO)18(PO)31(EO)18 and (EO)2(PO)15.5(EO)2, 
which resulted in mixed micelles rich in the polymer component rather than the surfactant 
component.128 The synergism observed was attributed to favourable reduction of the electrostatic 
repulsion between surfactant headgroups by intercalation of the copolymers in the mixed micelles.128 
However, differences in these interactions were observed based on the chemical structures of each 
component. Specifically, in comparison to the TTAB mixtures, the CTAB mixtures had stronger 
interactions with the triblock copolymers, likely due to stronger hydrophobicity imparted by a longer 
alkyl chain.128 Greater synergism was also observed for the copolymer possessing longer PEO chains, 
which was attributed to more effective reductions in surfactant headgroup repulsion.128   
The gemini surfactant and Pluronic mixtures previously studied indicate non-ideal mixing between 
these materials that are more complex than the interactions observed with traditional surfactant 
structures. The net interactions observed in these systems and the strength of these interactions are 
dictated by changes to the molecular structure of either component. Unfavourable (antagonistic) mixing 
behaviours were observed in mixtures of 12-2-12, 14-2-14, and 16-2-16 gemini surfactants with 
Pluronics of varying hydrophobicity (based on PEO/PPO ratio), as indicated by micellization occurring 
at surfactant concentrations higher than the expected ideal.129 This effect was thought to be due to 
differences in hydrophobicity of the two materials.129 The mixed micelles were determined to have a 
greater presence of Pluronic; however, the gemini surfactants have stronger hydrophobicity than the 
Pluronics (demonstrated by comparisons of the micropolarity of the pure components).129 Therefore, 
an increased amount of Pluronic in the mixed state is thought to weaken the hydrophobic environment 
of the mixed state, leading to de-mixing of the components.129 This effect appears greater with 
increasing hydrophilicity of the block copolymer.129 In contrast, increases to the tail length of the gemini 
surfactant are said to strengthen the hydrophobic environment of the Pluronic-rich mixed micelles, 
leading to weaker antagonism.129 The antagonism observed in these systems is consistent with other 
gemini surfactant – Pluronic interactions that consider the Pluronic as a neutral polymer rather than a 
nonionic surfactant.129,130 In general, titration of gemini surfactant into a monomeric Pluronic solution 
(at a concentration and temperature below the copolymer’s CMC or CMT, respectively) results in 
formation of gemini aggregates on or near the hydrophobic region of free Pluronic monomers.130,131 
This process results in a steep endothermic increase in the enthalpy, which is likely a result of 




of more or larger aggregates, until electrostatic repulsion between the gemini headgroups hinders this 
process and further addition of gemini at this point leads to the formation of free gemini micelles.130 
When the copolymer is present at concentrations above its CMC, two endothermic process are 
observed.130 Copolymer micelles and copolymer micelle clusters are initially present; however, the 
presence of even a small amount of gemini surfactant breaks down the Pluronic micelle clusters.130 
Further addition of gemini leads to swelling of the Pluronic micelles as the gemini enters the 
hydrophobic core of the polymer micelles.130 This is also accompanied by release of Pluronic monomers 
and formation of smaller sized mixed micelles due to an equilibrium of the hydrophobic interactions 
between the two components and electrostatic repulsion between the gemini surfactant 
headgroups.130,131 Eventually, the unassociated Pluronic monomers form mixed aggregates with the 
gemini.130 In the presence of both Pluronic monomers and micelles (e.g. at the CMT), the gemini 
surfactant alkyl tails penetrate the Pluronic micelle hydrophobic core, leading to gemini/Pluronic mixed 
micelle formation.131 As seen with micellar Pluronic solutions, further addition of the gemini surfactant 
destabilizes the mixed micelles due to electrostatic repulsion between the gemini head groups, leads to 
smaller mixed micelles consisting of gemini surfactant as the richer component in the aggregate, and 
releases Pluronic monomers into the solution (as depicted in Figure 1.5-2).131 Added gemini surfactant 
begins to bind the free monomers until saturation is reached, and free gemini surfactant micelles 
form.131 As previously mentioned, the nature of the Pluronic has some influence on these events; 
addition of 12-6-12 to monomer and micellar F127 (solution temperature = CMT) proceeds to gradual 
breakdown into small mixed micelles (as described) and eventually dissociation into F127 monomers 
and 12-6-12 micelles, whereas with P123 the gemini surfactant does not completely dissociate the 





Contrary to the interactions summarized above, binary mixtures of L64 with either 10-2-10, 12-2-
12, or 14-2-14 cationic gemini surfactants are reported to show synergistic mixing behaviour.132 
Nonetheless, similar to previous reports, mixing became more favourable with increased gemini 
surfactant tail length.132 Overall, the synergism was attributed to greater hydrophobic effect and reduced 
electrostatic repulsion on account of intercalation of the Pluronic PEO chains between the cationic 
gemini headgroups in the mixed micelle stern layer.132 This is also consistent with the increased specific 
conductance measured during the titration of gemini surfactant into copolymers solutions; Pluronic 
interaction at the surface of gemini surfactant micelles was thought to disrupt the binding of counterion 
(bromide ions in this case) to the surfactant headgroups, and result in the release of additional bromide 
ions into solution, and thus an increase in conductance.133 Fluorescence studies also revealed a decrease 
in the polarity of the micelles, which also suggests the copolymer interacts at the surface and palisade 
layer of the micelle, and displaces hydration water (which also provides further explanation of the 
increase in conductance).133 These effects did not appear to be influenced by changes in headgroup size 
from 12-3-12 to 12-6-12 surfactant structures, but greater interactions appeared for the more 
hydrophobic P103 versus F108 and F68.133  
Figure 1.5-2  Schematic depiction of mixed aggregate formation during titration of cationic gemini 
surfactant into monomeric and micellar Pluronic block copolymer solutions (under different 







In another study by Bakshi and Sachar, F127/12-2-12 and P103/12-2-12 mixed micelles were also 
determined to form through synergistic interactions.110 In both cases, the mixed micelles were said to 
be enriched with the gemini component, but synergism was stronger for the F127 systems over P103.110 
Increased synergism was attributed to the larger PEO chains of F127 that would be expected to provide 
more effective reduction of electrostatic repulsion between cationic gemini headgroups by introducing 
more hydration into the stern layer.110 (However, this theory conflicts with the fluorescence studies 
previously reported in the literature). Increasing the temperature from 21 to 40°C also induced greater 
synergism through dehydration of the Pluronic PPO blocks, thus enhancing hydrophobic interactions.110 
Furthermore, notable differences in the mixing interactions of F127 and P103 polymers were 
highlighted due to the overall hydrophobicity of the Pluronic component when mixed with monomeric 
(dodecyl-, tetradecyl-, or hexadecyltrimethylammonium bromide) and dimeric (m-2-m, where m = 10, 
12, 14, or 16) cationic surfactant series. All F127 mixtures showed synergistic mixing interactions and 
the calculated mixed micelle mole fractions indicated a greater amount of the cationic surfactant 
component over the F127 component in all cases.134 Although all the interaction parameters were 
negative, the average parameter values pass through a broad maximum with increasing length of the 
hydrocarbon chain, which was seen for both types (monomeric and dimeric) of surfactants.134 However, 
the synergism was stronger for the monomeric surfactant mixtures compared to those containing 
dimeric (gemini) surfactants.134 While synergism was attributed to neutralization of the electrostatic 
repulsion between the surfactant polar head groups, it was suggested that replacement of a monomeric 
head group for a dimeric one introduces steric hindrance in the stern layer of the mixed micelle, causing 
a reduction in the synergism.134 In contrast, the dimeric (gemini) surfactants resulted in greater 
synergism compared to the monomeric surfactants for P103 mixtures.134 The difference in trends in 
comparing the interaction parameter of F127 versus P103 mixtures was expected to be due to the 
increased hydrophobicity of P103, where mixed micelle formation would be favourable due to 
hydrophobic interactions.134 Accordingly, these hydrophobic interactions would be stronger for the 
dimeric surfactants compared to the monomeric counterparts.134 In addition, synergism increased with 
increasing carbon tail lengths (on account of greater surfactant hydrophobicity), shifting from 
antagonism (positive interaction parameter values) for P103/10-2-10 and P103/12-2-/12 to synergism 
(negative values) for P103/14-2-14 and P103/16-2-16 mixtures.134 Correspondingly, the monomeric 
surfactants show antagonistic mixing (positive interaction parameters) with Pluronic P103.134 The 




mixtures with monomeric surfactants, indicating the mixed micelles are expected to be equally 
occupied by both components; meanwhile, the P103/dimeric surfactant mixtures produced surfactant-







Project Aims, Hypothesis, and Objectives 
2.1 Combining Pluronics and Gemini Surfactants Builds on Rational Vector 
Design 
The use of helper lipids can be expensive, and in the absence of significant energy input (such as from 
ultrasonication or high pressure homogenization) the liposomes are inconsistently sized, which can 
pose a problem for predicting the pharmacokinetics of the delivery system. Gemini/DOPE/DNA 
lipoplexes also show decreased membrane integrity leading to increased sensitivity to DNase 
degradation over time.72 Furthermore, the presence of serum has been known to inhibit transfection of 
gemini/DOPE systems, which raises concerns for future applications in systemic delivery.135 As an 
alternative, addition of biocompatible Pluronics to a gemini surfactant gene delivery formulation is 
expected to provide stealth for i.v. administration in vivo, colloidal stability for storage, and enhance 
transfection activity through biological membrane interactions and activation of signaling pathways 
that aid in cellular uptake, nuclear localization, and transcription (as discussed above in previous 
formulations). Incorporating Pluronics in the gene delivery formulation also provides an opportunity 
for tissue-targeted delivery, since the Pluronic terminal hydroxyl groups can be functionalized with 
targeting molecules that become part of the ethylene oxide corona. Meanwhile, use of a dicationic 
gemini surfactant can condense the DNA, provide an overall positive charge to the nanoparticle 
(depending on the ratios used) for electrostatic interaction with cells, and possibly endosomal 
membrane disruption.  
The potential for improved transfection efficiencies by combining gemini surfactants and Pluronics 
motivated a preliminary investigation using national formulary-grade Pluronics (L44, F68, F87, F108, 
and F127) in combination with the 16-3-16 gemini surfactant, which was reported by Dr. Shawn 
Wettig’s research group (School of Pharmacy, University of Waterloo, Canada). In this study, human 
ovarian adenocarcinoma (OVCAR-3) cells were transfected in vitro with nanoparticles consisting of 
varying Pluronic concentrations and N+/P- charge ratios; however, the transfection efficiency was lower 
than that of the commercial positive control, Lipofectamine 2000 but cell viability was higher for the 
novel formulations compared to the control.73 Most nanoparticles showed appropriate particle sizes 




5:1 and 10:1).73 Despite the benefits that gemini surfactant and Pluronic block copolymers bring to 
pDNA transfection when used separately, the combination of these two materials together in a single 
formulation did not have a synergistic effect. However, these novel nanoparticle formulations showed 
the ability to transfect cells, which is a promising result, but further optimization is likely needed. Next 
steps could involve testing more charge ratios, Pluronic concentrations, order of mixing, surface 
functionalization, use of different gemini surfactant structures, different Pluronic block copolymers, 
and so on. Alternatively, a deeper understanding of the interactions between the components in these 
formulations that could be influencing the transfection efficiencies seen in vitro may be informative in 
helping to steer future optimization efforts. 
 
2.2 Project Aims 
The work presented here focuses on the influence of Pluronic block copolymer’s molecular structure; 
specifically, how it influences the mixing behaviour when combined with the 16-3-16/pDNA complex, 
and whether these mixing behaviours are related to in vitro transfection efficiency to potentially identify 
a new set of criteria for screening these transfection systems and choose a more appropriate combination 
(e.g. a different Pluronic) if necessary. Additionally, the presence of DNA has the potential to alter 
these interactions; therefore, DNA was included in the characterizations reported in this work.  
 
2.3 Hypothesis 
The interaction between Pluronics and a pre-formed 16-3-16/pDNA complex are expected to be 
synergistic, which increases in strength with higher PO content and PEO chain lengths of the Pluronic 
structure. The interaction parameter values for the complete Pluronic/16-3-16/pDNA mixtures are 
hypothesized to correlate with transfection efficiency. In particular, as synergism within the 







1) Determine the micellization properties of the pre-formed 16-3-16/pDNA complex (N+/P- = 10:1) 
in aqueous solution 
2) Investigate the interaction between Pluronics and the 16-3-16/pDNA complex, and the influence 
of the Pluronic composition (such as PPO length, PEO length, and hydrophobicity) on the mixing 
interaction 
(i) Determine the interaction parameters of Pluronic/16-3-16/pDNA mixtures with Pluronics F87 
P84, L121, F127, P103, and L44 
(ii) Investigate the effect of each Pluronic on the condensed state of the 16-3-16/pDNA complex 
3) Determine whether there is a relationship between these interactions and the in vitro transfection 
efficiency of these formulations 
(i) Characterize pDNA-loaded nanoparticles by size and zeta potential 







Cationic Gemini Surfactant – Plasmid Deoxyribonucleic Acid 
Condensates as a Single Amphiphilic Entity 
Adapted with permission from 136. Copyright (2018) American Chemical Society.  
3.1 Abstract 
A critical aggregate concentration for the surfactant-DNA “complex” or “condensate” consisting of the 
16-3-16 gemini surfactant and circular plasmid DNA was determined using surface tensiometry, 
dynamic light scattering and conductometry. This surfactant-DNA complex acts as an amphiphile itself, 
for example, decreasing the surface tension of water until a critical concentration is reached. The 
evidence presented here introduces a new way of thinking about these surfactant-DNA condensates – 
not simply as aggregates in solution, but as surface active agents in their own right. At concentrations 
below the critical aggregate concentration, there is some dissociation of surfactant molecules from the 
condensate, creating a more “loose” or “relaxed” complex; however, at and above the critical aggregate 
concentration, the surfactant-DNA system forms smaller and more uniformly distributed condensates 
once again. This behavior is analogous to the demicellization/micellization that occurs in typical 
surfactant systems. 
3.2 Introduction 
Use of various gemini surfactants in gene therapy applications continues as a topic of significant 
investigation. Of course, the interaction of deoxyribonucleic acid (DNA) with gemini surfactants is a 
complimentary topic of interest which has been the subject of many recent investigations and reviews 
over the past decade.65,67,117,125,137–147 Gemini surfactants are known to complex with DNA, eventually 
collapsing and condensing the DNA into globules of smaller size that can enter cells more easily. In 
general, the interaction of cationic surfactants with DNA has been equated to that seen in systems of 
surfactants with oppositely charged polyelectrolytes.117,118,121,148–150 Cationic gemini surfactants are 
thought to initially bind to the negatively charged DNA chains through electrostatic interaction.125 
Much like the interaction of cationic surfactants with anionic polymers, this binding is reported to occur 
well below the critical micelle concentration (CMC) of the surfactant.118 Surfactants with sufficiently 




surfactant molecules may then form micelle-like aggregates through hydrophobic interactions between 
their hydrocarbon tails, creating nucleation centres that DNA can wrap around to form a densely 
packed, or “bead-like”, structure.125 This compaction can be reversed to dissociate the DNA molecule 
from the surfactant (whether mono- or di-cationic) using a decrease in temperature or pH, or the 
addition of various reagents such as sodium dodecyl sulfate125,151 or other anionic surfactants151, 
cyclodextrin125,152,153, nonionic surfactants127, monovalent salts120, synthetic polyacids126, nucleotides.120 
Depending on the reagent used, varying levels of decompaction and different final DNA conformations 
are obtained.125  
Unlike previous studies where DNA is titrated into a surfactant solution or vice versa, we treated the 
already formed surfactant-DNA complex as a single entity and titrated into a known volume of water. 
The gemini surfactant N,N’-bis(dimethylhexadecyl)-1,3-propanediammonium dibromide, commonly 
known as 16-3-16 (having 16-carbon tails and a 3-carbon spacer between two quaternary amine 
headgroups), was used to condense the pVGtel.RL plasmid DNA at a (N+/P-) charge ratio of 10:1. Here 
we introduce evidence that the final gemini surfactant-DNA complex or condensate (16-3-16/pDNA) 
acts as a single amphiphilic entity in physicochemical studies where an abrupt change in the physical 
properties of a solution is observed at a critical concentration (referred to here as the critical aggregate 
concentration, CAC). 
3.3 Materials 
The 16-3-16 gemini surfactant was synthesized in our lab as described in previous work.154,155 The 
plasmid, pVG.telRL156, was extracted from DH5α cells (a gift from Dr. Roderick Slavcev, School of 
Pharmacy, University of Waterloo, Canada) using an Omega Bio-tek E.Z.N.A. Plasmid DNA Maxi Kit 
and HyClone HyPure Molecular Biology Grade Water for elution. Ultrapure MilliQ water (Millipore) 
was used for all sample preparations and experiments. Purified plasmid DNA concentration was 
measured by UV-Visible light absorbance at 260 nm using a Thermo Scientific NanoDrop 2000 
spectrophotometer, and the pDNA sample was accepted as “pure” for DNA (vs. RNA) for absorbance 
ratios at 260 nm and 280 nm (260/280) of ~ 1.8. Isolation of the pVG.telRL plasmid was confirmed by 
restriction enzyme digestion with HindIII followed by gel electrophoresis on 1.2% agarose gel to 





3.4.1 16-3-16/pDNA complex preparation 
16-3-16/pDNA complexes were prepared in water by mixing a 0.1 mM aqueous solution of 16-3-
16with an appropriate volume of the pDNA solution to achieve a charge ratio of 10:1 (N+/P-). These 2 
components were allowed to incubate for 15 minutes in a water bath (Fisher Scientific Isotemp® GPD 
10) set to 25°C. The 16-3-16 solution was filtered using a 0.22 µm polyethersulfone (PES) syringe filter 
(Sartorius) before use. 
3.4.2 Critical concentration determination by tensiometry 
Surface tension measurements were performed at room temperature using the Wilhelmy plate method 
with a KSV NIMA surface tension balance (KSV NIMA/Biolin Scientific, Finland). The plate was 
thoroughly cleaned and flame dried until glowing red before each experiment. The 16-3-16/pDNA 
condensate solution was titrated into 60 mL of Ultrapure MilliQ water (re-filtered using a 0.22 µm PES 
syringe filter before use). The solution was allowed to equilibrate (with magnetic stirring) for 5 minutes 
before measurement. All critical concentration determinations were carried out in triplicate. 
In each CAC experiment, the surface tension was plotted against the logarithm of the total amphiphile 
concentration (moles of 16-3-16 + moles of pDNA per litre). The CAC of the mixture was identified 
by the point of intersection of the linear trendlines before and after the first breakpoint in these plots. 
3.4.3 Critical concentration determination by dynamic light scattering 
Size and intensity measurements were carried out using a Malvern Zetasizer Nano ZS equipped with 
an MPT-2 Autotitrator connected to a quartz flow cell (Malvern Instruments, UK). The sample 
container was prepared with an initial 10 mL of Ultrapure MilliQ water (re-filtered using a 0.22 µm 
PES syringe filter before use). 20 additions of the 16-3-16/pDNA complex (in a single titrant container) 
were made to reach a final concentration of 6 µM final surfactant concentration, with the sample 
recirculated between repeat measurements. Three measurements were taken per concentration at a 




3.4.4 Critical concentration determination by conductivity 
Conductivity measurements were performed in a double-walled glass cell (Fisher Scientific, USA) 
connected to an RE304 circulating water bath (Lauda, Germany) set to 25°C. The 16-3-16/pDNA 
complex was titrated into 30 mL Ultrapure water (re-filtered using a 0.22 µm PES syringe filter before 
use). The solution stirred for 5 minutes before conductivity was measured. For each concentration point, 
three measurements were taken by rinsing the electrode between each measurement. The average 
conductivity of the solution was plotted against the logarithm of the total amphiphile concentration of 
the solution. The data was then fit to Equation 3.4-1 following the method presented by Carpena et 
al.157:  
𝜅 =  𝜅0 + 𝐴1𝑐 + ∆𝑥(𝐴2 − 𝐴1)𝑙𝑛 (
1+𝑒(𝑐−𝑐𝑚𝑐)/∆𝑥
1−𝑒−𝑐𝑚𝑐/∆𝑥
)  Equation 3.4-1 
where κ0 is the conductivity at concentration = 0, and A1 and A2 are the slopes at low (pre-CAC) and 
high concentrations (post-CAC), respectively. ∆x is a constant representing the width of the CAC 
transition region. The CAC was indicated by x0.  
The conductivity experiments were performed in triplicate. 
3.5 Results 
3.5.1 Tensiometry 
As seen in Table 3.5-1 the CAC determined from surface tension studies was 4.5 ± 1.5 µM. Figure 
3.5-1 shows a plot of surface tension vs. log concentration (of total amphiphile added) during titration 
of 16-3-16/pDNA condensates into water. There is a steep decrease in surface tension as the 16-3-
16/pDNA mixture is added to water, followed by a clear breakpoint or transition region leading to a 
plateau where the surface tension is minimally affected by further addition of the 16-3-16/pDNA. From 
these plots, we are able to gather a critical concentration value, much like that of a pure surfactant 
sample. (Surface excess concentration and molecular area calculations from the tensiometry 





Table 3.5-1  Average critical aggregate concentration values from triplicate measurements using each 
method – tensiometry, dynamic light scattering and conductometry  
CAC (µM) ± SD (n = 3) Method 
4.5 ± 1.5   Tensiometry 
1.7 ± 0.6 Dynamic Light Scattering 
31 ± 1 Conductometry 
3.5.2 Dynamic Light Scattering 
Likewise, in dynamic light scattering (DLS) measurements there is a sudden change (increase) in the 
intensity of the scattered light once the CAC is reached through titration of the condensate solution into 
water (Figure 3.5-2). At concentrations below the CAC the scattering intensities are approximately 




constant and near that of the UltraPure water. After the CAC the intensity increases linearly with the 
addition of more condensate solution. Using DLS, the CAC of 16-3-16/pDNA was found at 1.7 ± 0.6 

















Additionally, we see a sudden change in the hydrodynamic radius of the condensates around the 
CAC. Initially at low concentrations, the sizes are large and more heterogeneous (larger polydispersity 
index values), as seen in Figure 3.5-3. After the CAC, we see the size of the condensates is 
approximately 150nm, which remains constant with further addition of the condensate solution. Size 
measurements of the condensate stock solution reveal a hydrodynamic diameter of 150nm (data not 
shown).  
Figure 3.5-2  Scattered light intensity (left axis, ●) and Z-average hydrodynamic diameter (right axis, ○) 




The g1 correlation functions shown in Figure 3.5-4 start with an intercept of 0.35 following the first 
titration of the condensate solutions (red line), which trends upward approaching 1.0 with increasing 
concentration. At the start of titration, these correlation functions also have lower rates of decay (red, 
green and blue lines, corresponding to concentrations below the CAC) that increase as more 16-3-
16/pDNA is added to the sample. This rate of decay is eventually unchanged by increasing 





Figure 3.5-3  Mean Z-average hydrodynamic diameter (left axis, ○) and polydispersity index 





















The titration of the 16-3-16/pDNA mixture into water results in a steady increase in the conductivity of 
the solution, eventually followed by a decrease in the slope of the conductivity vs. concentration curve 
(Figure 3.5-1). Again, the break in the conductivity plot, where the change of slope begins, represents 
the 16-3-16/pDNA CAC. Our conductivity studies indicate a CAC of 31 ± 1 µM. 
↑concentration 











CAC values from all three methods discussed here are reported in Table 3.5-1. The CACs obtained 
from all three methods reported here are in very good agreement. Of course, CMC or CAC values vary 
in numerical value depending on the method used, sometimes by an order of magnitude.3 Even with 
pure surfactant systems, a precise CMC value can be somewhat arbitrary considering experimentally, 
micellization is observed as a transition over a concentration range.3,158 Although the CACs determined 
from tensiometry and DLS are close in number, the conductivity results are within an order of 
magnitude and are considered to be at an acceptable level of agreement with the others.  
In this study, we see typical plot shapes for each method (tensiometry, dynamic light scattering and 
conductometry) that would be expected in typical CMC determinations of a single amphiphile3,157,159,160 




despite the use of surfactant/pDNA condensates. Typical CMC experiments start with a concentrated 
solution where the amphiphile is in micellar/aggregated form which then gets diluted to monomers 
upon titration into a volume of water. As more of the amphiphile is titrated in, the amphiphile monomers 
eventually aggregate again into micelles at a threshold concentration known as the critical micelle 
concentration, which is detected by a sudden physical change.  
 In this case, our amphiphile in question is the 16-3-16/pDNA condensate. It is unlikely that all 16-
3-16 molecules completely dissociate from the plasmid DNA; however, there may be some dissociation 
or re-organization of the looser, hydrophobically-bound surfactant molecules (as depicted in Figure 
3.6-1(A). Based on our dynamic light scattering results we expect that the condensates from our 16-3-
16/pDNA stock solution become larger and have a more “relaxed” or dynamic structure upon titration 
into water (as suggested by the larger particle sizes at concentrations below the CAC). The g1 
correlation function intercepts in Figure 3.5-4 show good signal to noise ratios (greater than 0.2)160, 
which gives further confirmation that the hydrodynamic diameter measurements obtained, even at low 
concentrations below the CAC, correspond to the presence of aggregate structures such as surfactant-
DNA condensates rather than free monomers in solution. Moreover, the slower rates of decay in the 
correlation functions for c < CAC indicate the presence of large particles in solution.160,161 In this 
concentration range, we also see a steady increase in the conductivity of the solution (similar to typical 
micellization studies of a pure surfactant system). This is due to an increase in the number of charge 
carriers as the condensate solution is added to the sample. Again, we believe this is an indication of an 
initial incomplete dissociation of the condensates giving rise to some free surfactant molecules upon 
dilution (at the start of titration, c < CAC), which contributes to free surfactant ions (and counterions) 
in the bulk phase that increase the conductivity of the solution.  
Once the CAC is reached, the condensates re-form into their tightly-bound state (Figure 3.6-1B) and 
any additional condensates added from our stock remain in their condensed form (as seen by the smaller 
and more uniform particle sizes at concentrations above the CAC). With increasing 16-3-16/pDNA 
concentration, the intercepts of the correlation functions increase, which indicates the growing presence 
of condensates in the solution as titration continues. The rates of decay also increase, which is consistent 
with a change from large, “relaxed” particles to smaller, “condensed” particles. Eventually the rates of 
decay remain constant near and post-CAC, perhaps confirming any additional condensates added after 




determinations of block copolymers, like that described by Topel, et al).160 Typically, in conductivity 
studies of ionic surfactant micellization, addition of surfactant beyond the CMC increases the 
concentration of micelles which are larger and less efficient charge carriers (they diffuse through the 
solution slower), while the monomer concentration remains approximately unchanged. Hence, a 
decreased slope is observed in the conductivity vs. concentration plot. This change in slope is normally 
due to a decrease in either the number of or the mobility of the ions present. However, the DLS data 
for the 16-3-16/pDNA system does not provide evidence for the formation of larger aggregates beyond 
the CAC (in fact, it suggests a decrease in size, as discussed previously). Therefore, we hypothesize the 
trends observed through conductivity are solely due to a change in the number of free charge carriers 
(surfactant monomers and counterions) in solution rather than the size of the charged surfactant-DNA 
aggregates. When the 16-3-16/pDNA condensates reform into their condensed form at the CAC, this 
results in less charge carriers (surfactant ions) free in solution.  
In the surface tension measurements for concentrations below the CAC, there is a steady decrease, 
which is due to the condensates and free surfactant molecules associating at the water surface. Above 
the CAC, there is no longer a change in surface tension, likely indicating the surface is saturated with 
condensates. Previous surface tension studies, by Zhao et al., involving the titration of gemini surfactant 
into a DNA solution, reported increased surface tensions compared to the pure surfactant and suggest 
this is due to the formation of surface-inactive complexes in the bulk phase.138 However, our results 
clearly show the surfactant-pDNA complex is in fact surface-active. Furthermore, the condensates 
reduce the surface tension of water to a greater extent than the 16-3-16 surfactant alone158, indicating 
synergism between the two components.138,162 So, our observations are more consistent with those 
reported by Vongsetskul et al., who acknowledged decreases in surface tension for 12-6-12/DNA 
mixtures began at much lower concentrations than in the pure surfactant system.150  In the same report, 
neutron reflectometry studies showed the presence of DNA enhanced the surface adsorption of the 12-
6-12 surfactant and with higher concentrations of surfactant, thick structured layers were formed (which 
are thicker than the gemini surfactant monolayer on its own).150 However,  it should be noted that these 
earlier reports150 (and others88,113,114) involve a fixed concentration of DNA with increasing 





We propose that the pre-formed surfactant/pDNA condensates do not completely break up into their 
monomers upon dilution; rather, they become less compact below a threshold concentration (the CAC) 
determined here, and eventually re-form into their condensed state post-CAC. Despite this atypical 
behavior during titration of these condensates into water, significant changes in the physicochemical 
properties (surface tension, light scattering, and conductivity) of the solution occur at a critical 




aggregate concentration - analogous to a single surfactant system. This proposed behavior of the 
condensates in solution may have valuable implications for the use of gemini surfactant-condensed 
DNA for applications such as gene therapy where there is a requirement for the DNA to remain 
condensed for part of the journey (followed by de-condensation later on for transcription to occur). This 
knowledge might also contribute to many other fields and applications, including: i) DNA purification 
methods where CTAB is often used for precipitation and other cationic surfactants are currently under 
investigated for selective precipitation of various isoforms of plasmid DNA118,165; ii) synthesis of 
functionalized DNA molecules, for example DNA-lipid conjugates, where the DNA-surfactant 
complex overcomes differences in solubility between the hydrophilic DNA and the hydrophobic 
moiety; iii) DNA-surfactant complex-based vehicles or depots for small molecule therapeutics such as 






Mixing Behaviour of Pluronics with Gemini Surfactant/plasmid DNA 
Condensates: Effect of Pluronic Composition 
This chapter is adapted from 166 with permission from the PCCP Owner Societies. 
4.1 Abstract 
Nanoparticles prepared from plasmid DNA (pDNA) and N,N-bis(dimethylhexadecyl)-1,3-
propanediammonium bromide (16-3-16) have been mixed with various Pluronic block copolymers and 
investigated as binary surfactant systems in water using the previously demonstrated critical aggregate 
concentration of the surfactant-DNA complex. Surface tensiometry was used to determine critical 
micelle concentrations of mixed micelle formation within these Pluronic/16-3-16/pDNA mixtures. Use 
of mixed micelle theories reveal mixed micelle composition and the interaction parameter, β, are 
influenced by the structure, in particular hydrophobicity, of the Pluronic component. Ethidium bromide 
fluorescence studies demonstrate the ability of the Pluronics to de-condense the plasmid DNA from the 
cationic 16-3-16 gemini surfactant complex, and shows some relationship to the interaction parameter 
and Pluronic composition. 
4.2 Introduction 
Among the potential uses for dimeric surfactants (also known as gemini surfactants) throughout various 
fields, a significant one is their applicability in non-viral gene therapy formulations. Cationic gemini 
surfactants can be used to complex and condense nucleic acid cargo and, combined with other 
formulation components such as lipids or polymers, can achieve more favourable properties for 
successful delivery to cells. The reader is referred to the following publications and reviews of various 
in vitro and in vivo transfection studies utilizing gemini surfactant-based vehicles.54,62,64,69,167–172 
Gemini surfactants have the structure of two amphiphilic monomers covalently linked at or near their 
polar head group by a spacer.173 A commonly studied series of gemini surfactants is the N,N’-
bis(dimethylalkyl)-alkane-diammonium dibromide series, or “m-s-m” type, where the m in this notation 
refers to the number of carbon atoms in the symmetric alkyl tails, while s refers to the number of atoms 




A popular additive in gene therapy formulations are the neutral block copolymers known as Pluronics 
(BASF Corp.), or under the non-proprietary name “poloxamers”, which have been known to improve 
transfection efficiency in numerous gene delivery systems.76 These polymers have amphiphilic/surface 
active properties themselves, owing to their general structure of a hydrophobic polypropylene oxide 
(PPO) block flanked by two hydrophilic polyethylene oxide (PEO) chains, PEOx– PPOy – PEOx. 
Pluronic unimers adsorb to the air-water interface through the PPO block with the PEO chains 
extending into the aqueous solution.75 Micelles are then formed with polymer concentrations beyond 
the critical micelle concentration (CMC), that consist of a hydrophilic PEO outer shell or corona and a 
weakly hydrated hydrophobic PPO core that can solubilize hydrophobic compounds.76,128 The number 
of EO (ethylene oxide) and PO (propylene oxide) units, represented by x and y, respectively, can be 
varied to form a family of Pluronics with different molecular weights and water-solubility.  
A system combining cationic gemini surfactant and Pluronic holds potential for a gene therapy 
formulation where (sufficient excess of) the gemini surfactant component condenses the nucleic acid 
cargo and provides a positive charge for colloidal stability as well as interaction with biological 
membranes. Meanwhile, the Pluronic component has the potential to increase internalization of the 
cargo and intracellular trafficking as a biological response modifier.176 In vivo, the PEO corona of 
Pluronic micelles also helps to reduce non-specific interactions with blood components and clearance 
from the circulation by the immune system.177 
The interactions between some gemini surfactants and Pluronic block copolymers in solution have 
been the subject of a number of studies reported in the literature. Early studies by Wettig and Verrall 
demonstrated a decrease in micelle polarity which suggested that the polymers interact at the palisade 
layer of the surfactant micelle, resulting in the replacement of hydration water by the polymer, and 
resulting in a release of counterions (supporting the increased specific conductance reported).133 
Furthermore, the surfactant headgroup size had little effect on the interactions in this case; however, 
the greatest interaction was observed for the most hydrophobic of the Pluronics (P103) in the study.133 
Bakshi et al. found unfavourable mixing behaviours between m-2-m (m = 12, 14, 16) gemini surfactants 
and Pluronic block copolymers of varying PEO/PPO ratio, which produced Pluronic-rich mixed 
micelles; however, antagonism was reduced with increased hydrophobicity of the gemini component.129 
In another study, the same group identified synergism within the binary mixtures of L64 with 10-2-10, 




surfactant hydrophobicity (alkyl tail length) and this favourable mixing was attributed to 1) greater 
hydrophobic effects due to increased hydrophobicity and 2) neutralization of the electrostatic repulsion 
between gemini headgroups by intercalation of the L64 PEO chains in the mixed micelles.132 Increases 
in temperature have also been shown to increase synergism owing to dehydration of the PPO block 
which in turn enhances the hydrophobic interaction between Pluronics and gemini surfactants.110 No 
significant differences in micropolarity and aggregation number among the F127 and P103 systems 
were observed due to the mixed micelles being relatively rich in the cationic surfactant component (and 
poor in Pluronic), and temperature having little effect on the electrostatic interactions.110 More recently, 
Wang et al., exploited the critical micelle temperatures (CMT) of Pluronics F127 and P123 to 
differentiate between the interaction of copolymer monomers, micelles, or monomer and micelle 
mixtures with the cationic ammonium 12-6-12 surfactant.131 Below the Pluronic CMT, 12-6-12 binds 
to single copolymer unimers and initiates micelle formation similar to conventional single-chain ionic 
surfactant/copolymer systems; meanwhile, above the CMT 12-6-12 binding to the Pluronic micelles 
forms mixed micelles of smaller size due to an equilibrium of the hydrophobic interactions between the 
two components and electrostatic repulsion between the gemini surfactant headgroups.131 At the 
copolymer CMT, where both Pluronic unimers and micelles are present, addition of 12-6-12 leads to 
mixed 12-6-12/Pluronic micelle formation.131 Further addition of 12-6-16 eventually breaks down the 
mixed micelles into smaller 12-6-12-rich mixed micelles and releases Pluronic unimers. 12-6-12 binds 
the free unimers until saturation, then free 12-6-12 micelles are formed.131 
Given the interest in using these systems for gene therapy applications, here we report on the 
interactions of the 16-3-16 gemini surfactant with various Pluronic polymers in the presence of plasmid 
DNA (pDNA). It was recently demonstrated that the pre-formed complex of plasmid DNA condensed 
by the 16-3-16 gemini surfactant at a charge ratio of 10:1 (N+/P-) can be considered as a single 
amphiphile with its own critical aggregate concentration.136 This assumption was then used to 
investigate the interaction of the 16-3-16/pDNA condensate with six different Pluronic block 
copolymers (F87, P84, L121, F127, P103, and L44) as binary systems using Clint’s, Rubingh’s, 
Motomura’s, and Maeda’s mixed micelle theories. As seen in the literature, Pluronic micellization and 
interactions with ionic surfactants can be influenced by the composition of the Pluronic component. 
Therefore, the interactions reported here were assessed based on the Pluronic propylene oxide (PO) and 




For the purpose of gene therapy, de-condensation of DNA from its cationic surfactant complex by 
the addition of salts, anionic or neutral surfactants is also an important consideration, especially with 
the addition of such materials to the delivery formulation. He et al. reported that DNA compaction by 
the 12-3-12ˑ2Br gemini surfactant can be reversed by sufficient addition of Pluronic P123. This de-
condensation is attributed to a disruption of the equilibrium between DNA-associated surfactant 
aggregates and free surfactants in the bulk phase due to hydrophobic interaction of the block copolymer 
with the free gemini surfactants.127 Therefore, de-condensation of pDNA from the 16-3-16/pDNA 
complex upon the addition of Pluronic at fixed mole fractions was also included in an effort to further 
understand the mixed systems. 
4.3 Materials  
The Pluronic® block copolymers (F87, P84, L121, F127, P103, and L44) were provided as samples 
from BASF Corp. The 16-3-16 gemini surfactant was synthesized in the Wettig lab as described 
previously.154,155 The pVG.telRL plasmid156, was extracted from DH5α cells (provided as a gift from 
Dr. Roderick Slavcev, School of Pharmacy, University of Waterloo, Canada) using an E.Z.N.A. 
Plasmid DNA Maxi Kit (Omega Bio-tek) and HyPure Molecular Biology Grade Water (HyClone) for 
elution. Ultrapure MilliQ water (Millipore) was used for all sample preparations and experiments. 
Plasmid DNA concentrations and purity were measured by UV-Visible light absorbance at 260 nm, 
and the 260 nm/280 nm absorbance ratio using a Thermo Scientific NanoDrop 2000 spectrophotometer. 
Restriction enzyme digestion with HindIII and fragment separation by gel electrophoresis confirmed 
isolation of the pVG.telRL plasmid. The average molecular weight, composition and CMC of each 
























F87 122 40 7700 24 0.43 70 9.1 x10-5 
P84 38 43 4200 14 1.5 40 7.1 x10-5 
L121 10 68 4400 1 9.0 10 1.0 x10-6 
F127 200 65 12600 22 0.43 70 2.8 x10-6 
P103 34 60 4950 9 2.3 30 6.1 x10-6 
L44 20 23 2200 16 1.5 40 3.6 x10-3 
aAverage number of EO and PO units calculated from the average molecular weights, as reported in 
178, rounded to the nearest whole unit   
bAverage molecular weight (MW) provided by the manufacturer (BASF, Corp.) 
cCMCs reported in 178, determined by the pyrene solubilisation technique 
4.4 Methods 
4.4.1 16-3-16/pDNA complex preparation 
16-3-16/pDNA complexes prepared for CMC determination of the complex (without Pluronic) 
consisted of a 0.1 mM 16-3-16 aqueous solution mixed with pDNA (eluted in water) at a charge ratio 
of 10:1 (N+/P-). These 2 components were allowed to incubate for 15 minutes in a water bath set to 
25°C (Isotemp GPD 10, Fisher Scientific). The 16-3-16 solution was filtered using a 0.22 µm PES 
syringe filter (Sartorius) before use. 
4.4.2 Pluronic/16-3-16/pDNA complex preparation 
The 16-3-16 stock solution, Pluronic stock solution, and water were first filtered through a 0.22 µm 
PES syringe filter (Sartorius) prior to use in preparation of the complexes. The pDNA and 16-3-16 
components (along with an appropriate volume of water) were first mixed and allowed to incubate for 




then added to the 16-3-16/pDNA complex and allowed to incubate for 30 minutes in the 25°C water 
bath. 
Pluronic/16-3-16/pDNA mixtures were prepared with 0.1 mM 16-3-16 and Pluronic stocks with 
concentrations equal to approximately 35 times the Pluronic CMC (with the exception of the L44 stock 
which was approximately 6 times the L44 CMC, see Table 4.3-1). Mixtures containing varying mole 
fractions (αPluronic) of the Pluronic component were prepared while maintaining a total surfactant 
concentration of 8×10-6 M (using an appropriate amount of ultrapure water). For example, for a αF87 = 
0.4 mixture, 1.7×10-7 moles 16-3-16 and 1.1×10-7 moles F87 were used, whereas for αF87 = 0.8, 5.6×10-
8 moles 16-3-16 and 2.2×10-7 moles F87 were used. In each case, an appropriate amount of pDNA was 
added to provide a charge ratio of 10:1 (N+/P-), and an appropriate volume of ultrapure water was added 
to maintain a constant volume and total concentration. Although the moles of pDNA was also 
considered in the total moles of amphiphile during concentration calculations, it did not largely 
contribute to these values as most samples ranged from 10-14 – 10-12 moles of plasmid. 
The F87/16-3-16/pDNA mixture was also prepared at a F87 mole fraction of 0.4 with a 16-3-
16/pDNA charge ratio of 5:1 to briefly demonstrate the effect of pDNA content on the resulting 
interaction parameter. 
4.4.3 CMC determination by Tensiometry 
Surface tension measurements for the F87, F127, P103, and L44 systems were performed using the du 
Noüy ring method with a Lauda TE3 automated Tensiometer (Lauda, Germany). Temperature was 
maintained at 25°C (± 0.05°C) using an RE304 circulating water bath (Lauda, Germany) connected to 
the tensiometer. The ring was thoroughly cleaned with methanol and water then flame dried until 
glowing red before each experiment. A minimum of three successive measurements were performed 
per concentration until a maximum standard deviation of 0.1 mN/m was reached. Each surface tension 
value was corrected using the Harkins-Jordan correction factor.179 Surface tension measurements for 
the P84 and L121 systems were performed at room temperature using the Wilhelmy plate method with 
a KSV NIMA surface tension balance (KSV NIMA/Biolin Scientific, Finland). The plate was 
thoroughly cleaned using ethanol and water and flame-dried until it was glowing red before each 
experiment. In all cases, the 16-3-16/pDNA or Pluronic/16-3-16/pDNA complex was titrated into 60 
mL of Ultrapure MilliQ water (refiltered using a 0.22 μm PES syringe filter before use). The solution 




All CMC measurements were carried out in triplicate. In each CMC experiment, the surface tension 
was plotted against the logarithm of the total amphiphile concentration (moles of 16-3-16 + moles of 
pDNA + moles of Pluronic per liter). The point of intersection of the linear trendlines before and after 
the first breakpoint in these plots was recorded as the critical micelle concentration of the mixture. 
CMC values were also determined for the 16-3-16/pDNA complex and Pluronic alone and conducted 
in the same manner. Investigation of the individual components used 1% F87, 0.0077% L121, 8% P84, 
1% F127, 0.01% P103, 5% and 10% L44 stock solutions, and the 16-3-16/pDNA 10:1 complex 
prepared as previously described. All solutions were used at room temperature during preparation and 
surface tension titration experiments with the exception of L121 solutions which were kept on ice due 
to the low cloud point. 
4.4.4 DNA-Ethidium Bromide Fluorescence 
Fluorescence was detected at 595 nm with an excitation wavelength of 535 nm using a SpectraMax M5 
Multi-Mode Microplate Reader (Molecular Devices, California, USA). A 10 mg/mL ethidium bromide 
(EtBr) solution (Sigma-Aldrich) was diluted to 0.1 mg/mL and added to a 24-well plate (Sigma-
Aldrich) in volumes appropriate for a 1:4 molar ratio of pDNA:EtBr. Each well contained a total volume 
of 0.5 mL and a final amphiphile (16-3-16 + Pluronic) concentration of 5 x 10-4 M, therefore, an 
appropriate volume of ultrapure water was added to keep volume and concentration consistent across 
all wells. Fluorescence from wells containing EtBr + pDNA + water was used as I0. An appropriate 
volume of 1 mM aqueous 16-3-16 solution was added to achieve a charge ratio of 10:1 (N+/P-) between 
16-3-16 and pDNA. The plates were incubated for 15 minutes at room temperature protected from light, 
followed by measurement of fluorescence (giving I1). The Pluronic component was then added at 
desired mole fractions, followed by 30-minute incubation at room temperature in dark conditions and 
subsequent fluorescence reading (I2). Plates containing L121 were incubated at 4°C only after addition 
of the Pluronic to avoid phase separation of L121. Each experiment was carried out in triplicate.  
I2/I0 was normalized by first subtracting I1/I0 to account for remaining fluorescence after gemini 
surfactant condensation of the DNA. 
4.4.5 Transmission Electron Microscopy 
Mixtures were prepared as previously described, at a N+/P- charge ratio of 10:1 and a final amphiphile 




to the centre of a carbon coated 300 mesh copper grid and incubated for 15 seconds before the liquid 
was removed by blotting with filter paper. The sample was then stained with 10 µL of 1% (w/v) 
phosphotungstic acid for 20 seconds, followed by blotting with filter paper to remove excess liquid. 
Prepared grids were air dried overnight and examined with a Philips CM10 transmission electron 
microscope (TEM) in the Department of Biology, University of Waterloo.  
4.4.6 Statistical Analysis 
All statistical analysis was performed using R Studio software. A multiple linear regression analysis 
was used to determine the effect and statistical significance of each of the main independent variables 
on the β interaction parameter value (namely number of PO units, number of EO units, and mole 
fraction). Given the small sample size, two-factor interaction terms were excluded from the regression 
model in order to avoid over-fitting the data. Values of p < 0.05 were considered statistically significant. 
The linear model was checked for conditional homoscedasticity, normality of residuals and 
multicollinearity. 
4.5 Results 
4.5.1 F87/16-3-16/pDNA systems 
Sample plots of surface tension as a function of log concentration of F87/16-3-16/pDNA mixtures (with 
varying mole fractions, α, of F87) are shown in Figure 4.5-1. As concentration increases, each plot 
shows a steep decrease in surface tension followed by a plateau or change in the plot’s slope. For some 
samples, this transition is abrupt and there is a clear breakpoint (e.g. the 16-3-16/pDNA complex 
without Pluronic, α = 0) and for others the transition is more gradual and occurs over a small 
concentration range (e.g. α = 0.4). The intersection of the slopes of the pre- and post-breakpoint regions 







Figure 4.5-1  Plots of surface tension versus total amphiphile for F87/16-3-16/pDNA mixtures with 





Table 4.5-1  Average critical micelle concentrations (CMCexp.) determined by tensiometry, and 
corresponding calculated parameters (CMCideal, Xideal, X1, β, f1, f2, ∆Gex) for mixtures of Pluronic with 
















0 14.5 ± 1.16 - - - - - - - 
0.2 0.83 ± 0.14 17.9 0.009 0.382 -17.8 1.11×10-3 0.074 -10.4 
0.4 0.58 ± 0.10 23.6 0.024 0.412 -18.9 1.44×10-3 0.041 -11.3 
0.6 0.61 ± 0.12 34.3 0.053 0.431 -18.9 2.18×10-3 0.030 -11.5 
0.8 0.53 ± 0.15 63.1 0.129 0.458 -20.6 2.35×10-3 0.013 -12.7 
1 391 ± 96.7 - - - - - - - 
P84 
0 4.47 ± 1.45 - - - - - - - 
0.2 0.43 ± 0.05 5.57 0.002 0.345 -18.1 4.34×10-4 0.116 -10.1 
0.4 0.28 ± 0.10 7.41 0.005 0.378 -19.5 5.30×10-4 0.061 -11.4 
0.6 0.17 ± 0.06 11.0 0.012 0.408 -22.1 4.38×10-4 0.025 -13.2 
0.8 0.20 ± 0.03 21.7 0.031 0.429 -22.4 6.71×10-4 0.016 -13.6 
1 567 ± 71.9 - - - - - - - 
L121 
0 4.47 ± 1.45 - - - - - - - 
0.2 1.56 ± 0.11 1.29 0.769 0.921 1.48 1.01 3.52 0.268 
0.4 0.50 ± 0.16 0.752 0.899 0.729 -2.61 0.826 0.250 -1.28 
0.6 0.29 ± 0.02 0.531 0.952 0.725 -4.52 0.710 0.093 -2.23 
0.8 0.08 ± 0.05 0.411 0.982 0.657 -10.6 0.289 0.010 -5.90 
1 0.34 ± 0.10 - - - - - - - 
F127 
0 14.5 ± 1.16 - - - - - - - 
0.2 1.81 ± 0.18 6.74 0.628 0.535 -5.37 0.314 0.215 -3.31 
0.4 1.41 ± 0.34 4.39 0.818 0.603 -5.28 0.435 0.147 -3.13 
0.6 0.81 ± 0.12 3.26 0.910 0.625 -7.21 0.363 0.060 -4.18 
0.8 0.76 ± 0.22 2.59 0.964 0.667 -7.77 0.423 0.031 -4.28 
1 2.15 ± 1.17 - - - - - - - 
P103 
0 14.5 ± 1.16 - - - - - - - 
0.2 0.65 ± 0.07 0.815 0.955 0.819 -2.42 0.924 0.198 -0.886 
0.4 0.33 ± 0.04 0.420 0.983 0.845 -3.40 0.921 0.089 -1.10 
0.6 0.27 ± 0.01 0.282 0.992 0.962 -1.75 0.997 0.199 -0.158 
0.8 0.17 ± 0.01 0.213 0.997 0.873 -5.22 0.920 0.019 -1.43 
1 0.17 ± 0.02 - - - - - - - 
L44 
0 14.5 ± 1.16 - - - - - - - 
0.2 0.34 ± 0.04 18.1 0.002 0.384 -24.2 1.01×10-4 0.028 -14.2 
0.4 0.32 ± 0.04 24.0 0.006 0.399 -23.3 2.22×10-4 0.024 -13.8 
0.6 0.31 ± 0.03 35.7 0.013 0.417 -24.0 2.92×10-4 0.015 -14.4 
0.8 0.17 ± 0.00 69.9 0.035 0.444 -27.7 1.90×10-4 0.004 -17.0 





Clint’s model for ideal mixed micellar systems (Equation 4.5-1) is used to calculate the ideal CMC 
values of the mixtures (CMCideal), which are reported in Table 4.5-1. CMCideal assumes there is no net 
interaction between the two amphiphiles comprising the micelle/aggregate (i.e. ideal mixing) and its 









   Equation 4.5-1 
Here, α1 is the mole fraction of the Pluronic component in the total amphiphile mixture (bulk), and 
CMC1 and CMC2 are the CMC values of the pure Pluronic and pure 16-3-16/pDNA (10:1) condensate, 
respectively.  
The deviation of CMCexp. from the ideal values can be further characterized using Rubingh’s model, 
based on the regular solution approximation, (Equation 4.5-2) to determine the interaction parameter, 
β.  












2    Equation 4.5-2  
 
𝑋1 and 𝑋2 reflect the composition of the mixed micelle phase, representing the mole fractions of 
amphiphile 1 (in this case, Pluronic) and amphiphile 2 (16-3-16/pDNA condensate), respectively, in 











= 1   Equation 4.5-3 
 
𝑋1 can then be compared to the micelle mole fraction of Pluronic for the ideal state (𝑋𝑖𝑑𝑒𝑎𝑙), which 




   Equation 4.5-4 
 
The β and 𝑋1 values then allow for the calculation of the activity coefficients of the Pluronic 
component (f1) and the 16-3-16/pDNA component (f2), as seen in Equation 4.5-5 and Equation 4.5-6, 
which indicate the contribution of each component in the mixed micelle.  
𝑙𝑛𝑓1 = 𝛽(1 − 𝑋1)





2    Equation 4.5-6 
 
The excess free energy of micellization can be calculated using the activity coefficient for each 
component, as seen in Equation 4.5-7. 
∆𝐺𝑒𝑥 = 𝑅𝑇[𝑋1𝑙𝑛𝑓1 + (1 − 𝑋1)𝑙𝑛𝑓2] Equation 4.5-7 
 
For each mole fraction tested, the CMCexp. of the F87 mixtures are lower than the individual 
components (F87α=1, and α=0), and lower than the corresponding CMCideal (Table 4.5-1 and Figure 
4.5-2A). Therefore, there is a net interaction between F87 and the pre-formed 16-3-16/pDNA 
condensate, which is synergistic in nature. The mixed micelle composition, 𝑋1, remains relatively 
constant (0.38 – 0.46) throughout the range of F87 mole fractions (Table 4.5-1 and Figure 4.5-3A), 
suggesting the mixed micelle compositions are minimally influenced by the bulk solution composition. 
Comparing 𝑋1 to 𝑋𝑖𝑑𝑒𝑎𝑙, there is a positive deviation from the ideal state, which indicates the mixed 
micelles are enriched in the F87 component and poorer in the 16-3-16/pDNA. The interaction 
parameters of all F87 mixtures are negative with large magnitudes (-17.8 to -20.6), indicating strong 
synergism in all cases (Table 4.5-1). The calculated synergistic interactions generally increase with 
increasing F87 mole fraction, however β is unchanged from 0.4 to 0.6 mole fractions.  
All activity coefficients of the F87 mixtures reported in Table 4.5-1 are much less than unity, 
confirming there is non-ideal mixing behaviour of a strongly attractive nature. The negative excess free 
energies of mixing (∆Gex) values indicate the mixed micelles formed from the F87 and 16-3-16/pDNA 





Figure 4.5-2  Calculated ideal CMC (○) and experimentally determined CMC values (▲) for each 
Pluronic/16-3-16/pDNA mixtures at varying Pluronic mole fractions. A) shows F87 mixtures, B) P84, 





Figure 4.5-3  Calculated Xideal (○) and X1 values (▲) for Pluronic/16-3-16/pDNA mixtures at varying 




4.5.2 P84/16-3-16/pDNA systems 
Similar to the F87 system, there is a clear indication of synergistic interactions between P84 and the 
pre-formed 16-3-16/pDNA condensate within each mixture shown. The experimentally determined 
CMCs of the P84 mixtures were much lower than the expected ideal CMCs (for all mole fractions of 
P84 investigated), and much lower than the individual P84 and 16-3-16/pDNA components (as seen in 
Figure 4.5-2B, and Table 4.5-1). (Surface tension plots for the P84 mixtures are shown in Figure 4.5-4). 
The mole fraction of P84 in the bulk solution appears to have little effect on the composition of the 
mixed micelles, which lies within a narrow range (𝑋1 = 0.345 and 𝑋1=0.429 for αP84=0.2 and αP84=0.8, 
respectively). There is also a much larger presence of the P84 component than the 16-3-16/pDNA 
component within the mixed micelles compared to the ideal state (𝑋1 > 𝑋𝑖𝑑𝑒𝑎𝑙) for all mole fractions 
(Figure 4.5-3B). Rubingh’s interaction parameter, β, confirms there are synergistic interactions within 
the P84/16-3-16/pDNA mixtures for all mole fractions of P84. Furthermore, the large magnitudes (18.1- 
22.4) indicate not only is there synergism within the system, there is strong synergism, which grows 
with increasing mole fractions of P84.The activity coefficients of all P84 systems investigated are also 
less than 1, again indicative of a synergistic interaction between P84 and 16-3-16/pDNA. As with the 
F87 systems reported above, the ∆Gex values are negative suggesting the P84/16-3-16/pDNA mixed 
micelles are more stable than the pure micelles. 
Figure 4.5-4  Plots of surface tension versus total amphiphile for P84/16-3-16/pDNA mixtures with 





4.5.3  L121/16-3-16/pDNA systems 
The L121 mixtures follow a similar trend, where there is growing synergism with increasing mole 
fractions. Although interestingly, the 0.2 mole fraction L121 mixture is identified as having antagonistic 
interactions since the experimentally determined CMC of the mixture is slightly larger than Clint’s 
ideal CMC. Conversely, for mixtures αL121 = 0.4 – 0.8, the CMCexp of each mixture is lower than the 
calculated CMCideal (as seen in Table 4.5-1 and illustrated in Figure 4.5-2C and Figure 4.5-5). For the 
case of the L121/16-3-16/pDNA mixture containing an L121 mole fraction of 0.2, the mixed micelles 
are assumed to be enriched with the L121 component and poor in 16-3-16/pDNA, as indicated by the 
positive deviation of X1 from Xideal. Observing the entire range of X1 for the L121 systems, the bulk 
solution composition does appear to affect the composition of the mixed micelles; X1 values range from 
0.921 to 0.657 for αL121 = 0.2 and 0.8, respectively. However, for the αL121 = 0.4 – 0.8 mixtures only, X1 
lies in a much smaller range of 0.729 to 0.657, and a similar trend as seen previously with the F87 and 
P84 systems is observed; the composition of these mixed micelles is minimally influenced by the 
composition of the bulk solution. Furthermore, X1 is much lower than Xideal for the αL121 = 0.4, 0.6, and 
0.8 mixtures, implying that the resultant mixed micelles are poorer in L121 and richer in the 16-3-
16/pDNA component.  
Figure 4.5-5  Plots of surface tension versus total amphiphile for L121/16-3-16/pDNA mixtures with 





Rubingh’s interaction parameters reflect a slight antagonism for αL121 = 0.2, as indicated by a positive 
β value, but with a small magnitude. Meanwhile. synergism is indicated for αL121 = 0.4, 0.6, ad 0.8, 
given the negative interaction parameters (β), which increase in magnitude with increasing mole 
fractions of L121. The activity coefficients slightly above unity also indicate repulsion in the mixed 
αL121 = 0.2 system, and attraction for αL121 = 0.4 and greater (due to f1 and f2 values < 1). 
Correspondingly, the ∆Gex imply more stability in the separate micelles of the individual components 
than in the mixed micelles of the αL121 = 0.2 system. For αL121 = 0.4, 0.6 and 0.8 systems the reverse is 
true; ∆Gex indicates the L121/16-3-16/pDNA mixed micelles are more stable than the micelles of the 
individual components. 
4.5.4 F127/16-3-16/pDNA systems 
As seen in Table 4.5-1 and Figure 4.5-2D, the CMCexp. values are lower than the CMCideal for all 
F127/16-3-16/pDNA mixtures tested, and lower than the individual components of the mixtures (as 
seen in Figure 4.5-6). This indicates there are synergistic interactions between the F127 polymer and 
the pre-formed 16-3-16/pDNA complex. Comparison of X1 versus Xideal for these F127 systems shows 
a negative deviation from the ideal scenario, so mixed micelles are expected to have a greater presence 
of the 16-3-16/pDNA component than the F127 component. The calculated X1 value for αF127 = 0.2 is 
0.535, meanwhile that of αF127 = 0.8 is 0.667. This range of X1 values is fairly small, but larger than 
that seen with the F87 and P84 systems, implying the composition of the F127/16-3-16/pDNA mixed 
micelles may be ever so slightly influenced by the composition of the bulk solution. 
The interaction parameters calculated for these F127 mixtures range from -5.37 to -7.77, for αF127 = 
0.2 to 0.8, respectively. In all cases, F127 is said to have synergistic interactions with the 16-3-
16/pDNA. Activity coefficients below 1 also give support for the presence of synergistic, non-ideal 
mixing within the F127 systems. Negative excess free energies of mixing for all F127/16-3-16/pDNA 




4.5.5 P103/16-3-16/pDNA systems 
The P103/16-3-16/pDNA mixtures also show synergism at all mole fractions (CMCexp < CMCideal, and 
negative β values), although there is no clear pattern corresponding to the Pluronic mole fraction like 
that seen in the other systems reported. Increasing the mole fraction of P103 from 0.2 to 0.4 results in 
an increase in synergism (-2.42 to -3.40, respectively); however, further increase to 0.6 mole fraction 
of P103 results in a CMCexp. very close to the CMCideal, and subsequently reduces the magnitude of the 
interaction parameter (β = -1.75). At αP103 = 0.8, the magnitude of β increases once again. The activity 
coefficients are below 1, which confirm the non-ideal mixing behaviours are synergistic. The negative 
∆Gex values also suggest mixed micelles of P103/16-3-16/pDNA are more stable than the component 
micelles. (Surface tension plots of the P103 mixtures are shown in Figure 4.5-7) 
Figure 4.5-6  Plots of surface tension versus total amphiphile for F127/16-3-16/pDNA mixtures with 





For all mole fractions of P103, X1 is less than Xideal, indicating the mixed micelles are poor in the 
P103 component of the mixture. Considering the variability in X1 values of the P103 systems, the mixed 
micelle compositions appear to be dependent on the composition of the bulk.  
4.5.6 L44/16-3-16/pDNA systems 
L44 mixtures with the 16-3-16/pDNA complex also show synergistic mixing behaviour at all mole 
fractions used, as indicated by experimental CMC values below the calculated ideal CMCs and negative 
interaction parameter values (surface tension plots shown in Figure 4.5-8). The interaction parameter 
fluctuates slightly with values of -24.2, -23.3, and -24.0 for αL44 = 0.2, 0.4, and 0.6, respectively. 
However, for αL44 = 0.8 there is a greater increase in β to -27.7 with the increased L44 content. Again, 
the activity coefficients are below 1, which also suggest non-ideal mixing due to synergistic interaction 
between the components of the mixture. Excess free energies of mixing (∆Gex) for each of the L44 
mixtures are large and negative which also suggests the formation of mixed micelles is favourable and 
the mixed micelles are more stable than aggregation of the individual components separately in the 
mixture. 
Figure 4.5-7  Plots of surface tension versus total amphiphile for P103/16-3-16/pDNA mixtures with 





 The calculated values of X1 for each of the L44 mixtures are greater than their respective Xideal 
values, which suggests the formation of L44-rich mixed micelles. X1 exists in a small range of 0.384 to 
0.444 for L44 mole fractions from 0.2 to 0.8, suggesting the composition of the bulk mixture has little 
effect on the composition of the mixed micelles. 
  
Figure 4.5-8  Plots of surface tension versus total amphiphile for L44/16-3-16/pDNA mixtures with 





In all of the Pluronic/16-3-16/pDNA systems investigated here, there is generally an increase in the 
extent of synergism with increasing mole fraction of Pluronic in the mixtures (with the exception of the 
P103 systems and F87 at 0.4 and 0.6 moles fractions), based on the calculated Rubingh’s interaction 
parameter. As seen in Figure 4.5-9, the L44 mixtures show the largest magnitudes, and greatest 
synergism across all mole fractions tested. For low Pluronic mole fractions (α = 0.2 – 0.4), synergistic 
interactions increase in the order: L121 < P103 < F127 < F87 < P84 < L44, with 0.2 L121 showing 
weak antagonism (β is small in magnitude, but positive). However, for α = 0.6 and 0.8, this order 
changes slightly to: P103 < L121 < F127 < F87 < P84 < L44, and P103 < F127 < L121 < F87 < P84 < 
L44, respectively. 
 
Figure 4.5-9  Average interaction parameters of Pluronic/16-3-16/pDNA mixtures of varying 
Pluronic mole fraction calculated from experimental CMC determinations shown above. Each bar 





4.5.7 Maeda’s Interaction Parameters  
According to Maeda, Rubingh’s approach based on the regular solution theory takes the long-range 
electrostatic interactions that are important in mixed micelle formation into account116. However, 
Maeda proposes a measure of the mixed micelle stability (∆GMaeda) as a function of the ionic surfactant 
mole fraction within the mixed micelle (x2) and takes both hydrophobic chain-chain and electrostatic 
interactions into account (Equation 4.5-8) 116.  𝐵1, in Equation 4.5-8, is related to the free energy change 
associated with replacing a non-ionic monomer within a non-ionic micelle with an ionic monomer 116. 
This transfer process involves short-range interactions between the head groups and between the 
hydrophobic chains 116. Negative values of 𝐵1 indicate an important contribution by the hydrophobic 
chain interactions.   
∆𝐺𝑀𝑎𝑒𝑑𝑎 = 𝑅𝑇(𝐵0 + 𝐵1𝑥2 + 𝐵2𝑥2
2)  Equation 4.5-8 
 
In this case, 𝑥2, the mole fraction of ionic component in the mixed micelle is the 16-3-16/pDNA 
complex. 
B0 = 𝑙𝑛 𝐶𝑀𝐶16−3−16/𝑝𝐷𝑁𝐴  𝑐𝑜𝑚𝑝𝑙𝑒𝑥 
𝐵2 = -β, where β is the interaction parameter from Rubingh’s theory 
𝐵1 can then be determined according to 𝐵1 = 𝑙𝑛 (
𝐶𝑀𝐶𝑃𝑙𝑢𝑟𝑜𝑛𝑖𝑐
𝐶𝑀𝐶16−3−16/𝑝𝐷𝑁𝐴
) +  𝐵2 
 
The calculated Maeda parameters reported in Table 4.5-2 show negative free energy values, 
indicating mixed micelle stability (with the exception of αF127 = 0.2 and 0.4 mixtures). However, the 
magnitudes of ∆GMaeda are smaller than that of ∆Gex calculated from the regular solution theory. 
Negative B1 values suggest hydrophobic interactions are involved in mixed micelle stability, with the 
exception of the αL121 = 0.2 and αP103 = 0.2 – 0.6 mixture, which are positive. The B1 values of the F87, 





Table 4.5-2  Interaction parameters and free energy of micellization (∆GMaeda) calculated according to 
the Maeda approach 
System Mole fraction 
Pluronic 
(αPluronic) 
X2 B0 B1 B2 ∆GMaeda 
(kJ/mol) 
F87 
0.2 0.618 5.97 -21.100 17.805 -0.67 
0.4 0.588 5.97 -22.185 18.890 -1.35 
0.6 0.569 5.97 -22.232 18.937 -1.36 
0.8 0.542 5.97 -23.884 20.589 -2.30 
P84 
0.2 0.655 6.34 -22.906 18.062 -2.27 
0.4 0.622 6.34 -24.355 19.512 -3.12 
0.6 0.592 6.34 -26.901 22.058 -4.60 
0.8 0.571 6.34 -27.276 22.432 -4.76 
L121 
0.2 0.079 -1.09 4.076 -1.485 -1.94 
0.4 0.289 -1.09 -0.460 3.051 -2.41 
0.6 0.275 -1.09 -1.924 4.516 -3.18 
0.8 0.343 -1.09 -7.986 10.578 -6.42 
F127 
0.2 0.465 0.76 -3.458 5.367 0.78 
0.4 0.397 0.76 -3.366 5.275 0.64 
0.6 0.375 0.76 -5.297 7.206 -0.52 
0.8 0.333 0.76 -5.863 7.772 -0.81 
P103 
0.2 0.181 -1.77 2.025 2.416 -3.28 
0.4 0.155 -1.77 1.043 3.398 -3.78 
0.6 0.038 -1.77 2.695 1.746 -4.12 
0.8 0.127 -1.77 -0.778 5.218 -4.42 
L44 
0.2 0.616 7.38 -28.948 24.240 -3.11 
0.4 0.601 7.38 -28.001 23.294 -2.56 
0.6 0.583 7.38 -28.671 23.964 -2.95 
0.8 0.556 7.38 -32.451 27.744 -5.17 
 
 
4.5.8 F87/16-3-16/pDNA with charge ratio 5:1 
The αF87 = 0.4 mixture was also tested with a 16-3-16/pDNA charge ratio of 5:1 (N+/P-) to confirm the 
presence of pDNA influences the interaction parameter of the mixtures. From CMC measurements (by 
tensiometry, as previously described) obtained in duplicate, the interaction parameter (β) is calculated 
to be -28.9, and the resulting mixed micelles are expected to be enriched with the Pluronic component, 
as indicated by an X1 value greater than the expected Xideal. Further confirmation of synergism is seen 
in activity coefficients below 1, and a free energy of micellization (according the Rubingh’s theory) of 
-17.4 kJ/mole indicating an energetically favourable process. All CMC and calculated parameters for 





Table 4.5-3  Average critical micelle concentrations (CMCexp.) determined by tensiometry, and 
corresponding calculated parameters (CMCideal, Xideal, X1, β, f1, f2, ∆Gex) for a 0.4 F87 mole fraction 



















0 2.75 ± 1.70 
(n=3) 
- - - - - - - 
0.4 0.019 
(n=2) 
4.55 4.66×10-3 0.413 -28.9 4.78×10-5 7.20×10-3 -17.4 
1 391 ± 96.7 
(n=3) 
- - - - - - - 
 
 
4.5.9 Ethidium Bromide Relative Fluorescence Intensity 
Figure 4.5-10 shows the normalized relative ethidium bromide (EtBr) fluorescence after addition of the 
Pluronic component (at specified mole fractions) to the 16-3-16/pDNA complex. At the concentration 
and charge ratio used, there is only partial loss of EtBr binding after formation of the 16-3-16/pDNA 
complex (data not shown); however, the addition of Pluronic, any Pluronic present at any mole fraction 
shown, recovers at least a small amount of EtBr fluorescence. As the mole fraction of Pluronic present 
in the mixtures increases, there is a general decrease in the relative fluorescence. The greatest recovery 
of ethidium bromide fluorescence is observed with the addition of L121 across all mole fractions and 




4.5.10 Mixed micelle morphology 
TEM imaging of the 16-3-16/pDNA complex alone (without Pluronic) shows a rosette morphology that 
is consistent with previous reports of similar complexes analyzed by atomic force microscopy 180. 
Micrographs of the mixtures show spherical micelle structures after the addition of various Pluronics 
(Figure 4.5-11). Particle diameters for each mixture appear to be approximately 100 – 200 nm, which 




Figure 4.5-10  Relative fluorescence of ethidium bromide (595 nm excitation/535 nm emission) 
binding to 16-3-16-complexed pDNA followed by 30-minute incubation with Pluronic. Each bar 







Figure 4.5-11  Transmission electron micrographs of A) 16-3-16/pDNA 10:1 complex (without 
Pluronic) at 64000x magnification, B) 0.2 P84 at 46000x, C) 0.6 F127 at 64000x magnification, and D) 





The CMCs of each Pluronic copolymer determined through tensiometry are considered to be in 
agreement with previously reported literature values (generally within one order of magnitude) 181. 
Differences between our findings and those previously reported are attributed to the use of different 
methods. As seen in the surface tension plot of F127 (Figure 4.5-6), there is a gradual transition region 
rather than a sharp breakpoint typically seen with conventional surfactants, which has been attributed 
to composition polydispersity 75. As expected, the CMC of the 16-3-16/pDNA complex (presented as 
α = 0 in Table 4.5-1 above) is slightly below that of pure 16-3-16 (discussed in 136). As previously 
mentioned, the surface tension measurements of the F87, F127, P103, and L44 systems were completed 
on a different instrument than the L121 and P84 systems, therefore the CMC of 16-3-16/pDNA was 
measured with both instruments to account for any discrepancies due to instrumentation. As expected, 
there are slight differences in the 16-3-16/pDNA CMC due to the instruments used; however, the values 
are within an order of magnitude, which was considered acceptable.  
Although the mixing behaviour remains synergistic whether F87 is combined with 16-3-16/pDNA 
condensates of charge ratio 10:1 or 5:1, there is a marked increase in this synergism when the pDNA 
is doubled (to ratio 5:1) while the 16-3-16 and F87 components are kept constant.  As the ratio between 
the two charged species (cationic gemini surfactant and anionic plasmid DNA) approaches 0.50, the 
pre-formed 16-3-16/pDNA condensate may have more hydrophobicity due to charge neutralization. In 
turn, interactions between the condensate and F87 might be more favourable due to the hydrophobic 
effect. It is worth noting the CMC plot and interaction parameter appear unchanged when comparing 
the F87/16-3-16/pDNA charge ratio 10:1 mixture to F87/16-3-16 without pDNA (data not shown); 
however, this may be due to the small presence of pDNA in 10:1 mixture. Once the pDNA content is 
at least doubled, a difference is observed. 
4.6.1 Effect of PPO length on Interaction Parameter 
The mixed micellization is clearly influenced by the composition of the Pluronic component. Upon 
comparison of L121 vs. P84 or P103 vs. P84 systems, where there are similar molecular weights but 
less propylene oxide units in P84, the synergism within the mixed systems appears to increase with 
decreasing propylene oxide content. There is a similar observation for F87 vs. F127 and L44 vs. P84; 
although their % wt. EO are the same, the synergism reflected by the interaction parameter (β) shows 




appears there is a strong positive correlation between average PPO chain lengths in these Pluronics and 
the interaction parameter value. A multiple linear regression analysis estimates that the value of the 
interaction parameter increases by 0.53 with 1-unit increase in PPO length (p-value < 0.001) while PEO 
and mole fraction are held constant. Figure 4.6-1A clearly illustrates the trend between the size of the 
Pluronic PPO block and the interaction parameter. This result was unexpected considering increased 
hydrophobicity of either component is expected to strengthen the hydrophobic effect and onset of 
aggregation. 
Upon further analysis of the results, one may notice the L121, F127 and P103 mixtures’ X1 values 
are less than their respective Xideal (with the exception of αL121 = 0.2); therefore, although mixed micelles 
are formed with the 16-3-16/pDNA complex, they are poor in the Pluronic component of these systems. 
In contrast, the L44, F87, and P84 mixtures resulted in mixed micelles enriched with the Pluronic 
component, as indicated by X1 values greater than their respective Xideal. It is interesting to note that the 
different micelle compositions generally correspond to the size of the Pluronic PPO block, with the 
larger blocks (approximately 60-68 PO units) resulting in Pluronic-poor micelles (as shown in Figure 
4.6-2A). The decreased propensity of these Pluronics to form mixed micelles may be due to greater 






Figure 4.6-1  Scatter plots illustrating relationships between the interaction parameters and A) the 
number of PO units in the Pluronic component, B) the number of EO units in the Pluronic component, 








Figure 4.6-2  Scatter plots illustrating relationships between Rubingh’s interaction parameter and A) 
the number of PO units in the Pluronic component and the mixed micelle composition, B) the mole 
fraction of Pluronic in the mixture and the mixed micelle composition, C) Pluronic % wt. EO and # of 
PO units, D) the number of EO units in the Pluronic component and mixed micelle composition, E) 
the number of EO units and Pluronic PO content, and F) Pluronic % wt. EO and # of EO units, for all 
Pluronic/16-3-16/pDNA (charge ratio 10:1) mixtures. In all plots except panel B, the mean is shown 







Ethidium bromide fluorescence emission at 595 nm (with 535 nm excitation) is detected due to its 
intercalation with DNA. Similar to previous reports, there is a loss of EtBr fluorescence which 
accompanies condensation of pDNA by the gemini surfactant. Initially, the cationic ethidium bromide 
dye intercalates in the DNA strands and emits fluorescence, I0.127,182 This fluorescence decreases when 
the dye is competitively displaced from the DNA chains by complexation with the cationic 16-3-16 
surfactant (data not shown). Some of the fluorescence returns after Pluronic is added, indicating some 
reversal of the 16-3-16-induced condensation. Less de-condensation of the plasmid DNA appears in 
mixed micelles that are enriched in the Pluronic component and show the greatest level of synergism. 
This may be a case of solubilisation of the 16-3-16/pDNA complex by the Pluronic component, which 
show greater participation in the mixed micelle formation. The exact orientation of the components 
within a Pluronic-rich mixed micelle is unknown; however, it is reasonable to assume the 16-3-
16/pDNA complex could reside at any location within the micelle (i.e. PPO core, PEO corona, or the 
palisade layer) depending on the relative magnitudes of hydrophobic or ion-dipole interactions, where 
ion-dipole interactions could occur between the 16-3-16 headgroups and the oxygens of the EO or PO 
groups. 
There also appears to be an inverse relationship between synergism and de-condensation, where 
systems with lower synergism (more positive interaction parameter, β, values) correspond with greater 
pDNA de-condensation. Accordingly, the greatest return of EtBr fluorescence was in the αL121 = 0.2 
condition. Moreover, mixed micelles poor in the Pluronic component compared to the ideal state (αL121 
= 0.4-0.8 and all F127 and P103 mixtures) show greater ability to de-condense the pDNA from the pre-
formed 16-3-16/pDNA complex compared to the Pluronic-rich mixed micelles of the F87, P84, and 
L44 systems. In other words, the 16-3-16/pDNA complex stays more intact when F87, P84, or L44 is 
added. Recall, the Pluronic-poor micelles are observed in the mixed systems involving Pluronics with 
relatively larger PPO blocks (approximately 60 PO units, compared to approximately 40 units in F87 
and P84 and 23 units in L44). From the negative interaction parameter and excess free energy values, 
we see that mixed micelle formation does occur; however, it is less energetically favourable than for 
those Pluronics with a smaller PPO block. It is hypothesized that the larger PPO blocks encounter more 
steric hindrance and perhaps their incorporation results in partial de-complexation of the 16-3-
16/pDNA, possibly due to displacement of some 16-3-16 molecules, in order to accommodate the 




Alternatively, the de-condensation of DNA from the pre-formed gemini surfactant complex is 
typically attributed to Pluronic binding to free gemini surfactant in the bulk phase, which disrupts the 
thermodynamic equilibrium between DNA-associated surfactant aggregates and free surfactants in the 
bulk phase, as proposed by He et al. 127. In this case, the gemini surfactant may have the greatest 
interaction with the larger or more hydrophobic Pluronics, as previously reported 133, leading to greater 
change in the surfactant-induced DNA condensation. However, the current data shown does not allow 
us to discern whether the mixed aggregates/micelles strictly consist of all 3 components present 
(Pluronic, gemini surfactant, and pDNA) or a mixture of 3-component and smaller Pluronic/16-3-16 
aggregates (without pDNA) formed from Pluronic binding to free gemini surfactant in the bulk phase. 
Further analysis, perhaps using equilibrium dialysis, may provide confirmation. For now, the discussion 
has been limited to the formation of a 3-component mixed aggregate. Nonetheless, we acknowledge 
that interpretation of the EtBr fluorescence results is complicated by the possibility of entrapment of 
the fluorescent probe in the hydrophobic regions of the mixed micelles, or free gemini surfactant or 
Pluronic micelles reducing the opportunity to re-bind to the pDNA. Furthermore, multiple interactions 
may be responsible for the results observed, and cannot be separately identified through the 
experimentation presented here.  
Analysis according to Maeda’s theory suggests that hydrophobic interactions stabilize the mixed 
micelles of 16-3-16/pDNA with L44, F87 and P84, as evidenced by the large negative 𝐵1 values in the 
∆GMaeda calculation (Table 4.5-2), which supports our hypothesis of 16-3-16/pDNA being solubilized 
by the L44, F87 and P84 of Pluronic-rich micelles. On the other hand, hydrophobic interactions do not 
appear to play a major role in the micellization involving P103 and αL121 = 0.2, as seen with positive or 
small negative B1 values, which is possibly due to steric effects; however, the mixed micelles may be 
stabilized by electrostatic contributions instead. Micellar hydration has been associated with greater 
mixed micelle stability, which occurs with increased participation of the ionic component in 
octaoxyethylene monododecyl ether (C12E8) – cetyltrimethylammonium bromide (CTAB) mixtures 183. 
Similarly, the mixed micelles mainly consisting of the 16-3-16/pDNA component, may be stabilized 
by greater micelle hydration (although further investigation is required to confirm this). The presence 
of hydrated PEO chains may also introduce more water molecules in the Stern layer, also contributing 
some stability through reduction of head group repulsions.110 Interestingly, there does appear to be a 
hydrophobic contribution in the αL121 = 0.4-0.8 and all F127 systems, but the ∆GMaeda values indicate 




F127 and αL121 = 0.4-0.8 systems into account, we might also propose that the limited participation of 
these Pluronics in mixed micelle formation potentially leaves electrostatic repulsion between the 
cationic components, which leads to a breakdown of the mixed micelles, as reported previously for 12-
6-12/Pluronic systems.131 This may also support the EtBr fluorescence results which suggest a high 
level of pDNA de-condensation by Pluronics L121 and F127.  
The antagonism and low levels of synergism observed for the L121 mixtures may be a reflection of 
the poor solubility and phase separation of the L121 polymer in aqueous solutions above its cloud point 
(14°C for a 1% solution).76 Also, the increasing synergism in the L121 system at higher mole fractions 
may be a reflection of dehydration of the PPO block as CMC experiments were carried out above the 
L121 cloud point, therefore increasing the hydrophobic interactions, similar to that reported by Bakshi 
in investigating the influence of temperature on the interaction of F127 or P103 with the 12-2-12 gemini 
surfactant.110 Furthermore, L121 is reported to have multiple phases present even at low concentrations 
(and ambient temperatures) such as that used to prepare the L121 stock prior to addition to the 16-3-
16/pDNA complex. The presence of more ordered aggregates such as cubic 81 or lamellar structures 184 
may contribute to the antagonism observed and pDNA de-condensation from the 16-3-16 complex. The 
Pluronic mesophases might have a greater capacity for disrupting the equilibrium between free gemini 
surfactants and surfactants bound to the pDNA complex;however, further investigation is required to 
better understand the potential effect of higher order Pluronic structures on the interaction with the pre-
formed 16-3-16/pDNA complexes.  
4.6.2 Effect of PEO length on Interaction Parameter 
Previous discussions of gemini surfactant and Pluronic block copolymer interactions also include the 
role of the polymer PEO chains in mixed micelle formation. It was suggested the EO chains intercalate 
between the cationic headgroups of the gemini surfactants in the mixed micelle and consequently 
neutralize their repulsion, which favours mixed micelle growth.128,132 Furthermore, greater synergism 
was reported for mixtures of 12-2-12 with F127 versus the P103 system owing to the greater number 
of EO units in F127, while the PO content was similar between the polymers.110 Therefore, the effect 
of PEO chain lengths were also considered here. 
In general, PEO length appears to have only a small but significant effect on the interaction parameter 




with a 2-unit increase in EO number (1 EO unit added to each chain) while PPO length and mole 
fraction are held constant.  
Looking specifically at the F87 and P84 systems, the interaction parameters are very similar despite 
having notably different PEO chain lengths (seen in Figure 4.5-9 and Figure 4.6-2E, slope = 0.02). This 
suggests the effect of PPO length primarily dictates the strength of the interactions and changes to the 
PEO chain lengths have a small impact on Rubingh’s interaction parameter. Maeda’s B1 parameters for 
the F87 and P84 systems are also similar. Assuming similar PPO blocks result in comparable 
hydrophobic interactions, the small change in B1 values might suggest there is also a similar level of 
charge neutralization between neighbouring cationic surfactant headgroups despite very different PEO 
chain lengths. Likewise, the β interaction parameter is minimally impacted by the PEO chain length 
among the 60-unit PPO group of L121, F127 and P103 (Figure 4.6-2E, slope = -0.01). Similar trends 
are observed in β vs. % wt. EO plots (data not shown). There is however more variability in Maeda’s 
B1 values for these systems. Although these findings are not consistent with previous investigations of 
gemini surfactant/Pluronic mixtures, Marangoni and Kwak reported the CMC of 
dodecyltrimethylammonium bromide (DTAB) was insensitive to the addition of ethoxylated alcohols 
as the number of EO groups in the alcohol increased from 0 to 3.185 This indicated that EO groups did 
not contribute to the interactions between cationic DTAB and ethoxylated alcohols.185 Moreover, Din, 
et al. also observed a reduction in the interaction parameter magnitude and suggested it may be due to 
the PEO chain of Brij56 imposing steric constraints that restrict effective interactions between the non-
ionic surfactant and gemini surfactant headgroup.186 In addition, the longer alkyl tails of 16-3-16 and 
the presence of pDNA may also account for this deviation from previous literature on gemini 
surfactant/Pluronic mixing behaviours. 
 
Based on the above discussion, some trends between Pluronic composition and interaction parameter 
are clear but we also acknowledge there may be additional factors that are yet to be investigated (for 
example, micropolarity of the pure components) or combinations of multiple factors together should 
also be considered. As previously mentioned, β becomes more negative with increasing mole fraction 
of Pluronic in the mixture. Figure 4.6-1C shows two almost parallel groups (with the exception of the 
positive β values reflecting the L121 mixtures at mole fraction 0.2) showing an inverse correlation 
between mole fraction and the interaction parameter. When the results are sorted by Pluronic-rich and 




of the mixed micelle composition. Granted, the interaction parameter is notably more positive for the 
Pluronic-poor group, which is linked to the length of the Pluronic PPO block. Therefore, it can be said 
that both PPO and mole fraction influence the interaction parameter but independent of one another. 
(Overall, the interaction parameter value is estimated to change by -0.78 for every increase in mole 
fraction by 0.1, p-value < 0.001, at constant PPO and PEO chain lengths). What’s more, although an 
increase in PO content of the Pluronic component results in an increase in the interaction parameter 
value, even with consistent % wt. EO, Figure 4.6-2C illustrates PPO length has a greater impact on β 
at the higher EO content of 70% (F87 vs. F127) than at % wt. EO = 40% (P84 vs. L44) (slopes = 0.51 
and 0.08, respectively). The impact of PPO length on β in comparing F87 to F127 may be a reflection 
of reaching a threshold PPO length for favourable incorporation of the Pluronic component into a mixed 
micelle with 16-3-16/pDNA due to hindrance. Meanwhile, PEO chain length may have a greater impact 
on β for the more hydrophobic Pluronics with % wt. EO = 40% compared to the effect of PPO in this 
case (Figure 4.6-2F vs. Figure 4.6-2C, slopes = 0.24 vs. 0.08, respectively). Thus, the interaction 
parameter is primarily dictated by the length of the PPO block, however, other factors (e.g. bulk mixture 
composition) or in some cases an interaction between two factors (e.g. length of PEO at constant % wt. 
EO) may also play a role. As previously mentioned, 2-factor or higher order interaction terms were not 
included in the statistical analysis due to the sample size; accordingly, the conclusions made here may 
change if such terms were added to the linear regression.  
A full understanding of how the Pluronic structure influences the net interactions observed between 
the 16-3-16/pDNA and Pluronic components may require a wider range of methods and Pluronic 
compositions; however, here we have demonstrated that Pluronic composition and mole fraction can 
influence the mixed micelle composition, interaction parameters, and the ability of the Pluronic to 
decondense plasmid DNA from pre-formed 16-3-16 gemini surfactant condensates.  
4.7 Conclusion 
Overall, this study has shown synergistic interactions exist between pre-formed 16-3-16/pDNA 
complexes (with an N+/P- 10:1) and the Pluronic block copolymers in this study. However, one 
exception was observed; mixtures containing a 0.2 mole fraction of L121 demonstrated weak 
antagonism, which may be due to phase separation of the Pluronic at room temperature or the presence 




The strength of the interaction is dependent on the PO content of the polymers, PEO chain lengths, 
and the mole fraction of Pluronic present in the bulk mixture. These relationships also appear to be 
influenced by the overall percentage of EO in the Pluronic.  
An inverse relationship between synergism and pDNA de-condensation (shown through ethidium 
bromide fluorescence) has also been demonstrated here. The ethidium bromide fluorescence studies 
show a marked difference in the block copolymers’ ability to de-condense the plasmid DNA from the 
cationic gemini surfactant complex, which appears greater for those systems that form Pluronic-poor 
mixed micelles. 
Favourable mixing between the cationic 16-3-16 gemini surfactant/plasmid DNA complex and these 
Pluronic block copolymers is promising for gene therapy applications; not only are mixed micelles 
formed, but only low surfactant/polymer concentrations are required. However, as reported in the 
literature and also demonstrated here, the addition of Pluronics can reduce the level of pDNA 
condensation in surfactant-DNA complexes, which may influence the performance of these mixed 
micelles as gene delivery vectors. Therefore, a balance between synergism and plasmid de-
condensation should be considered. 
Lastly, when studied with other concentrations of plasmid DNA, the interaction between the gemini 
surfactant and Pluronic block copolymer may differ from what is reported here. We have demonstrated 
that the interactions between the surface active components of this gene delivery formulation can be 
studied in the presence of its nucleic acid cargo, which allows for a more accurate determination of the 





In Vitro Transfection Efficiency of Self-Assembled Gemini 
Surfactant/Pluronic-Based Nanoparticles and a Relationship to 
Mixing Behaviours  
5.1 Abstract 
Transfection efficiency remains a primary drawback in the utilization of non-viral gene delivery 
carriers, including self-assembled nanoparticles. Although gemini surfactants and Pluronic block 
copolymers are both promising families of molecules for building mixed micelle gene delivery 
formulations, vectors combining these two materials have only recently been investigated. In this work, 
nanoparticles combining the 16-3-16 gemini surfactant with various Pluronic block copolymers were 
used for in vitro transfection of COS-7 cells. In the past, factors such as nanoparticle size, surface 
potential, and stability have been shown to influence cellular uptake and transfection efficiency. 
However, there is less known about the significance of the mixing interactions between the amphiphilic 
molecules that form these nanocarriers.  
The transfection efficiencies of the Pluronic/16-3-16/pDNA presented here displayed poor 
correlation to the size and zeta potential of the nanoparticles, but there was a significant correlation to 
the mixing behaviour (characterized in Chapter 4) involved in the formation of these mixed micelle 
carriers. This relationship holds value for future mixed micelle gene delivery formulation development 
as it demonstrates the potential benefit of simultaneous investigation of these interactions in order to 
identify important criteria for physical characteristics needed for increased transfection efficiency.  
5.2 Introduction 
Gene therapy using recombinant viral vectors has seen many recent successes in clinical trials, 
including recent licensing by European and North American agencies; however, despite these success, 
cargo capacity and immunogenicity continue to limit viral use.13 Non-viral gene therapy provides an 
alternative solution in order to overcome these limitations, but remains impeded by poor transfection 
efficiency.  
Traditionally, non-viral gene therapy formulation development relies on a rational design approach, 




transfection. However, despite this rational design, optimization still tends to rely on an experiment-
heavy trial and error approach that may not be feasible long-term.2 It was recently proposed that the 
formulation development of drug delivery nanocarriers using polymer/surfactant mixed micelles would 
benefit from a comprehensive and predictive theory, in order to understand the interactions involved in 
mixing and support optimization of new mixtures.2 At the same time, non-viral gene therapy 
formulations using self-assembling materials, such as mixed micelles of polymers, lipids, and/or 
surfactants, could similarly benefit from a predictive theory to aid in the screening and optimization of 
these mixtures and potentially reduce the need for trial and error. Previous work in this field has 
demonstrated that cellular uptake mechanisms and transfection activity can be influenced by particle 
size, shape, charge, and supramolecular structure,187,188 which are typically characterized during 
development; however, in some cases these characteristics do not reliably account for all differences in 
transfection (as demonstrated in this current work). Consideration for the self-assembly phenomena 
involved in the formation of these mixed carriers may provide another piece to the puzzle.  
Recently, self-assembling nanoparticles consisting of dicationic 16-3-16 gemini surfactant, plasmid 
DNA (pDNA), and various non-ionic polyoxyethylene-polyoxypropylene-polyoxyethylene (PEO-
PPO-PEO) triblock copolymers (widely known as Pluronics (BASF Corp.) or by the non-proprietary 
name poloxamers), successfully transfected human ovarian adenocarcinoma (OVCAR-3) cells in vitro; 
however, the transfection efficiencies were lower than that of the commercial standard, Lipofectamine 
2000.73   
The 16-3-16 gemini surfactant consists of two lipophilic 16-carbon tails, and a 3-carbon spacer 
connecting two cationic quaternary amine headgroups, and belongs to the family of m-s-m gemini 
surfactants which are known to form condensed surfactant-DNA structures capable of cellular entry. 
While these complexes can transfect cells, the addition of helper lipids has been known to improve their 
transfection efficiency, or is even a requirement in some cases.54,62,189,190 For example, early 
investigations of the 12-s-12 gemini surfactant series did not show any transfection in the absence of 
the DOPE helper lipid.68 Correspondingly, the 16-3-16, and 18:1-s-18:1 formulations showed a large 
increase in transfection following the incorporation of DOPE.68  
Further, the addition of Pluronic block copolymers to non-viral transfection formulations has 
improved the transfection efficiencies of numerous materials by enhancing internalization and 




activity.57,76,91,100–103,107 Moreover, Pluronics are non-cytotoxic and their PEO chains reduce interactions 
with blood components and clearance by the immune system, allowing for prolonged circulation in 
intravenous administration.33,76,96–98 Although the addition of Pluronic block copolymers has enhanced 
pDNA transfection in previously reported systems, the combination of 16-3-16 with Pluronic did not 
necessarily enhance the transfection efficiency of 16-3-16 (as shown here). This work aimed to study 
the effect of the Pluronic component (namely the Pluronic composition) in the Pluronic/16-3-16/pDNA 
formulation on i) nanoparticle physicochemical characteristics in solution, and ii) in vitro transfection, 
as well as explore a potential link between the in vitro transfection efficiency and our previously 
reported mixing behaviours for these formulations (Chapter 4), which may inform the development and 
optimization of these (and similar) formulations.  
5.3 Materials 
The 16-3-16 gemini surfactant used in this study was synthesized in the Wettig lab according to 
methods previously described in the literature.191 Pluronic® block copolymers were provided as samples 
from BASF Corp, and used as is without further purification or modification.  
The pVG.telRL plasmid (depicted in Figure A-1) coding for enhanced green fluorescence protein 
(eGFP) downstream of a cytomegalovirus (CMV) immediate early promoter156, was extracted from 
DH5α cells (provided as a gift from Dr. Roderick Slavcev, School of Pharmacy, University of Waterloo, 
Canada). E.Z.N.A. Endo-Free Plasmid DNA Maxi Kit (Omega Bio-tek) was used for extraction of the 
plasmid from cells grown in lysogeny broth (Fisher Scientific) supplemented with kanamycin (Sigma-
Aldrich). HyPure Molecular Biology Grade Water (HyClone, GE Healthcare) was used for elution of 
the pDNA from the columns. Plasmid DNA concentrations and purity were measured by UV-Visible 
light absorbance at 260 nm using a Thermo Scientific NanoDrop 2000 spectrophotometer. Purity was 
assessed by the 260/280 nm absorbance ratio and gel electrophoresis following HindIII digestion. 
Ultrapure MilliQ water (Millipore) was used for all stock solution preparations and characterization 
experiments. Transfection experiments used HyPure water. Dimethyl sulfoxide (DMSO) and 
Canadian-origin fetal bovine serum (FBS) were obtained from Sigma-Aldrich (Oakville, ON, Canada). 
1X Dulbecco’s phosphate-buffered saline without magnesium and calcium (DPBS), Dulbecco’s 
Modified Eagle Medium (DMEM) formulated with high glucose and pyruvate (Gibco), DMEM/F-12 




EasYFlask cell culture flasks, cell culture coated 96-well plates (Nunc, Thermo Scientific), cell culture 
coated 6-well plates (Nunc, Thermo Scientific), Opti-MEM I Reduced Serum Medium (Gibco), and 
Lipofectamine 2000 (Invitrogen) were purchased from Thermo Fisher Scientific (Burlington, ON, 
Canada). COS-7 African Green monkey kidney fibroblast cells (ATCC CRL-1651) were purchased 
from American Type Culture Collection, ATCC (Manassas, VA, USA).  
5.4 Methods 
5.4.1 Preparation of transfection nanoparticles 
Transfection nanoparticles were made from mixtures containing varying mole fractions (αPluronic) of the 
Pluronic block copolymer while maintaining a total surfactant concentration of 0.5 mM. All mixtures 
contained a 16-3-16 to pDNA charge ratio of 10:1 (N+/P-).  
The 16-3-16 and Pluronic stock solutions were prepared at 1 mM and approximately 35 times the 
Pluronic CMC (with the exception of the L44 stock which was approximately 6 times the L44 CMC), 
respectively. Prior to use, all stock solutions and water were filtered through a sterile 0.22 µm 
polyethersulfone (PES) syringe filter (Sartorius). An aqueous mixture of pDNA and 16-3-16 (with 
N+/P- charge ratio 10:1) was allowed to incubate for 15 minutes at room temperature. Next, the Pluronic 
was added to the 16-3-16/pDNA complex, and an appropriate volume of molecular biology grade water 
was added to achieve the desired total amphiphile concentration. The solution was mixed gently and 
allowed to incubate for 30 minutes. 
5.4.2 Physical characterization of nanoparticles 
Hydrodynamic diameter and zeta potential analyses were performed on all Pluronic/16-3-16/pDNA 
mixtures and the 16-3-16/pDNA complex using a Zetasizer NanoZS set to 25°C (or 4°C for L121 
systems) (Malvern Instruments). Particle sizes were determined using the scattered light intensity 
distribution from dynamic light scattering with a measurement angle of 173° and three measurements 
completed per sample. Zeta potential was determined from laser Doppler electrophoresis taking three 
measurements per sample. Disposable folded capillary cells (Malvern Instruments) used for zeta 
potential were primed with the sample before loading. All samples were prepared as described 





L44 nanoparticles were also diluted in either water or DMEM/F-12 (warmed to 37°C) to a final 
pDNA concentration of 0.5 µg/mL (equal to 7.6 µM 16-3-16), as used in transfection, and incubated 
for 3 hours in a water bath set to 37°C (Isotemp GPD 10, Fisher Scientific), followed by particle size 
determination at 37°C.  
5.4.3 Cell culturing and 16-3-16 half maximal inhibitory concentration (IC50) 
determination 
COS-7 cells were cultured in DMEM (with pyruvate and high glucose) supplemented with 10% (v/v) 
FBS. Cells were incubated at 37°C with 5% carbon dioxide in a tissue culture incubator (Thermo 
Scientific). No antibiotics were used throughout the culturing and transfection of these cells. Cells were 
sub-cultured at least once before use in any transfection and viability experiments. Experiments were 
carried out with cultures having passage numbers 4 to 14. 
Cells were harvested, suspended in complete medium (DMEM with 10% FBS) and plated into cell 
culture-coated 96-well plates with 5,000 cells per well in 100 µL/well. All peripheral and blank wells 
were filled with DPBS. Cells were incubated overnight. The next day, the cells were rinsed with DPBS 
and incubated with 100 µL of serum-free DMEM one hour before treatment. To maintain consistent 
volumes across all wells, 10 µL of medium was removed from each treatment well and replaced with 
either 10 µL of a 16-3-16 stock (concentrations ranging from 5 µM to 1 mM), HyPure molecular 
biology grade water as a solvent control, or DMSO for a cell death control. All conditions were repeated 
in triplicate wells. Cells were incubated for five hours in a cell culture incubator, after which point the 
cells were rinsed with DPBS and 100 µL of complete medium was added to each well. The cells were 
incubated overnight and analyzed approximately 18 hours later. To prepare cells for analysis, the 
medium in all wells was refreshed with complete medium. Three blank wells (previously containing 
DPBS and no cells) were also filled with complete medium as “no cell” controls to be used for 
background absorbance correction. The plate was returned to the incubator for one hour. 20 µL of 
CellTiter 96Aqueous One Solution Reagent (Promega, Madison, WI, USA) was added to each well 
containing medium. Plates were returned to the cell culture incubator and incubated for four hours 
protected from light. Absorbance at 490 nm was measured using a SpectraMax M5 Multi-Mode 
Microplate Reader (Molecular Devices, California, USA).  
Average absorbance values (corrected by subtracting background absorbance) from triplicate wells 




was analyzed using a dose-response fitting function and the IC50 was determined from the centre of the 
curve (the dose resulting in half the maximal response). The IC50 assay was repeated in three 
independent experiments. 
5.4.4 In vitro transfection assay 
To initiate a transfection experiment, cells were harvested at approximately 90% confluence and 
suspended in complete medium and plated into 6-well plates at a density of 500,000 cells/well and 
volume of 2 mL/well. Plated cells were incubated overnight until treatment the next day. One hour prior 
to treatment, cells were washed with 1X DPBS and incubated with 2 mL DMEM without FBS. 
Meanwhile, all transfection treatments and controls were prepared fresh under aseptic conditions. All 
Pluronic and gemini surfactant stock solutions and HyPure water, were filtered through a sterile 0.22 
µm PES syringe filter (Sartorius) before use. 300 µL of the transfection complexes were prepared as 
described. An appropriate volume of the transfection nanoparticles was added to each well to achieve 
a plasmid dose of 1 µg/well (which corresponds to 1.5x10-8 moles/well of 16-3-16). To keep a consistent 
concentration of plasmid and gemini surfactant throughout all wells, first a volume of medium was 
removed from each well equal to the volume of treatment to be added. Treatments were then added to 
the wells dropwise, and the plates were gently rocked to ensure even distribution in the wells before 
being returned to the incubator. Following 5-hour incubation, the medium was aspirated from each 
well, the cells were rinsed with DPBS, and 2 mL of complete medium was added per well. Plates were 
incubated for an additional 40 hours until the cells were harvested for flow cytometry analysis to assess 
transgene (eGFP) expression and cell viability. Prior to harvesting, the medium was collected from 
each well and combined with the corresponding harvested cells.  
Lipofectamine 2000 was used as a positive transfection control, which was completed simultaneously 
with each transfection experiment. Lipofectamine-pDNA complexes were prepared in Opti-MEM 
Medium and optimized according to the manufacturer recommendations. Optimization revealed a ratio 
of 1 µg pDNA to 4 µL of Lipofectamine 2000 achieved the greatest transgene expression (data not 
shown). The final plasmid dose per well for Lipofectamine treatments was kept consistent with the test 
treatments at 1 µg/well.  
All transfection conditions were repeated in three independent experiments with freshly made 




5.4.5 Flow cytometry analysis 
Cells were harvested 40 hours after removal of the treatments. First, the supernatant medium was 
collected from each well, cells were rinsed with DPBS and detached with 1 mL 0.25% Trypsin-EDTA 
for 5 minutes in the cell culture incubator followed by neutralization with 2 mL of complete medium. 
The contents of each well was combined with its corresponding supernatant in 5 mL round-bottom 
polystyrene tubes (Falcon, Corning Life Sciences). All collected samples were then centrifuged for 10 
minutes at 125xg (Sorvall Legend RT, Thermo Scientific), the supernatant was aspirated, and cells were 
washed twice with 2 mL DPBS followed by centrifugation. The final cell pellet was re-suspended in 
700 µL of DPBS, and stored on ice, protected from light until analysis. Five to ten minutes before flow 
cytometry analysis, 3 µL of a 0.1 µg/mL propidium iodide (PI) solution (Sigma Aldrich) was added to 
each tube, with the exception of the unstained and eGFP-only control samples.  
Samples were analyzed using a BD FACSAria Fusion (BD Biosciences, San Jose, CA, USA) 
operated by the FACS Facility Manager (Department of Biology, University of Waterloo). Samples 
were excited with a 488 nm laser, and 10,000 events analyzed per sample. Cells that did not receive 
any additional treatment/transfection reagent, and were not stained with PI, were used as an unstained 
cell control to set initial parameters for voltage and gating. Cells treated with Lipofectamine/pDNA 
complexes without PI staining, and cells treated with a final 16-3-16 concentration of 23 µM (4.5x10-8 
moles/well of 16-3-16) and stained with PI were used as single colour controls, (+ GFP, − PI) and 
(−GFP, + PI), respectively. Single-colour samples were used for setting the fluorescence compensation 
to minimize spectral overlap prior to data collection.  
Data files were subsequently analyzed using FlowJo V10 software. Polygonal gating was used in a 
side scatter vs. forward scatter dot plot to distinguish cells of interest from debris. This population of 
interest was then plotted in a PI fluorescence intensity vs. GFP fluorescence intensity dot plot. Quadrant 
gating was then used to quantify subpopulations based on fluorescence.  
5.4.6 Statistical Analysis 
All statistical analyses were performed using R Studio software. Statistical comparison between groups 
(e.g. Pluronic-rich vs. Pluronic-poor in Figure 5.6-1) were made using Student’s t-test. Statistical 




variance (ANOVA) and Dunnet’s post-test (Figure 5.5-6 and Figure 5.5-7). Values of p < 0.05 were 
considered statistically significant. 
A predictive multiple linear regression model (Equation 5.6-1 and Equation 5.6-2) was developed 
through the validation set approach using random selection of 62 observations to make a training 
dataset (leaving the remaining 10 observations for the test set).192 Using a bootstrap method, each 
transfection result (1 replicate) was randomly assigned to an interaction parameter value (1 replicate) 
since these measurements were acquired separately (using different samples). Then the training data 
set was used to build multiple linear regression models using the following factors: PO units, EO 
units, mole fraction, interaction parameter value, Pluronic-rich vs. Pluronic-poor mixed micelles, zeta 
potential, and particle size. Each model was then used to predict the GFP value for the 10 test 
conditions, and these predicted values were used to calculate the mean squared error (MSE) for each 
model. This process was repeated 10,000 times through a loop (including random assignment of the 
transfection replicates), all predicted GFP values and MSEs were recorded and then averaged. The 
final model presented here was chosen based on having the lowest average MSE, since a lower MSE 
is an indication that the prediction values are closer to the actual value obtained experimentally. The 







i=1      Equation 5.4-1 
Where GFPi
* is the predicted value from the model for observation i of the test data set, and GFPi is 
the actual value obtained experimentally. Since the bootstrap was repeated 10,000 times the average 












𝑑=1    Equation 5.4-2 
 
Sample GFP prediction values from the model with the lowest average MSE are presented in Figure 




5.5 Results  
5.5.1 Physical characterization of nanoparticles 
TEM images of some nanoparticle mixtures reported in Chapter 4 showed spherical particles with sizes 
of 100-200 nm, which is in good agreement with our findings from dynamic light scattering shown 
below. For a given Pluronic, the mean hydrodynamic diameters of the Pluronic/16-3-16/pDNA 
nanoparticles varied only within a small range with varying mole fraction of Pluronic. However, 
variations in the Pluronic structure appeared to have a greater influence on the particle sizes, particularly 
at a Pluronic mole fraction of 0.2. With the exception of F87, P84, and L44 at mole fraction 0.2, all 
nanoparticle formulations showed a unimodal size distribution based on intensity and low 
























Table 5.5-1  Particle size and zeta potential of Pluronic/16-3-16/pDNA nanoparticles with varying 
mole fraction of each Pluronic measured at 25°C (L121 sample measured at 4°C). Mean values ± 
standard deviation for triplicate measurements (n=3) are reported. In the case of 16-3-16/pDNA 
without Pluronic, the mean ± standard deviation of 14 replicates are reported (n = 14).  







Mean PDI Mean Zeta 
Potential (mV) 
16-3-16/pDNA (10:1)  
(no Pluronic added) 
(n = 14) 
0 198.7 ± 35.6 0.21 ± 0.03 48 ± 7 
F87 0.2 See Table 5.5-2 31 ± 2 
0.4 164.6 ± 11.0 0.18 ± 0.01 26 ± 3 
0.6 155.5 ± 20.4 0.20 ± 0.02 26 ± 3 
0.8 153.2 ± 12.8 0.28 ± 0.05 25 ± 1 
P84 0.2 See Table 5.5-2 42 ± 5 
0.4 202.5 ± 27.3 0.21 ± 0.03 44 ± 4 
0.6 173.7  ± 16.3 0.21 ± 0.02 39 ± 4 
0.8 166.9  ± 6.5 0.22 ± 0.01 37 ± 4 
L121 
(4°C) 
0.2 164.5 ± 10.3 0.12 ± 0.03 51 ± 1 
0.4 160.9 ± 8.6 0.14 ± 0.02 52 ± 1 
0.6 147.0 ± 10.6 0.11 ± 0.02 51 ± 2 
0.8 139.3 ± 9.4 0.11 ± 0.04 48 ± 2 
F127 0.2 181.2 ± 9.2 0.18 ± 0.02 20 ± 1 
0.4 178.8 ± 19.5 0.18 ± 0.02 15 ± 1 
0.6 181.9 ± 15.2 0.20 ± 0.01 13 ± 1 
0.8 173.8 ± 16.0 0.29 ± 0.01 11 ± 1 
P103 0.2 229.5 ± 64.0 0.24 ± 0.03 38 ± 2 
0.4 185.4 ± 17.5 0.22 ± 0.01 33 ± 1 
0.6 180.2 ± 9.7 0.23 ± 0.02 33 ± 2 
0.8 173.6 ± 30.0 0.33 ± 0.05 31 ± 2 
L44 0.2 See Table 5.5-2 44 ± 1 
0.4 159.2 ± 12.1 0.19 ± 0.01 45 ± 2 
0.6 153.1 ± 24.5 0.19 ± 0.02 43 ± 2 




The nanoparticle formulations shown in Table 5.5-2 (0.2 mole fraction of F87, P84 or L44) show 
high polydispersity and overall increased hydrodynamic diameters suggesting aggregation occurs 
within these samples. Granted, there is some polydispersity expected in the molecular weight 
distribution of these Pluronic samples which may further complicate this DLS data and contribute to 
different sizes. Figure 5.5-1 provides a graphical representation of all particle sizes from Table 5.5-1 
and Table 5.5-2. 
 
Table 5.5-2 Particle size distribution for polydisperse samples. Mean peak values for triplicate 


















0.2 F87 644 53.1 176 46.6 5561 0.3 
0.2 P84 531 60.7 190 34.6 5136 4.7 







In contrast, the zeta potential measurements appear uniform for all samples. In addition, all 
nanoparticle formulations except that of F127 show zeta potentials around +30 mV or greater which is 
generally associated with high colloidal stability based on electrostatic repulsive forces; whereas F127 
nanoparticles might be classified as relatively stable based on zeta potentials between +10 to +20 mV193 
(Table 5.5-1, Figure 5.5-2). Compared to the initial 16-3-16/pDNA complex, the addition of Pluronic 
results in a decrease in the zeta potential, presumably due to shielding by the PEO chains, with the 
greatest reduction occurring upon the addition of F127 which possesses the longest PEO chains. 
However, PEGylation is also known to facilitate colloidal stability despite decreasing the zeta potential; 
therefore, the zeta potentials reported here may not reflect the entire picture of stability for these 
nanoparticles.193 Interestingly, the zeta potential tends to decrease linearly with the length of the 
Pluronic PEO chain lengths (Figure 5.5-3), which may be evidence that the PEO chains are fully 
extended in solution. Therefore, we can conclude that the zeta potentials are influenced by the Pluronic 
Figure 5.5-1  Mean hydrodynamic diameter of 16-3-16/pDNA (n = 14) and Pluronic/16-3-16/pDNA (n 
= 3) nanoparticles with varying mole fractions of each Pluronic. Error bars represent standard deviation. 
The major peak from the size distribution by intensity is shown for F87, P84, and L44 mixtures with 0.2 




structure; however, there are no notable changes in the zeta potential magnitudes as the mole fraction 
of Pluronic in the mixture is increased. 
  
Figure 5.5-2  Mean zeta potential of 16-3-16/pDNA (n = 14) and Pluronic/16-3-16/pDNA (n = 3) 







To briefly assess the impact of temperature and dilution, the L44 formulations were diluted to the 
concentrations used for transfection in either water or DMEM/F12 medium (without serum or phenol 
red), and incubated for 3 hours at 37°C. Aside from the 0.2 L44 mole fraction mixtures, the 
hydrodynamic diameters under these conditions were not considered significantly different from the 
measurements obtained in water at 25°C (as shown in Figure 5.5-4). Interestingly, the 0.2 mole fraction 
formulation showed a unimodal distribution and large decrease in size after dilution and incubation at 
37°C (regardless of medium). 
Figure 5.5-3  Mean zeta potential of Pluronic/16-3-16/pDNA nanoparticles as a function of the 





Figure 5.5-4  Mean hydrodynamic diameter of L44/16-3-16/pDNA nanoparticles with varying mole 
fractions of each L44 measured under different conditions: 1) 0.5mM mixtures in water, measured at 
25°C (same as shown in Figure 5.5-1), 2) mixtures diluted in 37°C water to a final 16-3-16 
concentration of 7.6 µM, measured at 37°C, and 3) mixtures diluted in 37°C DMEM/F12 to a final 16-
3-16 concentration of 7.6 µM, measured at 37°C. Error bars represent standard deviation (n = 3). 
Average size taken from the major peak of the intensity distribution is shown. 
 
5.5.2 In vitro transfection of COS-7 cells 
The COS-7 cell viability showed a dose-dependent response following treatment with varying 
concentrations of 16-3-16. Measurements of formazan production as an indicator of cell viability 
(measured by absorbance at 490 nm, shown in Figure 5.5-5) showed that a concentration of 18 µM ± 
2.6 resulted in a 50% reduction in formazan. Using this half maximal inhibitory concentration as a 
guide, transfection efficiency assays were then completed with a final 16-3-16 concentration of 7.6 µM 
per well (approximately 0.4x the half maximal inhibitory concentration). Considering the 16-3-16 




3-16/pDNA nanoparticles, the final concentration of 16-3-16 (and pDNA) was kept constant across all 
treatment conditions. This was a key step in optimizing the transfection protocol, in order to reduce the 
possibility of transfection to be influenced by variations in cell death by 16-3-16. 
Figure 5.5-5  Formazan absorbance in COS-7 cells at 490 nm measured 18h after treatment with 





Transfection efficiency determined by eGFP expression in viable COS-7 cells was dependent on the 
Pluronic component of the nanoparticles, as well as the mole fraction of Pluronic present in the 
nanoparticle formulation (Figure 5.5-6). However, the effect of mole fraction on transfection was not 
consistent for all nanoparticles. For example, an increasing Pluronic mole fraction in the formulation 
mixture resulted in a downward trend in transfection for F87 and P84 nanoparticles, whereas L44 and 
L121 nanoparticles generally increased in transfection efficiency with increasing mole fraction. F127 
and P103 nanoparticles produced the least (in effect, negligible) eGFP expression; while the greatest 
transfection was achieved with L44/16-3-16/pDNA nanoparticles from a 0.8 L44 mole fraction mixture 
(αL44 = 0.8). Addition of Pluronic to the 16-3-16/pDNA complex did not necessarily improve the in 
vitro transfection. In fact, only addition of L44 showed increases in transfection efficiency compared 
to the 16-3-16/pDNA alone; however, no statistically significant improvement was achieved. In 
comparison to the average transfection efficiency obtained with the Lipofectamine 2000 positive 
control, the average transfection efficiency of αL44 = 0.8 nanoparticles was equal to approximately 61% 
of that of Lipofectamine. These results are consistent with a previous study using NF-grade Pluronics 
with 16-3-16/pDNA at varying charge ratios and Pluronic concentrations in the OVCAR-3 cell line, 
















Cell viability, shown in Figure 5.5-7, was not significantly reduced by any of the transfection 
treatments when compared to the negative control (untreated cells). However, a “positive death control” 
using 23 µM 16-3-16 confirms our findings that higher doses of 16-3-16 can significantly impact cell 
viability. Similar cell viability results were also obtained for the F87 formulations in a smaller assay 
detecting the cellular metabolic capacity to reduce resazurin to resorufin (using the Promega CellTiter 
Blue reagent). A comparison of viability results from both methods are shown in Table C-4 of the 
Appendix. It is also interesting to note there was a large improvement in cell viability when the cells 
were harvested and analyzed two days following transfection as compared to the results obtained the 
Figure 5.5-6  Transfection efficiency in COS-7 cells treated with Pluronic/16-3-16/pDNA 
nanoparticles consisting of varying Pluronic mole fraction represented by the number of live cells 
expressing eGFP (as a percentage of total cells analyzed). Mean values are plotted with error bars 
representing standard deviation. Control conditions consisting of untreated cells (labelled “no 
treatment”), cells treated with Lipofectamine/pDNA complexes, and 16-3-16/pDNA complexes were 
replicated 12 times (n = 12). Treatment with naked pDNA was replicated 5 times (n = 5), while all 








The DLS and zeta potential measurements presented in Table 5.5-1, Figure 5.5-1 and Figure 5.5-2 give 
a preliminary illustration of these nanoparticle formulations in aqueous medium prior to use, which 
show promising characteristics for gene therapy applications. Particles above 30 nm are also likely able 
to by-pass clearance through glomerular filtration in vivo, which contributes to longer circulation 
 
Figure 5.5-7  Cell viability of COS-7 cells treated with Pluronic/16-3-16/pDNA nanoparticles with 
varying Pluronic mole fraction indicated by positive propidium iodide staining (shown as a percentage 
of total cells analyzed). Control conditions consisting of untreated cells (labelled “no treatment”), cells 
treated with Lipofectamine/pDNA complexes, 16-3-16/pDNA complexes, and 23 μM of 16-3-16 were 
replicated 12 times (n = 12). Treatment with 7.6 μM 16-3-16 was replicated 9 times (n = 9), and 
treatment with naked pDNA was replicated 5 times (n = 5). All Pluronic/16-3-16/pDNA nanoparticle 
treatments were repeated in triplicate (n = 3). Mean values are plotted with error bars representing 




times.35 For cancer gene therapy in particular, the particle sizes generated by these formulations are 
also typically promising for passive targeting to tumor tissue in vivo since they are expected to 
extravasate through the discontinuous epithelium of tumor vasculature (10 – 500 nm) but not through 
the tight junctions of normal vasculature (2 – 4 nm).36,37 Although the EPR effect may not be an 
appropriate approach for all tumors, as previously discussed in Chapter 1, there are some tissues that 
demonstrate a strong EPR effect that these nanoparticle sizes may be suitable for. 
Furthermore, the positive zeta potentials are generally desirable in order to facilitate interactions with 
cell membranes.35 Additionally, a particle size of 100-150 nm is generally optimal for endocytosis.69 
Most nanoparticle sizes reported here are within this range or are only slightly above 150 nm (aside 
from the polymodal samples identified above). It is also interesting to note the samples showing 
polymodal size distributions achieve some of the highest transfection efficiencies seen in this 
investigation (mixtures with 0.2 mole fractions of F87, P84 or L44). Previously, it was proposed that 
the enhanced transfection efficiencies achieved with RGD-conjugated gemini surfactant-based 
lipoplexes may be due in part to their polymodal size distribution, which may heighten the use of 
multiple endocytotic pathways.187 Likewise, the transfection achieved with the α = 0.2 F87, P84 and 
L44 formulations might similarly be due in part to their size distributions. However, it is also worth 
noting that a polymodal size distribution is not observed in the diluted L44 samples incubated and 
measured at 37°C (Figure 5.5-4). Further investigation of cellular uptake and intracellular distribution 
could shed more light on the differences in transfection between the various formulations. 
Despite having promising particle size and zeta potential characteristics for future use in vivo, these 
results cannot account for many of the differences in the in vitro transfection efficiency for these 
systems since the size and zeta potential of most mixtures are within a similar range (with the exception 
of the polydisperse samples shown in Table 5.5-2). Therefore, consideration of the physical interactions 
involved in the self-assembly of these materials might be useful in explaining the observed differences.  
The work presented in Chapter 4 used phenomenological mixed micelle theories to characterize the 
tendency of the 16-3-16/pDNA complex to assemble into mixed nanoparticles with these Pluronics (at 
varying mole fractions of Pluronic). An interaction parameter, β, which quantifies the nature (synergism 
vs. antagonism) and strength of the interactions within these mixed amphiphile systems, and X1, an 
estimate of the mole fraction of the Pluronic component within the resulting nanoparticles (at a 




reported characterizations and the transfection efficiencies shown here, a number of relationships were 
identified that may give further insight into key aspects of these self-assembled nanoparticles that 
impact transfection. Firstly, in terms of the X1 parameter, the concentrated mixtures (0.5 mM total 
surfactant concentration) used for the in vitro transfection experiments are estimated to produce 
transfection nanoparticles with a Pluronic mole fraction that is equal to the mole fraction of Pluronic in 
the mixture (denoted X1
stock in Table B-4). Even following dilution with medium when added to the 
transfection well, this value remained roughly constant for all formulations except the L121 mole 
fraction 0.2 mixture, which indicates a large increase in X1 to 0.711 upon dilution (denoted X1
stock in 
Table C-5), and is close to but slightly under the calculated Xideal value (0.769) expected for an ideal 
mixture with no net interaction between the Pluronic and 16-3-16/pDNA components. Although it is 
interesting to note the effect of dilution on these X1 values, this dilution occurred in cell culture medium, 
not simply water. Even considering the particle size data for L44 remained relatively unchanged upon 
dilution in medium and heating to 37°C, the impact that the medium components would have on the 
self-assembly behaviour and subsequent nanoparticle composition remain unknown; therefore, the 
X1
well values were not used for further analysis or discussion.  
A significant increase in transfection efficiency was achieved with nanoparticles estimated to be 
enriched with the Pluronic component (“Pluronic-rich”) versus those mixtures that produce “Pluronic-
poor” nanoparticles (Figure 5.6-1). This finding suggests greater involvement of the Pluronic 
component in the transfection nanoparticles may be important for transfection. Considering the reported 
ability of Pluronics to improve the transfection efficiency of numerous non-viral formulations through 
interaction with lipid membranes or activation of cell signaling pathways that can enhance nuclear 
transport57,76,91,100–103,107, we speculate that a greater presence of Pluronic may provide more opportunity 
for these critical events to occur. Alternatively, Pluronic-poor nanoparticles may leave excess Pluronic 
in solution, which is then free to interact with cell membranes and potentially inhibits internalization, 






Moreover, the nature of the interaction between the components in these mixed micellar transfection 
formulations may also influence the transfection efficiencies. More specifically, the strength 
(represented by the magnitude of β) of the synergism in this formulation may be important. A linear 
trend is clearly seen in Figure 5.6-2, which shows there is a negative correlation between the interaction 
parameter value of the mixture and the transfection efficiency (or keeping in mind negative β values 
indicate synergistic interactions, transfection efficiency rises with increasing/stronger synergism). This 
trend may correspond to the nanoparticle’s stability during delivery. 
Figure 5.6-1  Transfection efficiency according to mixed nanoparticle composition (Pluronic-rich vs. 




While the relationships between transfection efficiency and interaction parameter or nanoparticle 
composition are apparent, it is also important to consider the impact of the Pluronic structure. For 
example, the length of the Pluronic PPO block is unmistakably related to transfection efficiency, with 
a steady decline in transfection efficiency occurring while hydrophobic PPO block lengths increase 
(Figure 5.6-3). After all, not only was the Pluronic structure (most notably the PPO block length) found 
to clearly influence mixing behaviours and nanoparticle composition (Chapter 4), previous reports also 
show a relationship between Pluronic composition and their effect on cells and model membranes that 
are in agreement with some of the structure-based differences in transfection efficiency shown here.  
  
Figure 5.6-2  Relationship between transfection efficiency and the calculated Rubingh’s interaction 




For instance, previous work has demonstrated that both Pluronic PO and EO content influence the 
polymer's effect on cell membranes. Molecular dynamics simulations of Pluronic chain penetration in 
dipalmitoylphosphatidylcholine (DPPC) model membranes suggest that long PEO chains tend to 
adsorb just beneath the polar headgroup region of the lipid bilayer, interact with several lipid molecules 
and provide temporary stabilization to the membrane structure.102 Conversely, short PEO chains are 
more likely localized in a small region of the membrane and pull the lipid headgroups internally, 
causing bending of the membrane102 or formation of ion traversable pores.105  Also, decreases in the 
PEO chain length (of Pluronics with an equal PPO length) have been associated with a slight increase 
in lipid flip-flop activity between the inner and outer leaflets of liposomes.103 Further, in a systematic 
characterization of the optimal Pluronic structure for drug efflux modification in bovine brain 
microvessel endothelial cells, Group I polymers, consisting of hydrophilic Pluronics (similar to F87 
and F127 in our case), were found to adhere to the plasma membrane but typically showed poor 
internalization, and intracellular accumulation was presumably limited to endocytic compartments.104 





Conversely, hydrophobic Pluronics (HLB < 20) with intermediate-length PPO blocks (referred to as 
Group II), like that of P84 and P103, incorporated into and fluidized the cell membranes, spread 
throughout the cytoplasm (even reaching the nucleus to some extent), and were also associated with 
inhibiting ATP synthesis via changes to the electron transport in mitochondrial membranes.104 
Meanwhile, Group IIIa polymers similar to L44 that are classified as hydrophobic with a short PO 
block, showed a tendency to adhere to cell membranes, spread easily throughout the cytoplasm and 
reach the nucleus, similar to the behaviour of the intermediate hydrophobic Pluronic group.104 However, 
in spite of their intracellular distribution, this group of polymers did not impact ATP levels.104 On the 
other hand, Group IIIb consisting of hydrophobic polymers with a long PPO block (e.g. L121) showed 
significant fluidization of the plasma membrane due to its large hydrophobic PPO block and short PEO 
chains.104,105 However, L121 was also found to anchor into the membrane and remain localized in 
endocytic compartments, suggesting an ability to decrease the microviscocity of plasma membranes 
but not intracellular membranes.104 Moreover, the ability of Pluronics to bind cell membranes not only 
influences cellular uptake and distribution, but has also been shown to improve transfection by 
activating cell signaling pathways that enhance cellular uptake and nuclear transport of pDNA with a 
CMV promoter (recall, the pVG.telRL plasmid used in this study also contains a CMV promoter).57  
In summary, the transfection achieved by these Pluronic/16-3-16/pDNA nanoparticles may be due 
to the Pluronic’s ability to bind cell membranes, but in some cases these properties may also create 
limitations. For example, an initial expectation may be that greater membrane permeabilization by the 
Pluronic ultimately results in greater transfection efficiency. However, high levels of plasma membrane 
disruption by Pluronic L64 was previously associated with decreased cellular uptake and transfection 
efficiency of PEI/pDNA complexes due to inhibition of endocytosis in vitro.51 Taken together, it can 
be hypothesized that differences in transfection by the Pluronic-rich F87, P84, and L44 nanoparticles 
may be due to loss of membrane integrity or energy depletion in cells treated by P84 nanoparticles 
compared to those with F87 or L44. Similarly, although transfection was achieved with the L121 
systems, it may have been limited by poor endosomal escape, as previously reported with this particular 
Pluronic.  
It is interesting to note Pluronics with similar hydrophobicity and membrane interaction classified 
by Batrakova et al.104 do not necessarily show similar transfection efficiencies here. For example, 




according to previous reports104, F87-containing nanoparticles have significantly greater transfection 
efficiency over F127 nanoparticles. Similarly, both P84 and P103 should fluidize cell membranes and 
easily distribute throughout the cytoplasm based on their intermediate hydrophobicity104; however, P84 
nanoparticles greatly out-perform the P103 nanoparticles. Admittedly, the current data does not allow 
us to distinguish whether enhanced transfection efficiency is due to an increased ability to overcome 
particular barrier(s); for example, increased cellular entry, endosomal escape, nuclear entry, or plasmid 
transcription. Even so, given the relationships shown in Figure 5.6-1 and Figure 5.6-4, these differences 
may be a reflection of the nanoparticle compositions and mixing behaviours that were determined in 
our previous work. The F87 and P84 mixtures show strong synergism between the 16-3-16/pDNA 
complex and the Pluronic component, and a greater Pluronic presence in the mixed nanoparticles. 
Perhaps more Pluronic content may create more opportunity for the Pluronics to act as biological 
response modifiers and improve transfection, compared to those nanoparticles that are considered 
Pluronic-poor (such as F127 and P103).  
 
 Figure 5.6-4  Effect of interaction parameter on transfection efficiency for different Pluronic 
categories previously described by Batrakova et al.104 Mean values are represented by the symbols 





Although the L121 nanoparticles are considered Pluronic-poor, there is a measurable amount of 
transgene expression (compared to the negligible expression achieved by F127 and P103 
nanoparticles), which increases with the synergistic interaction parameter values. The greatest level of 
GFP expression achieved from L121 nanoparticles was achieved from a Pluronic mole fraction of 0.8, 
which showed an intermediate level of synergism in our previous characterizations. Thus, in addition 
to nanoparticle composition, stronger attraction (synergism), represented by negative interaction 
parameter values, is likely also important (Figure 5.6-5). Although more investigation is needed, 
synergism may be related to the nanoparticles’ ability to stay intact and protect the pDNA cargo while 
overcoming the many barriers to transfection. In fact, our previous work showed stronger synergism 
was associated with lower levels of ethidium bromide – DNA binding due to less dissociation of gemini 
molecules from the pDNA complex when Pluronic is added, which supposedly maintains the condensed 
pDNA form. While this may turn out to be an important feature for successful delivery in vivo, it is also 
worth noting that our previous characterization of the 16-3-16/pDNA complex (without Pluronic) 
suggests the cationic gemini surfactant does not completely dissociate from the plasmid DNA even 
when diluted below its critical aggregate concentration.136 This might limit the transfection efficiency 
due to incomplete unpacking of the pDNA cargo for transcription.24 Nonetheless, further research is 




Unfortunately, data from the L121 series is also complicated by poor solubility of L121 in aqueous 
solution at room temperature and above, which may impact the stability of the nanoparticles under the 
in vitro transfection conditions. (Note the cloud point of 1% aqueous solution of L121 is 14°C.76) The 
increased variability observed in the L121 transfection efficiencies, especially for the 0.8 L121 mole 
fraction (depicted by larger error bars in Figure 5.5-6) may be due to possible phase separation. 
Additionally, the L121 nanoparticle sizes and zeta potentials reported here were collected at 4°C to 
avoid phase separation during the measurement and also reflect the incubation conditions of these 
mixtures prior to use for in vitro transfection. However, size data collected at 25°C (Table C-2) 
generally show larger PDI values, most notably in the 0.8 mole fraction mixture, which may also 
reasonably occur at 37°C and under the conditions used for the in vitro transfection assays. This may 
be an indication of reduced stability for these systems but it is interesting to note that these changes are 
associated with greater transfection efficiency. Although multi-modal size distributions are not present, 
Figure 5.6-5  Simultaneous effect of interaction parameter and nanoparticle composition on 




this might be related to what was observed with the polydispersed samples of 0.2 mole fraction F87, 
P84 and L44 mixtures, and may be worth exploring further. 
5.6.1 Cross-validation model for transfection efficiency prediction 
With our current data, a preliminary cross-validation model using the interaction parameter (β), 
nanoparticle composition (𝑋1
𝑠𝑡𝑜𝑐𝑘  vs. Xideal), and Pluronic structure, represented by      
Equation 5.6-1 and Equation 5.6-2 (depending on nanoparticle composition), was able to predict the 
transfection efficiency (% eGFP expression) with an average mean standard error of 1.95.  
eGFP𝑃𝑙𝑢𝑟𝑜𝑛𝑖𝑐−𝑟𝑖𝑐ℎ  =  11.69 − 2.22(R) + 20.33(α1) − 0.06(β) − 0.68(PO × α1) + 0.04(PO × R)      
Equation 5.6-1 
𝑒𝐺𝐹𝑃𝑃𝑙𝑢𝑟𝑜𝑛𝑖𝑐−𝑝𝑜𝑜𝑟 = −1.81 − 2.22(𝑅) + 40.79(𝛼1) − 0.49(𝛽) − 0.68(𝑃𝑂 × 𝛼1) + 0.04(𝑃𝑂 × 𝑅) 
Equation 5.6-2 
Where R is the PO/EO weight ratio, α1 is the mole fraction of Pluronic present in the mixture, PO is 
the number of PO units in the Pluronic structure, and β is the interaction parameter (from Chapter 4). 
For formulations where a Pluronic-rich nanoparticle expected ( X1
stock > Xideal), the eGFP prediction is 
represented by Equation 5.6-1; whereas the eGFP expression prediction for Pluronic-poor nanoparticle 
formulations (X1
stock > Xideal) is represented by Equation 5.6-2. From the above equations, we see that 
in addition to the effect of the interaction parameter, and nanoparticle composition, the mole fraction 
of Pluronic in the overall mixture, and the Pluronic’s PO/EO ratio also have an influence on the eGFP 
prediction. For the purpose of improving the model’s predictions, the number of PO units was excluded 
as a main effect (because it increased the MSE value), but the 2-factor interactions in the above 
equations demonstrate that PO content influences the effects that the PO/EO ratio and Pluronic mole 
fraction have on the eGFP expression. As seen in Figure 5.6-6A, for a given PO/EO ratio a smaller PPO 
block results in greater transfection efficiency. Similarly, lower PO content generally increases 
transfection efficiency at a given Pluronic mole fraction in the formulation mixture (Figure 5.6-6B). 
Considering the strong correlation between PO and β, previously identified in Figure 4.6-1, the effect 
of PO is already accounted for by the presence of β in the model and the addition of a PO term as a 




replacing the β terms with PO will also increase the MSE and compromise the prediction. Likewise, 
PO was also shown to have a strong influence on nanoparticle composition (Pluronic-rich vs. Pluronic-






Figure 5.6-6 A) Influence of PO content on the effect of Pluronic PO/EO weight ratio on transfection 





For comparison, a linear regression model without any of the β or 𝑋1
𝑠𝑡𝑜𝑐𝑘 terms had an MSE of 7.43, 
which indicates a large improvement in the prediction with the addition of the mixed micellization 
parameters (Equation 5.6-3). 
eGFP = 3.03 + 3.76(R) + 13.10(𝛼1) − 0.28(𝑃𝑂 × 𝛼1) − 0.05(𝑃𝑂 × 𝑅)  
Equation 5.6-3 
In this case, without the use of mixed micellization parameters, the average MSE can be improved to a 
value of 3.86 by simply adding the number of PO units as a main effect (Equation 5.6-4).   
 
𝑒𝐺𝐹𝑃 = 23.00 − 0.37(𝑃𝑂) − 2.96(𝑅) − 4.60(𝛼1) + 0.07(𝑃𝑂 × 𝛼1) + 0.05(𝑃𝑂 × 𝑅) 
Equation 5.6-4 
 
As seen in Figure 5.6-7 , the predictions from Equation 5.6-4 do not appear very different from those 
of Equation 5.6-1 and Equation 5.6-2; however, interaction studies may still have a place in helping to 
explain differences in transfection efficiency between systems that are seemingly similar based on the 





The above analysis demonstrates the utility of interaction studies, such as that used in our previous 
work (Chapter 4), within the development process of formulations that involve mixed micelles. With 
the relationships currently identified, one could likely exclude Pluronic/16-3-16/pDNA combinations 
that demonstrate antagonism or weak synergism. Perhaps by establishing a basic relationship between 
mixing behaviours and transfection efficiency, like that shown here, similar interaction studies might 
be useful in predicting the success of future formulations of a similar nature or as an additional 
screening tool during the optimization process 
5.7 Conclusion 
In vitro transfection efficiency in COS-7 cells were clearly dependent on the Pluronic composition of 
the Pluronic/16-3-16/pDNA transfection complexes; meanwhile, cell viability was not significantly 
impacted by the treatments/concentrations used. To our knowledge, this is the first report showing a 
Figure 5.6-7  Comparison of experimentally observed transfection efficiencies for randomly selected 





clear relationship between transfection efficiency and parameters determined from phenomenological 
mixed micelle theories. Of note, nanoparticles enriched with the Pluronic component, and those with 
strong synergistic interactions and mixed micelle stability were associated with greater in vitro 
transfection efficiency. The trends revealed here may lead to greater understanding of the 
physicochemical properties involved in the transfection success or failure of these systems in vitro, and 
in the future, may inspire the use of such interaction studies as an additional tool for formulation 






Conclusions and Future Directions 
With recent successes in improving the safety of recombinant viral vectors and increasing efficiency of 
liposomal formulations for gene delivery to treat genetic diseases, the potential of gene therapy has 
finally reached the market. However, many synthetic gene therapy carriers in development continue to 
suffer from poor transfection efficiency. One such example, is the combination of the 16-3-16 gemini 
surfactant and National Formulary-grade Pluronic block copolymers, which was previously tested in 
the Wettig lab for in vitro delivery of pDNA to OVCAR-3 cells but showed limited transfection 
efficiencies. In this work, the pDNA/16-3-16/Pluronic formulation was revisited by expanding to other 
Pluronic compositions and evaluating the self-assembly tendencies involved in the formation of these 
nanoparticles. 
In Chapter 3, a critical aggregate concentration was reported for the 16-3-16/pDNA condensate (also 
referred to as a “complex”) prepared at a (N+/P-) charge ratio of 10:1. Based on the physical changes 
detected by tensiometry, conductivity, and light scattering methods as the pre-formed complex was 
titrated into water, it is suggested that the 16-3-16/pDNA complex only partially dissociates upon 
dilution in water. This is thought to result in a “loose” aggregate structure as some of the surfactant 
monomers likely dissociate from the complex, as evidenced by larger particle sizes and a steep slope 
in the conductivity curve that decreases to a slower rate of change as the concentration of 16-3-
16/pDNA added to the system increases. Once the CAC is reached (indicated by a breakpoint in each 
of these characterizations), a more condensed complex re-forms. Surface activity was also detected for 
this complex, which allowed for: 1) CAC determination through tensiometry, 2) treatment of 16-3-
16/pDNA as a single amphiphilic component in the pDNA/16-3-16/Pluronic mixtures, and 3) mixing 
behaviour characterizations in the presence of the intended pDNA cargo. 
Addition of the various Pluronic block copolymers to the 16-3-16/pDNA complex generally showed 
mixing of these two components is energetically favourable, with the exception of L121 at a mole 
fraction of 0.2, which showed antagonistic mixing. More importantly, the magnitude of the synergistic 
interactions responsible for the mixed micelle stability is influenced by the Pluronic molecular 
structure, and the composition of the mixture. Contrary to the initial hypothesis, longer Pluronic PPO 




that opposes mixed micelle formation. Depending on the PO content, the deviations from ideal mixed 
micellization are attributed to different micelle compositions; for PPO block lengths of approximately 
20 – 43 units (like that of L44, F87, and P84), the mixed aggregates are rich in the Pluronic component, 
whereas larger PO blocks result in 16-3-16/pDNA-rich mixed aggregates. While the PO content is the 
primary factor that dictates the interaction parameter value, there is generally a small but statistically 
significant decrease in β with increasing PEO chain lengths, which might be attributed to favourable 
charge neutralization between adjacent gemini surfactant headgroups by intercalation of PEO chains. 
Nevertheless, the effect of PO on the interaction parameter was also found to be influenced by the 
number of EO units (and vice versa), and the overall percentage of EO. In addition, increasing the mole 
fraction of Pluronic in the mixture also increased the synergism, but this effect appears to be 
independent of the effect(s) of PO content. Finally, reducing the N+/P- charge ratio to 5:1 increased the 
synergism of the F87 system, indicating that the presence of pDNA also plays a role in the mixed 
aggregate formation and should be explored further.  
Similar to previous literature reports, ethidium bromide-DNA binding studies indicate that addition 
of Pluronic to the 16-3-16/pDNA complex results in some de-condensation of the complex. In general, 
the level of dye binding (DNA de-condensation) is inversely related to the synergism present in the 
mixture. Although the exact mechanism of mixed micelle formation is unknown for these systems, 
these results may indicate encapsulation of the pDNA/16-3-16 complex in Pluronic-rich nanoparticles 
versus - de-mixing that allows for greater ethidium bromide binding in the Pluronic-poor nanoparticles. 
Most of the formulations tested produce nanoparticles with sizes below 250 nm, which is desirable 
for future in vivo applications to reduce clearance by glomerular filtration and potentially for passive 
targeting of tumors with a strong EPR effect (although the existence of an EPR effect is debatable). 
The different polymers and mole fractions used generally show no effect on the nanoparticle sizes (only 
the F87, P84 and L44 samples with Pluronic mole fractions of 0.2 showed size polydispersity), but 
longer PEO chain lengths appear to introduce shielding effects that generally decreased the zeta 
potential of the nanoparticles. In terms of in vitro transfection efficiency in COS-7 cells, reporter gene 
expression (eGFP) varies significantly depending on the Pluronic and the mole fraction in the 
formulation. In general, Pluronics with smaller PPO blocks, such as L44, F87 and P84, show greater 
transfection, but only the formulation containing L44 at mole fraction 0.8 produces a statistically 




Pluronic mole fraction also influences the transfection efficiencies, but this effect varies for different 
Pluronics. No significant reduction in cell viability was detected, which is partly attributed to restricting 
the 16-3-16 concentration to well below the IC50 of the gemini surfactant. 
The differences in transfection efficiencies observed in these systems reflect some of the trends 
previously reported in the literature between cell membrane interactions and Pluronic structure and 
hydrophobicity. In particular, hydrophobic polymers with short PPO blocks are known to bind cellular 
membranes and spread throughout the cytoplasm, which may have contributed to the L44 formulations 
showing the highest transfections throughout. In addition to PPO block length, the PO/EO ratio, and 
mole fraction of Pluronic in the formulation mixture appeared to influence the transfection efficiencies 
that were observed for these systems. In contrast, the hydrodynamic diameter of the various 
nanoparticles did not assist in understanding the differences in transfection efficiencies between the 
systems since the majority of the particles were so similar in size. Furthermore, transfection showed a 
general increase with more positive zeta potentials, but the results were still quite variable even at high 
magnitudes. 
Taking all findings reported in this work into account, some important relationships between 
transfection efficiency and the estimated mixing behaviours involved in the Pluronic/16-3-16/pDNA 
nanoparticle self-assembly have come to light. Most notably, transfection increased with stronger 
synergistic interactions in the mixed systems, which is thought to be an indication of a sufficient level 
of nanoparticle stability necessary for protection of the pDNA. The ethidium bromide binding studies 
are also generally consistent with this theory since those mixtures with stronger synergism appear to 
maintain a condensed pDNA state more than those with medium or weak synergism. Synergism 
resulting from a greater presence of the Pluronic component in the nanoparticles is also associated with 
higher transfection efficiency (as opposed to the nanoparticles that are considered “Pluronic-poor”), 
which might be attributed to the Pluronics’ cell membrane interactions and activity as biological 
response modifiers. 
 As seen with the Pluronic/16-3-16/pDNA system, the rational design approach for non-viral gene 
therapy formulation development does not guarantee improvements to transfection efficiency; 
however, the influence of interaction parameter and mixed micelle composition on transfection 
efficiency can be used for guiding the optimization of these systems in future work. Furthermore, few 




that predictions of in vitro transfection efficiencies can be improved by taking these mixed micellization 
parameters into account. This points to the importance of considering and quantifying the interactions 
within self-assembled gene delivery carriers, especially for systems like the Pluronic/16-3-16/pDNA 
nanoparticles that cannot be distinguished by parameters such as particle size or zeta potential. 
Based on the results of this work, for a Pluronic mixture with 16-3-16/pDNA complexes having a 
charge ratio of 10:1 it is recommended to pursue mixtures that have strong synergism (indicated by a 
negative interaction parameter with a large magnitude) and a mixed aggregation composition that is 
rich in the Pluronic component (as opposed to the 16-3-16/pDNA component), as these mixtures should 
have the greatest potential for maximizing transfection efficiency. According to the findings of Chapter 
4, this would likely require a Pluronic with a small PPO block (less than 60 units), at larger Pluronic 
mole fraction. Although % PEO showed some influence on synergism, its effect is also influenced by 
the PPO length (and vice versa). Based on the small sample size of this study, a lower % PEO is 
recommended for increasing synergism with small PPO block Pluronic mixtures, but more work to 
confirm these trends is still needed.  
 
6.1 Future Directions 
6.1.1 Further Characterization of Mixed Micelle Formation 
A number of additional mixtures and techniques have been identified as potential extensions of this 
work in order to build a deeper understanding of the Pluronic/16-3-16/pDNA systems, and potentially 
confirm some of the more speculative points made during the interpretation of the non-ideal mixing 
interactions that are presented.  
The relationships between the Pluronic molecular structure and interaction parameter could be 
strengthened by testing other Pluronic block copolymers. For example, expansion of the 40% PEO 
group to include Pluronic P104, which consists of approximately 61 PO units, would add a third data 
set to the series to help confirm the effect of PPO length across the entire range of PO for the 40% PEO. 
Similarly, to investigate whether other highly lipophilic Pluronics would also show any antagonistic 
mixing with the 16-3-16/pDNA complex, it would be interesting to test polymers such as L81 and L62, 
which have only 10% and 20% PEO, respectively, but much smaller PPO blocks compared to L121 




chains longer than 50 EO units – future work should also include Pluronics with PEO chains greater 
than 50 units.  
Isothermal titration calorimetry studies would be a valuable addition to the physical characterization 
of these mixtures, as deviations from ideal mixing conditions may be confirmed through 
calorimetrically determined enthalpies of mixed micelle formation (and subsequent calculation of 
excess enthalpies of mixing). Similar to previous literature reports, some additional characterization 
may also include DLS measurements to monitor changes in hydrodynamic diameter over a range of 
Pluronic concentrations as the polymer is titrated into a solution of 16-3-16/pDNA complexes. Smaller 
aggregates resulting from aggregation of pure gemini surfactant or polymer could potentially be 
detected as a result of dissociation from the pDNA complex (using DLS or nanoparticle tracking 
analysis). If these results can be observed, it may offer confirmation of antagonistic mixing, for example 
in the 0.2 mole fraction L121 sample where the Pluronic is expected to form aggregates separate from 
the mixed micelle, or may even support the ethidium bromide study results presented here. Appearance 
of aggregates of a size consistent with that of a Pluronic/16-3-16 aggregate might be evidence that the 
16-3-16 dissociates from the gemini/pDNA complex to bind to the Pluronic component, leading to de-
condensation of the pDNA. Alternatively, equilibrium dialysis could also be useful in determining 
whether gemini surfactant binding to the Pluronic block copolymers in solution is responsible for the 
pDNA de-condensation results that are observed.  
Two-dimensional nuclear magnetic resonance (NMR) spectra, specifically nuclear Overhauser effect 
spectroscopy (NOESY), have also been helpful additions to mixed micelle studies since the 
intermolecular cross-peaks help identify atoms that are in close proximity (<0.5 nm) to each other. 
Admittedly, the presence of pDNA in these particular systems, may make the spectra too complex to 
interpret.  
The ratio of the first and third vibronic peaks of the pyrene fluorescence emission spectrum provides 
a measure of the polarity of the medium that the pyrene is dissolved in (i.e. the micelle core). As seen 
in previous literature reports, antagonistic mixing behaviour can be attributed to differences in the 
micropolarity of the pure components. Therefore, it would be worthwhile to measure the micropolarity 
of the pure Pluronic micelles, and the 16-3-16/pDNA complex as another means of understanding the 
differences in mixed aggregate stabilities. Similarly, the micropolarities of the 16-3-16/pDNA 




might provide an explanation for the stronger synergism observed in the F87 mixtures with the 5:1 
complex.  
6.1.2 Improvements for Transfection Efficiency 
As previously discussed, the gene delivery vector and pDNA cargo need to overcome several barriers 
prior to transgene expression. Seeing as the level of cellular entry can account for variations in 
transfection efficiency, cellular uptake studies are a recommended addition to this work. Cellular uptake 
is often determined by fluorescently tagging the pDNA to be delivered, followed by quantification of 
the fluorescent probe within the cells by techniques such as flow cytometry. Similarly, co-localization 
of fluorescently-labelled pDNA or nanoparticle components and various cellular compartments 
visualized by live cell confocal microscopy is typically used to learn more about the vector’s 
distribution throughout the cell. For example, co-localization of the pDNA and lysosome fluorescent 
signals would qualitatively indicate poor endosomal escape. Alternatively, localization at the nucleus 
is usually observed for nanoparticles that achieve high transfection. However, it is important to 
acknowledge that the presence of a fluorescent probe may alter the self-assembly of the system (through 
increased hydrophobic effect), or cleavage of the dye from the nanoparticle within biological systems 
can produce fluorescent metabolites that cannot be distinguished from the labelled molecule of interest. 
Some more recent cellular uptake and distribution studies of gemini surfactant-based vectors have used 
label-free methods such as differential centrifugation (to isolate organelles/subcellular fractions of 
interest, such as the nuclei, cytosol, plasma membranes, and endosomes), followed by quantification of 
the gemini surfactant component within each fraction using mass spectrometry.71  
Efforts to improve the transfection efficiency of a non-viral system often include the use of targeting 
ligands to increase uptake in the cells of interest. This approach also has potential to improve the 
Pluronic/16-3-16/pDNA systems proposed here, where the terminal hydroxyl groups of the Pluronic 
would most likely be exploited for functionalizing the nanoparticle. However, these modifications may 
only be practical for formulations with synergistic interactions, since de-mixing of the nanoparticle 
components might negate the effects of a targeting moiety if the functionalized component (e.g. labelled 
Pluronic) dissociates and is internalized by the cells separate from the pDNA component. 
Due to high transfectability, the COS-7 cells are often used as a standard cell line for non-viral 
transfection studies in general, and especially utilized in the evaluation of numerous gemini surfactant-




stage of exploration in this work. However, in order to assess the potential of these formulations as 
cancer treatments, transfection studies should also be conducted in a cancer cell line in vitro as well as 
an in vivo model appropriate for the disease of interest. For example, this research project was initiated 
with a particular focus on gene therapy of ovarian epithelial cell cancer; thus the OVCAR-3 or OVCAR-
8 cell lines would be suggested for use as in vitro models which can also be used for aggressive tumor 
formation in xenograft mouse models.195 Still, factors such as gene mutations of interest, formation of 
ascites fluid, and chemotherapy sensitivity will also influence the choice of cell line. More recent 
improvements to in vitro models such as three-dimensional spheroids derived from either primary 
patient cells or cell lines also provide an opportunity to gather transfection data that is more reflective 
of the cellular responses in vivo.196,197 Typically, in vitro transfection efficiencies have poor translation 
in vivo; however, this will depend on the disease of interest, the models used, and the formulation. In 
fact, the in vivo results of the amino acid substituted gemini surfactant-based systems for vaginal genetic 
vaccination reflected those seen in vitro.94 Even so, the in vitro-in vivo correlation for the 
Pluronic/gemini surfactant systems need to be determined. 
The transfection achieved with all of the formulations explored in this work were still significantly 
below the commercially available reagent, Lipofectamine 2000. Despite the comparatively low 
transfection efficiencies seen to date with these Pluronic/16-3-16/pDNA systems, the previous studies 
conducted in OVCAR-3 cells used higher concentrations of the transfection reagents than were used in 
this work, and showed greater cell viability than Lipofectamine 2000. Therefore, a gemini surfactant 
and Pluronic combo remains of interest. Although more characterization is needed, based on the 
solution behaviour of the 16-3-16/pDNA complex described in Chapter 3 and the ethidium bromide 
fluorescence studies reported in Chapter 4, it is conceivable that the low transfection efficiencies of the 
mixtures may be related to strong binding between the pDNA and gemini surfactant which may be 
hindering efficient endosomal escape, nuclear import and/or transcription of the pDNA on account of 
incomplete de-condensation and dissociation from the 16-3-16 molecules. Granted, those mixtures 
showing greater synergism (suggesting greater nanoparticle stability during delivery) and greater 
pDNA condensation (estimated by lower EtBr binding) produced the highest transgene expression, but 
it may be a matter of striking a balance between the two to achieve sufficient pDNA release at the 
correct moment. Thus, in addition to testing other Pluronic copolymers (as previously discussed), 




changes to the charge ratio of the 16-3-16/pDNA complex, the order of mixing, use of different gemini 
surfactants, or nanoparticle preparation in the presence of added salt.  
Although many of these suggested changes to the formulation would likely alter the strength and 
possibly the nature of the interactions within the mixtures, the work in this thesis clearly demonstrates 
that researchers in the field of self-assembled gene therapy formulation must consider and continue to 
systematically study the interactions within these multi-component systems in the presence of the 
genetic cargo as much as possible. Uncovering conditions that contribute to higher (or lower) 
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Table A-1  Conductivity of 16-3-16/pDNA (10:1) complex in water 

























0.00 1.67 0.02 0.00 1.24 0.03 0.00 1.56 0.02 
4.70 3.10 0.04 4.70 2.13 0.02 4.70 2.44 0.01 
8.98 4.16 0.18 8.98 2.82 0.08 8.98 3.28 0.02 
12.89 5.25 0.09 12.89 3.54 0.04 12.89 4.00 0.04 
16.47 5.82 0.68 16.47 4.18 0.04 16.47 4.57 0.10 
19.76 6.95 0.04 19.76 4.73 0.04 19.76 5.26 0.03 
22.80 7.26 0.45 22.80 5.11 0.14 22.80 5.84 0.05 
25.62 8.04 0.34 25.62 5.50 0.19 25.62 6.15 0.16 
28.23 8.65 0.34 28.23 6.01 0.02 28.23 6.60 0.12 
30.66 9.30 0.12 30.66 6.34 0.06 30.66 6.97 0.04 
32.93 9.55 0.25 32.93 6.64 0.08 32.93 7.29 0.04 
35.06 9.98 0.11 35.06 6.87 0.02 35.06 7.55 0.02 
37.05 10.24 0.31 37.05 7.04 0.01 37.05 7.79 0.01 
38.92 10.64 0.34 38.92 7.25 0.01 38.92 7.99 0.03 
40.68 10.90 0.28 40.68 7.43 0.03 40.68 8.16 0.02 
   42.34 7.59 0.04 42.34 8.33 0.02 




Dynamic Light Scattering  
Table A-2  Scattered light intensity, Z-average, and polydispersity index of 16-3-16/pDNA complex 
titrated into water 
Concentration (M) Intensity (kcps) Z-Average (nm) Polydisperisty Index 
0.00 104.90 319.40 0.31 
0.00 114.30 325.00 0.42 
0.00 139.60 433.00 0.43 
2.89 x 10-7 93.40 231.80 0.35 
2.89 x 10-7 71.40 197.40 0.33 
2.89 x 10-7 128.00 252.50 0.33 
5.79 x 10-7 152.00 207.90 0.32 
5.79 x 10-7 128.70 222.70 0.40 
5.79 x 10-7 145.50 213.40 0.31 
8.69 x 10-7 160.00 185.80 0.33 
8.69 x 10-7 154.10 182.70 0.31 
8.69 x 10-7 143.10 175.50 0.30 
1.16 x 10-6 169.20 165.50 0.28 
1.16 x 10-6 152.40 155.80 0.24 
1.16 x 10-6 161.20 163.60 0.25 
1.45 x 10-6 165.40 151.80 0.23 
1.45 x 10-6 164.30 149.20 0.24 
1.45 x 10-6 166.70 156.10 0.22 
1.74 x 10-6 187.30 148.70 0.23 
1.74 x 10-6 194.00 152.80 0.23 
1.74 x 10-6 201.70 156.20 0.26 
2.03 x 10-6 201.40 145.30 0.21 
2.03 x 10-6 214.40 147.30 0.22 
2.03 x 10-6 212.90 151.40 0.21 
2.31 x 10-6 233.50 146.80 0.19 
2.31 x 10-6 235.40 150.10 0.21 
2.31 x 10-6 250.80 155.50 0.22 
2.60 x 10-6 265.00 154.50 0.23 
2.60 x 10-6 259.00 150.00 0.19 
2.60 x 10-6 252.30 147.00 0.22 
2.89 x 10-6 313.60 152.20 0.21 
2.89 x 10-6 313.50 149.70 0.21 
2.89 x 10-6 315.70 150.30 0.23 
3.18 x 10-6 326.20 150.60 0.22 
3.18 x 10-6 341.30 151.80 0.22 
3.18 x 10-6 343.50 156.00 0.21 
3.47 x 10-6 371.20 157.40 0.23 
3.47 x 10-6 384.80 156.00 0.23 






Table A-2  Scattered light intensity, Z-average, and polydispersity index of 16-3-16/pDNA complex 
titrated into water 
Concentration (M) Intensity (kcps) Z-Average (nm) Polydisperisty Index 
3.76 x 10-6 402.70 155.10 0.22 
3.76 x 10-6 398.00 154.10 0.27 
3.76 x 10-6 400.40 154.10 0.24 
4.05 x 10-6 429.30 155.40 0.24 
4.05 x 10-6 401.80 153.10 0.23 
4.05 x 10-6 407.50 153.00 0.22 
4.34 x 10-6 432.70 150.60 0.24 
4.34 x 10-6 424.30 154.90 0.23 
4.34 x 10-6 403.60 151.90 0.24 
4.63 x 10-6 423.00 149.10 0.23 
4.63 x 10-6 415.70 145.40 0.21 
4.63 x 10-6 414.20 145.60 0.22 
4.92 x 10-6 419.70 144.10 0.18 
4.92 x 10-6 396.80 141.40 0.17 
4.92 x 10-6 417.70 142.10 0.19 
5.22 x 10-6 443.40 154.60 0.25 
5.22 x 10-6 434.90 150.10 0.26 
5.22 x 10-6 421.90 143.50 0.24 
5.50 x 10-6 442.90 141.60 0.19 
5.50 x 10-6 457.10 144.50 0.21 






Table B-1  Surface tension of 16-3-16/pDNA (10:1) complexes in water at 25°C 













0.00 71.0 0.00 71.0 0.00 70.8 
1.21 x 10-6 64.6 1.21 x 10-6 66.3 1.21 x 10-6 63.4 
2.39 x 10-6 50.4 2.39 x 10-6 58.7 2.39 x 10-6 48.3 
3.54 x 10-6 45.7 3.54 x 10-6 53.5 3.54 x 10-6 44.5 
4.67 x 10-6 43.5 4.67 x 10-6 49.5 4.67 x 10-6 42.4 
5.76 x 10-6 41.8 5.76 x 10-6 46.7 5.76 x 10-6 40.3 
6.84 x 10-6 40.5 6.84 x 10-6 44.8 6.84 x 10-6 39.2 
7.89 x 10-6 39.3 7.89 x 10-6 43.4 7.89 x 10-6 38.4 
8.91 x 10-6 38.7 8.91 x 10-6 42.1 8.91 x 10-6 37.7 
9.91 x 10-6 37.9 9.91 x 10-6 41.1 9.91 x 10-6 36.8 
1.09 x 10-5 37.3 1.09 x 10-5 40.2 1.09 x 10-5 36.5 
1.18 x 10-5 36.7 1.18 x 10-5 39.2 1.18 x 10-5 36.1 
1.28 x 10-5 36.3 1.28 x 10-5 38.5 1.28 x 10-5 35.6 
1.37 x 10-5 36.0 1.37 x 10-5 37.9 1.37 x 10-5 35.3 
1.46 x 10-5 35.7 1.46 x 10-5 37.5 1.46 x 10-5 35.3 
1.55 x 10-5 35.6 1.55 x 10-5 37.2 1.55 x 10-5 34.8 
1.63 x 10-5 35.6 1.63 x 10-5 36.9 1.63 x 10-5 34.6 
1.72 x 10-5 35.4 1.72 x 10-5 36.6 1.72 x 10-5 34.5 
1.80 x 10-5 35.5 1.80 x 10-5 36.4 1.80 x 10-5 34.3 
1.88 x 10-5 35.2 1.88 x 10-5 36.2 1.88 x 10-5 34.2 
1.96 x 10-5 35.2 1.96 x 10-5 36.0 1.96 x 10-5 34.1 
2.04 x 10-5 35.1 2.04 x 10-5 36.0 2.04 x 10-5 34.1 
2.11 x 10-5 35.2 2.11 x 10-5 35.9 2.11 x 10-5 34.1 
2.19 x 10-5 35.1 2.19 x 10-5 35.7 2.19 x 10-5 34.2 
2.26 x 10-5 34.9 2.26 x 10-5 35.7 2.26 x 10-5 34.1 
2.33 x 10-5 35.0 2.33 x 10-5 35.5 2.33 x 10-5 34.0 
2.40 x 10-5 35.0 2.40 x 10-5 35.5 2.40 x 10-5 34.0 
  2.47 x 10-5 35.3 2.47 x 10-5 33.9 
  2.54 x 10-5 35.3 2.54 x 10-5 33.9 
  2.61 x 10-5 35.2 2.61 x 10-5 33.9 
  2.67 x 10-5 35.1 2.67 x 10-5 34.0 
  2.74 x 10-5 35.1 2.74 x 10-5 34.0 




Table B-2  Surface tension of F87/16-3-16/pDNA mixtures of varying F87 mole fraction in water at 25°C 
Trial 1 











γ (mN/m) Concentration 
(mol/L) 
γ (mN/m) 
0.00 69.1 0.00 68.8 0.00 69.1 0.00 69.3 
6.67 x 10-10 68.0 6.67 x 10-10 67.8 6.72 x 10-10 67.2 6.67 x 10-10 68.4 
1.33 x 10-9 68.1 1.33 x 10-9 67.7 1.34 x 10-9 66.8 1.33 x 10-9 68.1 
2.00 x 10-9 68.1 2.00 x 10-9 67.6 2.01 x 10-9 65.7 2.00 x 10-9 67.6 
2.93 x 10-9 68.0 2.93 x 10-9 67.5 2.95 x 10-9 66.1 2.93 x 10-9 67.7 
4.26 x 10-9 67.7 4.26 x 10-9 66.0 4.30 x 10-9 65.6 4.26 x 10-9 65.9 
6.26 x 10-9 67.6 6.26 x 10-9 65.2 6.31 x 10-9 64.2 6.26 x 10-9 65.3 
9.59 x 10-9 67.5 9.59 x 10-9 62.5 9.66 x 10-9 63.6 9.59 x 10-9 63.7 
1.42 x 10-8 66.5 1.42 x 10-8 60.0 1.43 x 10-8 62.6 1.42 x 10-8 62.7 
2.09 x 10-8 66.1 2.09 x 10-8 58.9 2.10 x 10-8 60.8 2.09 x 10-8 61.2 
3.15 x 10-8 65.1 3.15 x 10-8 58.0 3.17 x 10-8 58.7 3.15 x 10-8 59.2 
4.73 x 10-8 63.6 4.73 x 10-8 56.7 4.77 x 10-8 57.5 4.73 x 10-8 57.2 
7.36 x 10-8 62.1 7.36 x 10-8 55.5 7.41 x 10-8 55.7 7.36 x 10-8 55.3 
1.13 x 10-7 60.3 1.13 x 10-7 53.7 1.14 x 10-7 53.8 1.13 x 10-7 53.6 
1.77 x 10-7 58.5 1.77 x 10-7 50.4 1.78 x 10-7 51.3 1.77 x 10-7 51.3 
2.71 x 10-7 55.6 2.71 x 10-7 49.4 2.73 x 10-7 49.3 2.71 x 10-7 49.7 
3.94 x 10-7 52.3 3.94 x 10-7 48.5 3.97 x 10-7 48.8 3.94 x 10-7 48.7 
5.70 x 10-7 50.5 5.70 x 10-7 47.5 5.75 x 10-7 48.0 5.70 x 10-7 47.9 
7.94 x 10-7 49.5 7.94 x 10-7 46.9 8.00 x 10-7 47.3 7.94 x 10-7 47.4 
1.05 x 10-6 48.9 1.05 x 10-6 46.4 1.06 x 10-6 46.8 1.05 x 10-6 47.0 
1.34 x 10-6 48.7 1.39 x 10-6 46.4 1.40 x 10-6 46.4 1.39 x 10-6 46.4 
1.61 x 10-6 48.4 1.73 x 10-6 46.2 2.06 x 10-6 46.2 1.82 x 10-6 46.3 
1.85 x 10-6 48.0 2.05 x 10-6 46.1 2.41 x 10-6 45.7 2.32 x 10-6 46.1 
2.08 x 10-6 47.8       
2.29 x 10-6 47.7       
2.49 x 10-6 47.5       
2.67 x 10-6 47.5       






Table B-2 (cont’d) Surface tension of F87/16-3-16/pDNA mixtures of varying F87 mole fraction in water at 25°C 
Trial 2 











γ (mN/m) Concentration 
(mol/L) 
γ (mN/m) 
0.00 68.3 0.00 68.8 0.00 68.9 0.00 69.1 
6.67 x 10-10 67.2 6.67 x 10-10 67.7 6.67 x 10-10 67.4 6.67 x 10-10 67.7 
1.33 x 10-9 67.4 1.33 x 10-9 67.9 1.33 x 10-9 67.0 1.33 x 10-9 67.6 
2.00 x 10-9 67.4 2.00 x 10-9 67.5 2.00 x 10-9 65.9 2.00 x 10-9 66.9 
2.93 x 10-9 67.6 2.93 x 10-9 67.4 2.93 x 10-9 65.1 2.93 x 10-9 65.4 
4.26 x 10-9 67.5 4.26 x 10-9 67.3 4.26 x 10-9 64.7 4.26 x 10-9 64.1 
6.26 x 10-9 67.6 6.26 x 10-9 66.9 6.26 x 10-9 64.0 6.26 x 10-9 62.8 
9.59 x 10-9 67.7 9.59 x 10-9 65.8 9.59 x 10-9 62.4 9.59 x 10-9 60.9 
1.42 x 10-8 67.7 1.42 x 10-8 64.9 1.42 x 10-8 60.8 1.42 x 10-8 59.3 
2.09 x 10-8 67.7 2.09 x 10-8 62.6 2.09 x 10-8 59.3 2.09 x 10-8 57.5 
3.15 x 10-8 67.3 3.15 x 10-8 61.0 3.15 x 10-8 58.1 3.15 x 10-8 55.9 
4.73 x 10-8 66.9 4.73 x 10-8 58.8 4.73 x 10-8 56.7 4.73 x 10-8 54.1 
7.36 x 10-8 65.6 7.36 x 10-8 57.0 7.36 x 10-8 55.2 7.36 x 10-8 52.0 
1.13 x 10-7 63.3 1.13 x 10-7 55.4 1.13 x 10-7 52.8 1.13 x 10-7 49.6 
1.77 x 10-7 59.1 1.77 x 10-7 52.4 1.77 x 10-7 50.6 1.77 x 10-7 48.6 
2.71 x 10-7 56.6 2.71 x 10-7 49.7 2.71 x 10-7 49.5 2.71 x 10-7 47.6 
3.94 x 10-7 54.0 3.94 x 10-7 49.0 3.94 x 10-7 48.7 3.94 x 10-7 46.9 
5.70 x 10-7 50.7 5.70 x 10-7 48.1 5.70 x 10-7 48.3 5.70 x 10-7 46.4 
7.94 x 10-7 49.3 7.94 x 10-7 47.1 7.94 x 10-7 47.9 7.94 x 10-7 46.0 
1.05 x 10-6 48.4 1.05 x 10-6 46.6 1.39 x 10-6 47.4 1.05 x 10-6 45.8 
1.34 x 10-6 48.0 1.30 x 10-6 46.5 1.73 x 10-6 47.2 1.39 x 10-6 45.7 
1.61 x 10-6 47.3 1.52 x 10-6 46.3 2.05 x 10-6 46.8 1.73 x 10-6 45.7 
1.85 x 10-6 47.0 1.73 x 10-6 46.2 2.31 x 10-6 46.7 2.05 x 10-6 45.8 
2.08 x 10-6 46.7 1.93 x 10-6 46.2   2.33 x 10-6 45.4 
2.29 x 10-6 46.4 2.12 x 10-6 46.1     
2.49 x 10-6 46.3 2.29 x 10-6 45.8     
2.67 x 10-6 46.2       




Table B-2 (cont’d)  Surface tension of F87/16-3-16/pDNA mixtures of varying F87 mole fraction in water at 25°C 
Trial 3 











γ (mN/m) Concentration 
(mol/L) 
γ (mN/m) 
0.00 69.0 0.00 68.1 0.00 67.3 0.00 68.2 
6.67 x 10-10 67.6 6.72 x 10-10 66.7 6.67 x 10-10 66.1 6.67 x 10-10 67.0 
1.33 x 10-9 67.5 1.34 x 10-9 67.0 1.33 x 10-9 66.1 1.33 x 10-9 66.9 
2.00 x 10-9 67.5 2.00 x 10-9 66.9 2.00 x 10-9 66.1 2.00 x 10-9 66.4 
2.93 x 10-9 67.5 2.93 x 10-9 66.9 2.93 x 10-9 65.9 2.93 x 10-9 66.1 
4.26 x 10-9 67.5 4.26 x 10-9 66.8 4.26 x 10-9 65.1 4.26 x 10-9 65.4 
6.26 x 10-9 67.4 6.26 x 10-9 66.68 6.26 x 10-9 64.7 6.26 x 10-9 64.3 
9.59 x 10-9 67.6 9.59 x 10-9 66.7 9.59 x 10-9 64.3 9.59 x 10-9 63.0 
1.42 x 10-8 67.6 1.42 x 10-8 66.4 1.42 x 10-8 63.8 1.42 x 10-8 61.0 
2.09 x 10-8 67.4 2.09 x 10-8 65.8 2.09 x 10-8 62.4 2.09 x 10-8 59.8 
3.15 x 10-8 66.9 3.15 x 10-8 65.4 3.15 x 10-8 61.2 3.15 x 10-8 58.4 
4.73 x 10-8 66.6 4.73 x 10-8 64.2 4.73 x 10-8 59.7 4.73 x 10-8 57.0 
7.36 x 10-8 65.7 7.36 x 10-8 61.5 7.36 x 10-8 58.2 7.36 x 10-8 55.2 
1.13 x 10-7 63.6 1.13 x 10-7 58.8 1.13 x 10-7 56.7 1.13 x 10-7 53.4 
1.77 x 10-7 60.8 1.77 x 10-7 56.9 1.77 x 10-7 53.9 1.77 x 10-7 51.3 
2.71 x 10-7 58.1 2.71 x 10-7 53.5 2.71 x 10-7 51.4 2.71 x 10-7 49.6 
3.94 x 10-7 55.7 3.94 x 10-7 50.3 3.94 x 10-7 49.8 3.94 x 10-7 48.5 
5.70 x 10-7 51.9 5.70 x 10-7 49.0 5.70 x 10-7 48.7 5.70 x 10-7 47.7 
7.94 x 10-7 50.2 7.94 x 10-7 48.2 7.94 x 10-7 47.9 7.94 x 10-7 47.1 
1.05 x 10-6 49.1 1.05 x 10-6 48.4 1.05 x 10-6 47.2 1.05 x 10-6 46.9 
1.34 x 10-6 48.5 1.34 x 10-6 47.4 1.34 x 10-6 46.8 1.34 x 10-6 46.4 
1.61 x 10-6 48.3 1.61 x 10-6 46.9 1.61 x 10-6 46.4 1.61 x 10-6 46.3 
1.85 x 10-6 47.7 1.85 x 10-6 46.8 1.85 x 10-6 46.4 1.85 x 10-6 46.0 
2.08 x 10-6 47.3 2.08 x 10-6 46.5 2.08 x 10-6 45.9 2.08 x 10-6 45.9 
2.29 x 10-6 47.4 2.29 x 10-6 46.4 2.29 x 10-6 45.7 2.29 x 10-6 45.9 
2.49 x 10-6 47.0 2.49 x 10-6 46.0 2.49 x 10-6 45.5 2.49 x 10-6 45.7 
2.67 x 10-6 46.8 2.67 x 10-6 45.9 2.67 x 10-6 45.4 2.67 x 10-6 45.7 




Table B-3  Surface tension of P84/16-3-16/pDNA mixtures of varying P84 mole fraction in water at 25°C 
Trial 1 

















0.00 73.1 0.00 72.0 0.00 72.4 0.00 72.5 
7.87 x 10-9 73.2 7.87 x 10-9 71.6 7.87 x 10-9 72.1 7.87 x 10-9 71.4 
9.18 x 10-9 73.0 9.18 x 10-9 70.8 9.18 x 10-9 72.0 9.18 x 10-9 70.2 
1.10 x 10-8 72.6 1.10 x 10-8 69.2 1.10 x 10-8 70.5 1.10 x 10-8 69.2 
1.36 x 10-8 72.5 1.36 x 10-8 67.7 1.36 x 10-8 67.8 1.36 x 10-8 68.6 
1.68 x 10-8 72.5 1.68 x 10-8 65.3 1.68 x 10-8 66.2 1.68 x 10-8 66.3 
2.07 x 10-8 71.6 2.07 x 10-8 63.0 2.07 x 10-8 65.1 2.07 x 10-8 64.5 
2.59 x 10-8 70.7 2.59 x 10-8 61.4 2.59 x 10-8 62.8 2.59 x 10-8 62.3 
3.25 x 10-8 69.9 3.25 x 10-8 60.4 3.25 x 10-8 61.2 3.25 x 10-8 61.2 
4.16 x 10-8 69.4 4.16 x 10-8 58.6 4.16 x 10-8 59.4 4.16 x 10-8 59.5 
5.33 x 10-8 68.7 5.33 x 10-8 57.3 5.33 x 10-8 57.4 5.33 x 10-8 58.3 
6.89 x 10-8 68.0 6.89 x 10-8 56.2 6.89 x 10-8 54.9 2.26 x 10-7 49.3 
8.84 x 10-8 66.9 8.84 x 10-8 55.0 8.84 x 10-8 53.5 2.89 x 10-7 48.7 
1.10 x 10-7 65.6 1.10 x 10-7 53.5 1.10 x 10-7 51.1 3.65 x 10-7 48.2 
1.36 x 10-7 63.4 1.36 x 10-7 52.7 1.36 x 10-7 50.1 4.65 x 10-7 47.7 
1.75 x 10-7 61.9 1.75 x 10-7 51.8 1.75 x 10-7 49.3 5.99 x 10-7 47.1 
2.26 x 10-7 60.0 2.26 x 10-7 51.6 2.26 x 10-7 48.9 7.56 x 10-7 46.6 
2.89 x 10-7 56.7 2.89 x 10-7 51.4 2.89 x 10-7 48.4 9.38 x 10-7 46.3 
3.65 x 10-7 54.2 3.65 x 10-7 51.1 3.65 x 10-7 48.1 1.14 x 10-6 45.6 
4.65 x 10-7 51.8 4.65 x 10-7 51.1 4.65 x 10-7 47.7 1.37 x 10-6 45.2 
5.99 x 10-7 50.4 5.99 x 10-7 51.2 5.99 x 10-7 47.5 1.58 x 10-6 45.1 
7.56 x 10-7 49.4 7.56 x 10-7 51.2 7.56 x 10-7 47.1 1.79 x 10-6 44.8 
9.38 x 10-7 48.6 9.38 x 10-7 51.0 9.38 x 10-7 46.9 2.00 x 10-6 44.4 
1.14 x 10-6 47.5 1.14 x 10-6 50.8 1.14 x 10-6 47.0 2.23 x 10-6 44.2 
1.37 x 10-6 46.6 1.37 x 10-6 50.1 1.37 x 10-6 47.2   




Table B-3 (cont’d)  Surface tension of P84/16-3-16/pDNA mixtures of varying P84 mole fraction in water at 25°C 
Trial 2 

















0.00 73.1 0.00 73.3 0.00 73.5 0.00 73.6 
2.62 x 10-8 73.1 7.87 x 10-9 73.2 7.87 x 10-9 73.3 7.87 x 10-9 73.3 
1.82 x 10-7 71.2 9.18 x 10-9 73.3 9.18 x 10-9 72.6 9.18 x 10-9 72.6 
2.58 x 10-7 68.3 1.10 x 10-8 73.0 1.10 x 10-8 71.6 1.10 x 10-8 71.2 
2.83 x 10-7 64.2 1.36 x 10-8 72.9 1.36 x 10-8 70.1 1.36 x 10-8 70.6 
3.09 x 10-7 59.8 1.68 x 10-8 71.7 1.68 x 10-8 68.4 1.68 x 10-8 68.6 
3.34 x 10-7 54.1 2.07 x 10-8 69.9 2.07 x 10-8 65.7 2.07 x 10-8 65.8 
3.59 x 10-7 51.5 2.59 x 10-8 68.5 2.59 x 10-8 63.4 2.59 x 10-8 64.0 
3.84 x 10-7 50.5 3.25 x 10-8 67.7 3.25 x 10-8 61.1 3.25 x 10-8 63.0 
4.06 x 10-7 49.9 4.16 x 10-8 65.7 4.16 x 10-8 59.0 4.16 x 10-8 62.1 
4.31 x 10-7 49.6 5.33 x 10-8 63.3 5.33 x 10-8 56.7 5.33 x 10-8 60.4 
4.56 x 10-7 49.3 6.89 x 10-8 61.5 6.89 x 10-8 55.3 6.89 x 10-8 58.8 
4.81 x 10-7 49.0 8.84 x 10-8 60.4 8.84 x 10-8 53.6 8.84 x 10-8 56.7 
5.30 x 10-7 48.8 1.10 x 10-7 52.5 1.10 x 10-7 52.1 1.10 x 10-7 54.9 
5.79 x 10-7 48.6 1.36 x 10-7 51.7 1.36 x 10-7 51.2 1.36 x 10-7 52.2 
6.28 x 10-7 48.3 1.75 x 10-7 50.6 1.75 x 10-7 50.1 1.75 x 10-7 51.6 
6.76 x 10-7 48.1 2.26 x 10-7 50.0 2.26 x 10-7 49.5 2.26 x 10-7 51.0 
7.36 x 10-7 47.8 2.77 x 10-7 49.7 2.89 x 10-7 48.9 2.89 x 10-7 50.6 
8.07 x 10-7 47.5 3.27 x 10-7 49.2 3.65 x 10-7 48.5 3.65 x 10-7 50.2 
9.01 x 10-7 47.0 3.78 x 10-7 48.9 4.65 x 10-7 47.9 4.65 x 10-7 49.9 
1.02 x 10-6 46.2 4.40 x 10-7 48.7 5.99 x 10-7 47.2 5.99 x 10-7 49.8 
1.15 x 10-6 45.2 5.14 x 10-7 48.3 7.56 x 10-7 46.3 7.56 x 10-7 49.8 
1.31 x 10-6 43.4 6.12 x 10-7 48.0 9.38 x 10-7 45.6 9.38 x 10-7 49.9 
1.51 x 10-6 41.3 7.32 x 10-7 47.5 1.14 x 10-6 44.3 1.14 x 10-6 49.9 
1.72 x 10-6 40.7 8.74 x 10-7 46.7 1.37 x 10-6 43.1   
1.92 x 10-6 38.2 1.10 x 10-6 45.9 1.58 x 10-6 42.4   




Table B-3 (cont’d)  Surface tension of P84/16-3-16/pDNA mixtures of varying P84 mole fraction in water at 25°C 
Trial 3 

















0.00 72.5 0.00 72.4 0.00 73.9 0.00 74.1 
2.62 x 10-8 72.5 7.87 x 10-9 72.3 7.87 x 10-9 73.7 7.87 x 10-9 73.8 
1.82 x 10-7 71.9 9.18 x 10-9 72.3 9.18 x 10-9 73.4 9.18 x 10-9 73.2 
2.58 x 10-7 70.2 1.10 x 10-8 72.2 1.10 x 10-8 73.0 1.10 x 10-8 72.8 
2.83 x 10-7 66.4 1.36 x 10-8 72.1 1.36 x 10-8 72.5 1.36 x 10-8 71.5 
3.09 x 10-7 64.5 1.68 x 10-8 71.9 1.68 x 10-8 71.2 1.68 x 10-8 69.2 
3.34 x 10-7 61.6 2.07 x 10-8 71.5 2.07 x 10-8 69.1 2.07 x 10-8 67.8 
3.59 x 10-7 59.3 2.59 x 10-8 71.0 2.59 x 10-8 67.3 2.59 x 10-8 65.9 
3.84 x 10-7 57.1 3.25 x 10-8 70.0 3.25 x 10-8 65.9 3.25 x 10-8 64.5 
4.09 x 10-7 54.2 4.16 x 10-8 68.9 4.16 x 10-8 64.9 4.16 x 10-8 63.4 
4.34 x 10-7 52.5 5.33 x 10-8 67.6 5.33 x 10-8 63.8 5.33 x 10-8 61.2 
4.59 x 10-7 50.7 6.89 x 10-8 66.4 6.89 x 10-8 61.8 6.89 x 10-8 59.6 
4.83 x 10-7 49.7 8.84 x 10-8 64.7 8.84 x 10-8 60.4 8.84 x 10-8 58.1 
5.32 x 10-7 49.1 1.10 x 10-7 62.9 1.10 x 10-7 58.3 1.10 x 10-7 56.0 
5.81 x 10-7 48.6 1.36 x 10-7 60.9 1.36 x 10-7 56.2 1.36 x 10-7 53.8 
6.30 x 10-7 48.2 1.75 x 10-7 58.8 1.75 x 10-7 53.7 1.75 x 10-7 52.1 
6.78 x 10-7 47.6 2.26 x 10-7 56.4 2.26 x 10-7 51.8 2.26 x 10-7 50.9 
7.38 x 10-7 47.3 2.77 x 10-7 52.8 2.89 x 10-7 50.7 2.89 x 10-7 50.2 
8.09 x 10-7 46.8 3.27 x 10-7 51.4 3.65 x 10-7 49.9 3.65 x 10-7 49.8 
9.03 x 10-7 46.2 3.77 x 10-7 50.5 4.65 x 10-7 49.4 4.65 x 10-7 49.3 
1.02 x 10-6 45.3 4.39 x 10-7 50.0 5.99 x 10-7 48.8 5.99 x 10-7 49.1 
1.16 x 10-6 44.2 5.13 x 10-7 49.4 7.56 x 10-7 48.5 7.56 x 10-7 48.7 
1.31 x 10-6 42.5 6.12 x 10-7 49.0 9.38 x 10-7 48.0 9.38 x 10-7 48.4 
1.51 x 10-6 40.8 7.32 x 10-7 48.5 1.14 x 10-6 47.3 6.89 x 10-8 73.8 
1.72 x 10-6 39.2 8.74 x 10-7 47.9 1.37 x 10-6 46.9   
1.93 x 10-6 36.3 1.10 x 10-6 46.7 1.58 x 10-6 46.6   




Table B-4  Surface tension of L121/16-3-16/pDNA mixtures of varying L121 mole fraction in water at 25°C 
Trial 1 

















1.31 x 10-9 71.0 7.87 x 10-9 73.0 7.87 x 10-9 72.2 7.87 x 10-9 72.3 
2.62 x 10-9 71.1 9.18 x 10-9 73.0 2.10 x 10-8 71.5 1.83 x 10-8 71.4 
3.93 x 10-9 71.2 1.18 x 10-8 72.8 3.40 x 10-8 69.9 2.49 x 10-8 70.8 
5.77 x 10-9 71.2 1.57 x 10-8 72.7 4.71 x 10-8 67.5 3.14 x 10-8 69.2 
8.39 x 10-9 71.2 2.10 x 10-8 72.7 5.75 x 10-8 66.0 3.92 x 10-8 62.9 
1.23 x 10-8 71.2 2.75 x 10-8 72.5 7.05 x 10-8 60.5 4.71 x 10-8 60.8 
1.89 x 10-8 71.2 3.66 x 10-8 72.2 8.74 x 10-8 56.1 5.75 x 10-8 58.6 
2.80 x 10-8 71.2 4.84 x 10-8 71.6 1.07 x 10-7 54.8 7.05 x 10-8 56.3 
4.24 x 10-8 71.1 6.14 x 10-8 71.3 1.33 x 10-7 53.0 8.61 x 10-8 51.4 
6.58 x 10-8 70.6 7.83 x 10-8 70.4 1.58 x 10-7 51.3 1.06 x 10-7 47.3 
9.70 x 10-8 70.2 9.78 x 10-8 67.7 1.84 x 10-7 47.9 1.28 x 10-7 46.3 
1.36 x 10-7 68.7 1.21 x 10-7 65.5 2.22 x 10-7 45.4 1.53 x 10-7 45.3 
1.87 x 10-7 67.2 1.60 x 10-7 62.4 2.73 x 10-7 43.4 1.92 x 10-7 44.1 
2.64 x 10-7 65.1 1.98 x 10-7 59.1 3.36 x 10-7 43.1 2.43 x 10-7 43.1 
3.64 x 10-7 60.4 2.49 x 10-7 53.3 4.16 x 10-7 42.6 3.06 x 10-7 42.5 
4.89 x 10-7 55.8 3.38 x 10-7 49.3 5.15 x 10-7 41.9 3.82 x 10-7 41.9 
6.35 x 10-7 51.3 4.38 x 10-7 47.2 6.37 x 10-7 41.4 5.05 x 10-7 41.2 
8.03 x 10-7 48.2 5.73 x 10-7 44.2 7.81 x 10-7 40.9 6.52 x 10-7 40.7 
9.67 x 10-7 44.9 7.18 x 10-7 42.2 9.68 x 10-7 40.6 8.42 x 10-7 40.2 
1.13 x 10-6 42.0 9.07 x 10-7 40.8 1.20 x 10-6 40.5 1.07 x 10-6 39.6 
1.28 x 10-6 40.1 1.14 x 10-6 39.4 1.42 x 10-6 40.9 1.30 x 10-6 39.4 
1.44 x 10-6 38.8 1.36 x 10-6 38.4 1.63 x 10-6 40.7 1.52 x 10-6 39.0 
1.63 x 10-6 37.4 1.58 x 10-6 37.5 1.84 x 10-6 40.7 1.73 x 10-6 38.8 
1.84 x 10-6 37.5 1.79 x 10-6 36.8 2.04 x 10-6 40.9 1.93 x 10-6 38.7 
2.04 x 10-6 38.2 1.99 x 10-6 36.0 2.24 x 10-6 41.5 2.13 x 10-6 38.6 
2.18 x 10-6 36.6 2.19 x 10-6 35.2 2.43 x 10-6 41.9 2.33 x 10-6 38.5 




Table B-4 (cont’d) Surface tension of L121/16-3-16/pDNA mixtures of varying L121 mole fraction in water at 25°C 
Trial 2 

















2.62 x 10-8 74.4 5.23 x 10-8 71.9 7.87 x 10-9 72.4 7.87 x 10-9 71.6 
5.23 x 10-8 74.4 6.53 x 10-8 70.6 1.05 x 10-8 72.2 1.83 x 10-8 70.9 
7.83 x 10-8 74.5 7.83 x 10-8 69.6 1.31 x 10-8 71.9 2.10 x 10-8 69.5 
9.13 x 10-8 74.5 9.13 x 10-8 67.2 1.57 x 10-8 71.3 2.36 x 10-8 67.7 
1.04 x 10-7 74.4 1.07 x 10-7 65.1 1.83 x 10-8 70.0 2.75 x 10-8 64.4 
1.20 x 10-7 74.4 1.22 x 10-7 61.4 2.10 x 10-8 69.5 3.19 x 10-8 59.2 
1.40 x 10-7 73.8 1.43 x 10-7 60.1 2.49 x 10-8 66.0 3.64 x 10-8 56.2 
1.64 x 10-7 73.6 1.66 x 10-7 56.4 2.88 x 10-8 61.9 4.16 x 10-8 52.7 
1.89 x 10-7 73.1 1.89 x 10-7 55.4 3.40 x 10-8 59.6 4.81 x 10-8 50.9 
2.15 x 10-7 72.4 2.12 x 10-7 54.0 3.92 x 10-8 57.1 5.46 x 10-8 49.5 
2.53 x 10-7 71.5 2.38 x 10-7 52.8 4.45 x 10-8 54.2 6.24 x 10-8 50.3 
2.91 x 10-7 70.1 2.63 x 10-7 51.8 5.23 x 10-8 53.4 7.28 x 10-8 49.8 
3.41 x 10-7 68.4 2.88 x 10-7 49.2 6.27 x 10-8 51.2 8.45 x 10-8 47.9 
4.04 x 10-7 66.5 3.26 x 10-7 48.5 7.57 x 10-8 50.2 1.00 x 10-7 46.5 
4.83 x 10-7 64.0 3.77 x 10-7 47.4 9.13 x 10-8 48.7 1.18 x 10-7 45.6 
5.81 x 10-7 61.7 4.26 x 10-7 46.5 1.07 x 10-7 47.5 1.38 x 10-7 44.9 
7.02 x 10-7 57.7 5.01 x 10-7 45.5 1.27 x 10-7 46.4 1.63 x 10-7 44.7 
8.45 x 10-7 55.2 5.98 x 10-7 44.4 1.51 x 10-7 45.5 2.15 x 10-7 44.4 
1.03 x 10-6 52.9 7.19 x 10-7 42.2 1.76 x 10-7 45.1 2.91 x 10-7 44.2 
1.26 x 10-6 50.9 8.85 x 10-7 40.8 2.02 x 10-7 44.8 3.91 x 10-7 44.4 
1.48 x 10-6 48.5 1.09 x 10-6 39.6 2.28 x 10-7 44.6   
1.69 x 10-6 47.3 1.32 x 10-6 38.9 2.78 x 10-7 44.2   
1.90 x 10-6 46.9 1.53 x 10-6 38.9 3.29 x 10-7 44.0   
2.10 x 10-6 46.8 1.75 x 10-6 38.6 4.04 x 10-7 44.1   
2.29 x 10-6 46.7 1.95 x 10-6 38.5 5.03 x 10-7 43.9   




Table B-4 (cont’d) Surface tension of L121/16-3-16/pDNA mixtures of varying L121 mole fraction in water at 25°C 
Trial 3 

















7.87 x 10-9 72.4 7.87 x 10-9 72.0 7.87 x 10-9 72.2 7.87 x 10-9 72.1 
2.09 x 10-8 72.3 2.09 x 10-8 72.0 1.05 x 10-8 72.2 1.83 x 10-8 70.4 
3.40 x 10-8 72.3 3.40 x 10-8 71.9 1.31 x 10-8 72.0 2.10 x 10-8 65.6 
4.71 x 10-8 72.3 4.71 x 10-8 71.8 1.57 x 10-8 71.9 2.36 x 10-8 61.0 
6.27 x 10-8 72.3 6.01 x 10-8 71.5 1.83 x 10-8 71.7 2.62 x 10-8 56.3 
7.83 x 10-8 72.2 7.57 x 10-8 71.2 2.10 x 10-8 71.3 2.88 x 10-8 53.8 
9.91 x 10-8 72.0 9.65 x 10-8 70.5 2.49 x 10-8 70.9 3.27 x 10-8 50.6 
1.22 x 10-7 71.8 1.20 x 10-7 69.1 3.01 x 10-8 69.7 3.66 x 10-8 48.3 
1.48 x 10-7 71.5 1.46 x 10-7 67.1 3.53 x 10-8 68.5 4.19 x 10-8 46.7 
1.74 x 10-7 70.9 1.71 x 10-7 61.9 4.06 x 10-8 62.8 4.84 x 10-8 46.5 
2.12 x 10-7 69.8 2.10 x 10-7 58.1 4.58 x 10-8 61.8 5.62 x 10-8 46.3 
2.50 x 10-7 68.1 2.48 x 10-7 52.6 5.10 x 10-8 60.9 6.66 x 10-8 45.8 
3.01 x 10-7 65.8 2.99 x 10-7 50.5 5.88 x 10-8 59.7 7.83 x 10-8 45.5 
3.64 x 10-7 61.4 3.61 x 10-7 46.8 6.66 x 10-8 58.5 9.38 x 10-8 45.2 
4.44 x 10-7 58.1 4.41 x 10-7 44.4 7.96 x 10-8 57.3 1.12 x 10-7 44.5 
5.42 x 10-7 55.2 5.40 x 10-7 42.6 9.51 x 10-8 53.8 1.31 x 10-7 44.2 
6.64 x 10-7 51.5 6.61 x 10-7 41.5 1.16 x 10-7 51.7 1.57 x 10-7 44.1 
8.07 x 10-7 48.2 8.05 x 10-7 40.3 1.39 x 10-7 49.9 2.08 x 10-7 43.6 
9.94 x 10-7 44.5 9.92 x 10-7 39.3 1.65 x 10-7 48.3 2.85 x 10-7 43.3 
1.22 x 10-6 41.8 1.22 x 10-6 38.8 1.90 x 10-7 46.6 3.85 x 10-7 43.0 
1.44 x 10-6 39.7 1.44 x 10-6 38.7 2.16 x 10-7 45.1 5.09 x 10-7 42.7 
1.66 x 10-6 38.8 1.65 x 10-6 38.0 2.67 x 10-7 43.7 6.55 x 10-7 42.3 
1.86 x 10-6 38.5 1.86 x 10-6 38.0 3.18 x 10-7 42.7   
2.07 x 10-6 37.7 2.06 x 10-6 37.6 3.93 x 10-7 41.8   
2.26 x 10-6 37.5 2.26 x 10-6 37.5 4.92 x 10-7 40.8   




Table B-3  Surface tension of F127/16-3-16/pDNA mixtures of varying F127 mole fraction in water at 25°C 
Trial 1 

















0.00 69.8 0.00 69.8 0.00 69.5 0.00 70.2 
6.67 x 10-10 68.8 6.67 x 10-10 68.8 6.67 x 10-10 69.1 6.67 x 10-10 69.6 
1.33 x 10-9 68.7 1.33 x 10-9 69.4 1.33 x 10-9 69.2 1.33 x 10-9 69.2 
2.67 x 10-9 68.7 2.00 x 10-9 69.2 2.00 x 10-9 68.8 2.00 x 10-9 69.0 
5.33 x 10-9 68.7 3.33 x 10-9 69.3 3.33 x 10-9 68.2 3.33 x 10-9 68.1 
9.32 x 10-9 68.7 5.33 x 10-9 69.1 5.33 x 10-9 67.6 5.33 x 10-9 66.3 
1.46 x 10-8 68.5 8.66 x 10-9 68.8 8.66 x 10-9 66.9 8.66 x 10-9 65.1 
2.26 x 10-8 68.5 1.40 x 10-8 68.2 1.40 x 10-8 65.6 1.40 x 10-8 63.4 
3.58 x 10-8 68.3 2.19 x 10-8 67.4 2.19 x 10-8 61.9 2.19 x 10-8 61.2 
5.56 x 10-8 66.8 3.52 x 10-8 65.8 3.52 x 10-8 61.0 3.52 x 10-8 59.9 
8.83 x 10-8 64.6 5.82 x 10-8 63.0 5.82 x 10-8 59.5 5.82 x 10-8 58.1 
1.40 x 10-7 61.8 9.10 x 10-8 60.1 9.10 x 10-8 58.6 9.10 x 10-8 56.4 
2.17 x 10-7 59.7 1.43 x 10-7 58.4 1.43 x 10-7 56.8 1.43 x 10-7 54.2 
3.29 x 10-7 58.1 2.19 x 10-7 56.0 2.19 x 10-7 53.4 2.19 x 10-7 51.7 
4.73 x 10-7 55.6 3.43 x 10-7 53.2 3.43 x 10-7 50.7 3.43 x 10-7 50.1 
9.48 x 10-7 50.5 5.34 x 10-7 50.4 5.34 x 10-7 48.8 5.34 x 10-7 48.3 
1.39 x 10-6 49.6 8.13 x 10-7 48.4 8.13 x 10-7 47.2 8.13 x 10-7 47.2 
1.81 x 10-6 48.4 1.22 x 10-6 47.1 1.22 x 10-6 46.1 1.22 x 10-6 45.8 
2.26 x 10-6 48.1 1.67 x 10-6 46.3 1.58 x 10-6 44.9 1.75 x 10-6 45.5 
2.76 x 10-6 47.6 2.13 x 10-6 45.7 2.06 x 10-6 44.8 2.34 x 10-6 45.5 
3.27 x 10-6 47.7 2.71 x 10-6 45.1 2.65 x 10-6 44.1 2.94 x 10-6 44.4 
3.70 x 10-6 47.7 3.19 x 10-6 45.1 3.28 x 10-6 44.5   
4.31 x 10-6 45.9 3.71 x 10-6 44.9 3.85 x 10-6 44.5   






Table B-5 (cont’d)  Surface tension of F127/16-3-16/pDNA mixtures of varying F127 mole fraction in water at 25°C 
Trial 2 

















0.00 68.5 0.00 69.8 0.00 69.4 0.00 69.7 
1.33 x 10-9 68.0 1.33 x 10-9 68.6 1.33 x 10-9 68.0 1.67 x 10-9 67.9 
2.67 x 10-9 67.9 2.67 x 10-9 68.3 2.67 x 10-9 64.8 3.33 x 10-9 64.1 
4.53 x 10-9 67.9 4.53 x 10-9 66.8 4.53 x 10-9 60.0 5.00 x 10-9 61.5 
7.20 x 10-9 67.5 7.20 x 10-9 65.1 7.20 x 10-9 58.5 8.34 x 10-9 59.8 
1.12 x 10-8 67.3 1.12 x 10-8 63.2 1.12 x 10-8 58.2 1.33 x 10-8 58.7 
1.78 x 10-8 66.9 1.78 x 10-8 61.9 1.78 x 10-8 57.2 2.16 x 10-8 58.4 
2.85 x 10-8 66.4 2.85 x 10-8 60.7 2.85 x 10-8 57.0 3.49 x 10-8 57.6 
4.44 x 10-8 65.1 5.50 x 10-8 60.0 4.44 x 10-8 55.7 5.48 x 10-8 56.9 
7.09 x 10-8 63.6 8.41 x 10-8 59.0 7.09 x 10-8 54.7 8.79 x 10-8 55.1 
1.13 x 10-7 61.8 1.26 x 10-7 58.4 1.13 x 10-7 53.0 1.44 x 10-7 52.8 
1.79 x 10-7 59.7 1.92 x 10-7 56.8 1.79 x 10-7 51.7 2.26 x 10-7 51.1 
2.82 x 10-7 57.7 2.95 x 10-7 54.5 2.82 x 10-7 50.1 3.55 x 10-7 49.0 
4.35 x 10-7 55.4 4.48 x 10-7 51.9 4.35 x 10-7 48.3 5.46 x 10-7 47.3 
6.83 x 10-7 50.7 6.96 x 10-7 49.4 6.83 x 10-7 47.4 8.57 x 10-7 46.1 
1.06 x 10-6 48.6 1.08 x 10-6 47.4 1.06 x 10-6 46.2 1.33 x 10-6 45.7 
1.62 x 10-6 46.9 1.63 x 10-6 46.7 1.62 x 10-6 45.4 2.03 x 10-6 44.9 
2.44 x 10-6 46.1 2.45 x 10-6 46.5 2.44 x 10-6 45.0 3.05 x 10-6 44.3 
3.50 x 10-6 45.6 3.50 x 10-6 46.2 3.50 x 10-6 44.6 4.77 x 10-6 43.4 
4.68 x 10-6 46.0 4.68 x 10-6 45.6 4.68 x 10-6 44.2 7.60 x 10-6 40.6 
5.71 x 10-6 45.3 5.88 x 10-6 45.7 5.87 x 10-6 44.2   
    6.84 x 10-6 44.0   
    7.78 x 10-6 43.3   





Table B-4 (cont’d)  Surface tension of F127/16-3-16/pDNA mixtures of varying F127 mole fraction in water at 25°C 
Trial 3 

















0.00 69.1 0.00 69.6 0.00 68.5 0.00 69.2 
1.33 x 10-9 68.3 1.33 x 10-9 68.7 1.33 x 10-9 67.5 1.33 x 10-9 67.7 
2.67 x 10-9 68.2 2.67 x 10-9 68.4 2.67 x 10-9 66.0 2.67 x 10-9 64.5 
4.53 x 10-9 67.8 4.53 x 10-9 67.3 4.53 x 10-9 64.6 4.00 x 10-9 62.2 
7.20 x 10-9 67.2 7.20 x 10-9 63.8 7.20 x 10-9 63.7 6.66 x 10-9 60.4 
1.12 x 10-8 66.7 1.12 x 10-8 62.4 1.12 x 10-8 60.8 1.07 x 10-8 59.6 
1.78 x 10-8 65.0 1.78 x 10-8 60.3 1.78 x 10-8 59.7 1.73 x 10-8 58.9 
2.85 x 10-8 63.1 2.85 x 10-8 59.6 2.85 x 10-8 59.0 2.80 x 10-8 58.7 
4.44 x 10-8 61.4 4.44 x 10-8 59.1 4.44 x 10-8 57.6 4.39 x 10-8 57.9 
7.09 x 10-8 59.4 7.09 x 10-8 58.6 7.09 x 10-8 56.8 7.04 x 10-8 56.9 
1.13 x 10-7 58.7 1.13 x 10-7 57.4 1.13 x 10-7 55.1 1.13 x 10-7 55.7 
1.79 x 10-7 58.1 1.79 x 10-7 56.3 1.79 x 10-7 51.3 1.78 x 10-7 53.3 
2.82 x 10-7 57.0 2.82 x 10-7 53.9 2.82 x 10-7 48.7 2.82 x 10-7 51.0 
4.35 x 10-7 54.7 4.35 x 10-7 51.5 4.35 x 10-7 47.4 4.35 x 10-7 49.6 
6.83 x 10-7 50.7 6.83 x 10-7 49.8 6.83 x 10-7 46.1 6.83 x 10-7 47.6 
1.06 x 10-6 48.4 1.06 x 10-6 48.1 1.06 x 10-6 45.4 1.06 x 10-6 46.4 
1.62 x 10-6 47.1 1.62 x 10-6 47.0 1.62 x 10-6 45.1 1.62 x 10-6 45.5 
2.44 x 10-6 46.1 2.44 x 10-6 45.7 2.44 x 10-6 44.2 2.44 x 10-6 45.2 
3.50 x 10-6 45.5 3.50 x 10-6 45.1 3.50 x 10-6 43.2 3.50 x 10-6 44.7 
4.68 x 10-6 45.9 4.68 x 10-6 44.9 4.68 x 10-6 42.8 4.68 x 10-6 44.0 






Table B-6  Surface tension of P103/16-3-16/pDNA mixtures of varying P103 mole fraction in water at 25°C 
Trial 1 

















0.00 68.8   0.00 69.6 0.00 69.3 
6.67 x 10-10 68.5 6.67 x 10-10 69.2 6.67 x 10-10 68.0 1.33 x 10-9 68.1 
1.33 x 10-9 68.5 1.33 x 10-9 69.2 1.33 x 10-9 67.9 2.00 x 10-9 68.1 
2.00 x 10-9 68.4 2.00 x 10-9 69.0 2.00 x 10-9 68.1 2.93 x 10-9 68.0 
2.93 x 10-9 68.2 2.93 x 10-9 68.9 2.93 x 10-9 68.1 4.26 x 10-9 68.0 
4.26 x 10-9 68.1 4.26 x 10-9 68.7 4.26 x 10-9 68.0 6.93 x 10-9 67.7 
6.26 x 10-9 68.1 6.26 x 10-9 68.6 6.26 x 10-9 67.7 1.09 x 10-8 67.3 
8.92 x 10-9 68.1 8.92 x 10-9 68.4 8.92 x 10-9 67.6 1.62 x 10-8 66.2 
1.29 x 10-8 67.9 1.29 x 10-8 68.1 1.29 x 10-8 67.2 2.22 x 10-8 65.0 
1.96 x 10-8 67.6 1.96 x 10-8 67.9 1.96 x 10-8 66.6 2.88 x 10-8 60.6 
2.88 x 10-8 67.3 2.88 x 10-8 67.6 2.88 x 10-8 65.1 3.68 x 10-8 59.0 
4.20 x 10-8 66.9 4.20 x 10-8 66.6 4.20 x 10-8 63.8 4.60 x 10-8 57.5 
6.83 x 10-8 66.2 6.83 x 10-8 64.6 6.83 x 10-8 61.5 5.72 x 10-8 55.3 
1.07 x 10-7 64.9 1.07 x 10-7 61.6 1.07 x 10-7 58.3 7.03 x 10-8 50.1 
1.53 x 10-7 63.0 1.53 x 10-7 56.4 1.53 x 10-7 52.9 8.99 x 10-8 46.9 
2.16 x 10-7 60.6 2.16 x 10-7 47.3 2.16 x 10-7 44.9 1.16 x 10-7 44.1 
3.10 x 10-7 58.0 3.10 x 10-7 43.9 3.10 x 10-7 42.7 1.55 x 10-7 43.1 
4.31 x 10-7 51.3 4.31 x 10-7 42.5 4.31 x 10-7 41.5 2.18 x 10-7 42.0 
6.06 x 10-7 44.6 6.06 x 10-7 41.6 6.62 x 10-7 40.6 3.05 x 10-7 41.2 
8.27 x 10-7 42.5 8.27 x 10-7 40.1 9.33 x 10-7 40.0 4.15 x 10-7 40.5 
1.13 x 10-6 41.5 1.13 x 10-6 40.5 1.28 x 10-6 39.7 5.91 x 10-7 39.7 
1.59 x 10-6 41.2 1.59 x 10-6 40.1 1.72 x 10-6 39.0 8.12 x 10-7 39.2 
1.99 x 10-6 41.2 1.99 x 10-6 39.8 2.10 x 10-6 38.9 1.12 x 10-6 38.7 
2.48 x 10-6 40.9 2.48 x 10-6 39.6 2.45 x 10-6 38.8 1.58 x 10-6 38.3 
2.78 x 10-6 40.7 2.89 x 10-6 39.9 2.75 x 10-6 38.6 1.98 x 10-6 38.0 




Table B-6 (cont’d)  Surface tension of P103/16-3-16/pDNA mixtures of varying P103 mole fraction in water at 25°C 
Trial 2 

















0.00 69.5 0.00 69.4 0.00 70.3 0.00 69.6 
6.67 x 10-10 68.8 2.00 x 10-9 66.3 2.00 x 10-9 68.9 1.33 x 10-9 67.6 
1.33 x 10-9 68.7 4.00 x 10-9 69.1 4.00 x 10-9 68.8 2.00 x 10-9 68.0 
2.00 x 10-9 68.6 6.00 x 10-9 69.1 6.00 x 10-9 68.6 2.93 x 10-9 67.8 
2.93 x 10-9 68.4 7.99 x 10-9 69.0 8.66 x 10-9 68.3 4.26 x 10-9 67.6 
4.26 x 10-9 68.7 1.07 x 10-8 68.8 1.26 x 10-8 68.0 6.93 x 10-9 67.2 
6.26 x 10-9 68.3 1.46 x 10-8 68.4 1.80 x 10-8 67.8 1.09 x 10-8 66.7 
8.92 x 10-9 68.5 2.00 x 10-8 68.1 2.46 x 10-8 66.9 1.62 x 10-8 65.6 
1.29 x 10-8 68.4 2.52 x 10-8 67.6 3.39 x 10-8 66.4 2.22 x 10-8 63.8 
1.96 x 10-8 68.3 3.19 x 10-8 66.9 4.70 x 10-8 64.8 2.88 x 10-8 62.4 
2.88 x 10-8 68.2 4.11 x 10-8 65.8 6.68 x 10-8 62.9 3.67 x 10-8 60.5 
4.20 x 10-8 68.0 5.43 x 10-8 63.7 9.29 x 10-8 58.0 4.60 x 10-8 58.6 
6.83 x 10-8 67.5 8.05 x 10-8 60.8 1.32 x 10-7 53.5 5.72 x 10-8 56.9 
1.07 x 10-7 66.8 1.20 x 10-7 56.5 1.70 x 10-7 48.2 7.03 x 10-8 54.3 
1.53 x 10-7 64.3 1.58 x 10-7 52.2 2.15 x 10-7 44.8 8.99 x 10-8 50.9 
2.16 x 10-7 60.5 2.22 x 10-7 47.1 2.77 x 10-7 42.3 1.16 x 10-7 46.5 
3.10 x 10-7 55.6 3.15 x 10-7 43.9 3.69 x 10-7 41.6 1.55 x 10-7 43.9 
4.31 x 10-7 47.9 4.36 x 10-7 42.4 4.89 x 10-7 41.0 2.18 x 10-7 42.5 
6.06 x 10-7 43.8 6.11 x 10-7 41.7 7.17 x 10-7 40.2 3.05 x 10-7 41.6 
8.27 x 10-7 42.3 8.32 x 10-7 40.9 9.83 x 10-7 39.6 4.15 x 10-7 40.5 
1.13 x 10-6 41.7 1.14 x 10-6 40.1 1.28 x 10-6 39.0 5.91 x 10-7 39.8 
1.59 x 10-6 41.4 1.60 x 10-6 39.3 1.72 x 10-6 38.8 8.12 x 10-7 39.2 
1.99 x 10-6 41.3 2.00 x 10-6 39.0 2.10 x 10-6 38.4 1.12 x 10-6 38.7 
2.48 x 10-6 41.3 2.48 x 10-6 38.6 2.44 x 10-6 38.2 1.58 x 10-6 38.0 
2.78 x 10-6 41.3 2.89 x 10-6 38.4 2.75 x 10-6 38.2 1.98 x 10-6 37.6 
2.86 x 10-6 41.1   2.86 x 10-6 38.2 2.40 x 10-6 37.5 





Table B-5 (cont’d)  Surface tension of P103/16-3-16/pDNA mixtures of varying P103 mole fraction in water at 25°C 
Trial 3 

















0.00 69.5 0.00 70.2 0.00 69.5 0.00 68.9 
1.33 x 10-9 68.5 2.00 x 10-9 69.0 6.67 x 10-10 68.3 1.33 x 10-9 68.3 
2.67 x 10-9 68.8 4.00 x 10-9 69.0 1.33 x 10-9 68.2 2.00 x 10-9 68.1 
4.00 x 10-9 68.7 6.00 x 10-9 68.9 3.33 x 10-9 68.2 2.93 x 10-9 68.0 
5.33 x 10-9 68.6 7.99 x 10-9 68.9 6.00 x 10-9 68.2 4.26 x 10-9 67.8 
7.33 x 10-9 68.8 1.07 x 10-8 69.0 9.99 x 10-9 68.0 6.93 x 10-9 67.3 
9.99 x 10-9 68.7 1.46 x 10-8 68.6 1.53 x 10-8 67.8 1.09 x 10-8 66.9 
1.53 x 10-8 68.6 2.00 x 10-8 68.5 2.19 x 10-8 67.4 1.62 x 10-8 65.6 
2.33 x 10-8 68.6 2.52 x 10-8 68.4 3.12 x 10-8 66.6 2.22 x 10-8 63.8 
3.39 x 10-8 68.6 3.19 x 10-8 68.2 4.44 x 10-8 65.4 2.88 x 10-8 61.6 
4.71 x 10-8 68.5 4.11 x 10-8 67.8 6.41 x 10-8 63.0 3.68 x 10-8 58.8 
6.68 x 10-8 68.4 5.43 x 10-8 67.1 9.03 x 10-8 59.5 4.60 x 10-8 56.9 
9.29 x 10-8 67.8 8.05 x 10-8 65.8 1.29 x 10-7 53.1 5.72 x 10-8 53.7 
1.32 x 10-7 67.3 1.20 x 10-7 62.2 1.68 x 10-7 46.3 7.03 x 10-8 50.2 
1.83 x 10-7 65.5 1.58 x 10-7 58.7 2.12 x 10-7 43.6 8.99 x 10-8 47.6 
2.46 x 10-7 59.9 2.22 x 10-7 50.3 2.75 x 10-7 42.3 1.16 x 10-7 45.2 
3.39 x 10-7 51.7 3.15 x 10-7 44.6 3.67 x 10-7 41.3 1.55 x 10-7 43.3 
4.59 x 10-7 45.8 4.36 x 10-7 42.5 4.87 x 10-7 40.4 2.18 x 10-7 41.8 
6.33 x 10-7 42.9 6.11 x 10-7 41.2 7.15 x 10-7 39.9 3.05 x 10-7 40.8 
8.52 x 10-7 41.8 8.32 x 10-7 40.6 9.81 x 10-7 39.3 4.15 x 10-7 40.2 
1.16 x 10-6 41.2 1.14 x 10-6 40.0 1.28 x 10-6 38.9 5.91 x 10-7 39.5 
1.61 x 10-6 41.1 1.60 x 10-6 39.5 1.72 x 10-6 38.5 8.12 x 10-7 38.7 
2.01 x 10-6 41.1 2.00 x 10-6 39.4 2.10 x 10-6 38.4 1.12 x 10-6 38.2 
2.49 x 10-6 41.0 2.48 x 10-6 39.4 2.80 x 10-6 38.3 1.49 x 10-6 37.7 
2.90 x 10-6 41.2 2.89 x 10-6 39.4   1.91 x 10-6 37.4 




Table B-7  Surface tension of L44/16-3-16/pDNA mixtures of varying L44 mole fraction in water at 25°C 
Trial 1 

















6.67 x 10-10 68.6 6.67 x 10-10 69.2 6.67 x 10-10 68.2 6.67 x 10-10 68.8 
1.33 x 10-9 68.5 1.33 x 10-9 69.0 1.33 x 10-9 67.9 1.33 x 10-9 68.7 
2.27 x 10-9 68.6 2.27 x 10-9 69.3 2.27 x 10-9 67.7 2.27 x 10-9 68.5 
3.60 x 10-9 68.6 3.60 x 10-9 69.2 3.60 x 10-9 67.6 3.60 x 10-9 68.4 
6.26 x 10-9 68.7 6.26 x 10-9 69.3 6.26 x 10-9 67.4 6.26 x 10-9 68.2 
1.03 x 10-8 68.7 1.03 x 10-8 69.2 1.03 x 10-8 67.0 1.03 x 10-8 67.5 
1.69 x 10-8 68.6 1.69 x 10-8 69.1 1.69 x 10-8 66.5 1.69 x 10-8 67.3 
2.62 x 10-8 68.6 2.62 x 10-8 69.1 2.62 x 10-8 65.8 2.62 x 10-8 66.6 
3.94 x 10-8 68.5 3.94 x 10-8 69.1 3.94 x 10-8 64.9 3.94 x 10-8 65.2 
6.57 x 10-8 68.7 6.57 x 10-8 69.1 6.57 x 10-8 63.8 6.57 x 10-8 63.1 
9.84 x 10-8 68.1 1.05 x 10-7 68.5 1.05 x 10-7 61.3 1.05 x 10-7 60.4 
1.31 x 10-7 66.8 1.56 x 10-7 66.2 1.56 x 10-7 58.9 1.56 x 10-7 57.1 
1.63 x 10-7 64.5 2.20 x 10-7 61.2 2.20 x 10-7 56.8 2.20 x 10-7 55.7 
1.95 x 10-7 61.8 3.07 x 10-7 57.2 3.07 x 10-7 56.0 3.07 x 10-7 54.5 
2.26 x 10-7 59.4 4.17 x 10-7 56.5 4.17 x 10-7 55.0 4.17 x 10-7 53.8 
2.64 x 10-7 58.4 5.35 x 10-7 55.1 5.35 x 10-7 54.4 5.35 x 10-7 53.1 
3.13 x 10-7 57.0 7.05 x 10-7 54.3 7.05 x 10-7 53.6 7.05 x 10-7 52.8 
3.75 x 10-7 56.5 1.02 x 10-6 53.6 1.02 x 10-6 52.6 1.02 x 10-6 52.1 
4.70 x 10-7 55.9 1.36 x 10-6 52.6 1.50 x 10-6 51.9 1.36 x 10-6 51.6 
5.87 x 10-7 55.0 1.71 x 10-6 52.1 1.98 x 10-6 51.4 1.71 x 10-6 51.1 
7.54 x 10-7 54.4 2.10 x 10-6 51.7 2.53 x 10-6 50.5 2.10 x 10-6 50.9 
9.67 x 10-7 53.8 2.50 x 10-6 51.1 2.77 x 10-6 49.5 2.50 x 10-6 50.3 
1.26 x 10-6 53.1 2.71 x 10-6 50.7   2.96 x 10-6 50.1 
1.62 x 10-6 52.3 2.91 x 10-6 50.5   3.44 x 10-6 49.9 






Table B-7 (cont’d) Surface tension of L44/16-3-16/pDNA mixtures of varying L44 mole fraction in water at 25°C 
Trial 2 

















1.00 x 10-10 69.01 6.67 x 10-10 68.8 6.67 x 10-10 69.6 6.67 x 10-10 69.4 
2.00 x 10-9 69.1 1.33 x 10-9 68.8 1.33 x 10-9 69.5 1.33 x 10-9 69.5 
3.40 x 10-9 69.2 2.27 x 10-9 68.7 2.27 x 10-9 69.5 2.27 x 10-9 69.4 
5.40 x 10-9 69.1 3.60 x 10-9 68.7 3.60 x 10-9 69.7 3.60 x 10-9 69.5 
9.39 x 10-9 69.1 6.26 x 10-9 68.6 6.26 x 10-9 69.5 6.26 x 10-9 69.4 
1.54 x 10-8 69.0 1.03 x 10-8 68.7 1.03 x 10-8 69.3 1.03 x 10-8 69.3 
2.53 x 10-8 68.9 1.69 x 10-8 68.6 1.69 x 10-8 69.4 1.69 x 10-8 69.0 
3.92 x 10-8 68.9 2.62 x 10-8 68.6 2.62 x 10-8 68.7 2.62 x 10-8 68.7 
5.90 x 10-8 68.8 3.94 x 10-8 68.7 3.94 x 10-8 67.9 3.94 x 10-8 67.9 
9.82 x 10-8 68.5 6.57 x 10-8 67.9 5.92 x 10-8 67.1 5.26 x 10-8 66.4 
1.47 x 10-7 68.0 9.84 x 10-8 66.8 7.88 x 10-8 65.2 6.57 x 10-8 64.3 
1.95 x 10-7 65.8 1.31 x 10-7 63.7 1.05 x 10-7 62.6 8.53 x 10-8 61.7 
2.51 x 10-7 63.0 1.63 x 10-7 60.7 1.44 x 10-7 59.8 1.05 x 10-7 59.6 
3.26 x 10-7 59.3 1.95 x 10-7 58.6 1.95 x 10-7 57.8 1.31 x 10-7 58.1 
4.17 x 10-7 57.7 2.26 x 10-7 57.5 2.58 x 10-7 56.6 1.69 x 10-7 56.9 
5.23 x 10-7 56.3 2.58 x 10-7 56.9 3.32 x 10-7 55.4 2.20 x 10-7 56.2 
6.43 x 10-7 55.4 2.95 x 10-7 55.7 4.29 x 10-7 54.7 2.83 x 10-7 55.0 
7.92 x 10-7 54.8 3.44 x 10-7 55.3 5.35 x 10-7 54.2 3.56 x 10-7 54.4 
9.51 x 10-7 54.1 4.05 x 10-7 54.7 6.49 x 10-7 53.5 4.52 x 10-7 53.5 
1.25 x 10-6 53.4 4.76 x 10-7 54.7 8.67 x 10-7 53.2 5.58 x 10-7 52.8 
1.65 x 10-6 52.3 5.58 x 10-7 54.1 1.17 x 10-6 52.4 7.27 x 10-7 52.4 
2.12 x 10-6 50.8 6.60 x 10-7 54.0 1.54 x 10-6 51.9 9.41 x 10-7 51.8 
2.61 x 10-6 49.4 7.71 x 10-7 53.2 1.87 x 10-6 51.0 1.24 x 10-6 51.4 
3.11 x 10-6 48.0 9.82 x 10-7 52.7 2.24 x 10-6 50.0 1.60 x 10-6 50.8 
3.58 x 10-6 46.8 1.28 x 10-6 51.0 2.62 x 10-6 49.1 2.00 x 10-6 50.5 
4.02 x 10-6 46.7 1.63 x 10-6 50.0 3.07 x 10-6 48.0 2.48 x 10-6 50.0 
4.38 x 10-6 46.7 2.03 x 10-6 48.7 3.53 x 10-6 47.6 3.00 x 10-6 49.7 
  2.57 x 10-6 50.1   3.56 x 10-6 49.2 




Table B-76 (cont’d) Surface tension of L44/16-3-16/pDNA mixtures of varying L44 mole fraction in water at 25°C 
Trial 3 

















6.67 x 10-10 69.5 6.67 x 10-10 69.1 6.67 x 10-10 69.0 6.67 x 10-10 69.1 
1.33 x 10-9 69.7 1.33 x 10-9 69.1 1.33 x 10-9 69.0 1.33 x 10-9 69.0 
2.27 x 10-9 69.6 2.27 x 10-9 68.9 2.27 x 10-9 69.0 2.27 x 10-9 69.0 
3.60 x 10-9 69.8 3.60 x 10-9 68.9 3.60 x 10-9 68.8 3.60 x 10-9 68.9 
6.26 x 10-9 69.7 6.26 x 10-9 68.8 6.26 x 10-9 68.9 6.26 x 10-9 68.8 
1.03 x 10-8 69.9 1.03 x 10-8 68.7 1.03 x 10-8 68.9 1.03 x 10-8 69.0 
1.69 x 10-8 69.9 1.69 x 10-8 68.5 1.69 x 10-8 68.8 1.69 x 10-8 68.5 
2.62 x 10-8 69.8 2.62 x 10-8 68.3 2.62 x 10-8 68.5 2.62 x 10-8 68.2 
3.94 x 10-8 69.7 3.94 x 10-8 68.2 3.94 x 10-8 68.2 3.94 x 10-8 67.5 
6.57 x 10-8 69.5 6.57 x 10-8 67.8 5.92 x 10-8 67.4 5.26 x 10-8 65.9 
9.84 x 10-8 69.3 9.84 x 10-8 66.3 7.88 x 10-8 66.0 6.57 x 10-8 63.9 
1.31 x 10-7 68.4 1.31 x 10-7 63.5 1.05 x 10-7 63.3 8.53 x 10-8 60.9 
1.63 x 10-7 65.7 1.63 x 10-7 60.2 1.44 x 10-7 59.7 1.05 x 10-7 58.7 
1.95 x 10-7 63.3 1.95 x 10-7 58.0 1.95 x 10-7 57.6 1.31 x 10-7 57.6 
2.26 x 10-7 60.9 2.26 x 10-7 56.9 2.58 x 10-7 56.4 1.69 x 10-7 56.6 
2.64 x 10-7 58.7 2.58 x 10-7 56.4 3.32 x 10-7 54.9 2.20 x 10-7 55.9 
3.13 x 10-7 57.7 2.95 x 10-7 55.2 4.29 x 10-7 54.1 2.83 x 10-7 54.6 
3.75 x 10-7 57.0 3.44 x 10-7 54.9 5.35 x 10-7 53.7 3.56 x 10-7 54.3 
4.70 x 10-7 55.7 4.05 x 10-7 54.6 6.49 x 10-7 53.2 4.52 x 10-7 53.6 
5.87 x 10-7 55.0 4.76 x 10-7 54.2 8.67 x 10-7 52.6 5.58 x 10-7 53.2 
7.54 x 10-7 54.5 5.58 x 10-7 53.7 1.17 x 10-6 52.0 7.27 x 10-7 52.3 
9.67 x 10-7 53.8 6.60 x 10-7 52.9 1.54 x 10-6 51.1 9.41 x 10-7 51.9 
1.26 x 10-6 53.5 7.71 x 10-7 52.7 1.87 x 10-6 50.9 1.24 x 10-6 51.3 
1.62 x 10-6 52.9 9.82 x 10-7 52.2 2.24 x 10-6 50.5 1.60 x 10-6 50.8 
2.02 x 10-6 52.3 1.28 x 10-6 51.7 2.62 x 10-6 50.1 2.00 x 10-6 50.3 
2.56 x 10-6 51.4 1.63 x 10-6 51.4 3.07 x 10-6 50.2 2.48 x 10-6 49.9 
3.11 x 10-6 50.7 2.03 x 10-6 51.2 3.57 x 10-6 49.9 3.00 x 10-6 49.6 
  2.57 x 10-6 50.7   3.56 x 10-6 49.0 
  3.12 x 10-6 50.7     
 187 
Table B-8 Surface tension of F87 in water at 25°C 













0.00 70.6 0.00 70.4 0.00 70.3 
3.17 x 10-5 43.2 3.17 x 10-5 42.73 3.17 x 10-5 42.8 
6.18 x 10-5 42.2 6.18 x 10-5 41.9 6.18 x 10-5 42.1 
9.06 x 10-5 41.7 9.06 x 10-5 41.4 9.06 x 10-5 41.5 
1.18 x 10-4 41.3 1.18 x 10-4 41.0 1.18 x 10-4 41.2 
1.44 x 10-4 40.9 1.44 x 10-4 40.7 1.44 x 10-4 40.8 
1.69 x 10-4 40.6 1.69 x 10-4 40.5 1.69 x 10-4 40.5 
1.93 x 10-4 40.4 1.93 x 10-4 40.3 1.93 x 10-4 40.4 
2.16 x 10-4 40.0 2.16 x 10-4 40.2 2.16 x 10-4 40.2 
2.39 x 10-4 39.8 2.39 x 10-4 39.9 2.39 x 10-4 40.1 
2.60 x 10-4 39.7 2.60 x 10-4 39.8 2.60 x 10-4 40.0 
2.80 x 10-4 39.6 2.80 x 10-4 39.7 2.80 x 10-4 39.8 
3.00 x 10-4 39.5 3.00 x 10-4 39.7 3.00 x 10-4 39.8 
3.19 x 10-4 39.5 3.19 x 10-4 39.6 3.19 x 10-4 39.7 
3.37 x 10-4 39.5 3.37 x 10-4 39.5 3.37 x 10-4 39.6 
3.54 x 10-4 39.4 3.54 x 10-4 39.5 3.54 x 10-4 39.5 
3.71 x 10-4 39.4 3.71 x 10-4 39.5 3.71 x 10-4 39.5 
4.03 x 10-4 39.4 3.87 x 10-4 39.4 3.87 x 10-4 39.4 
4.33 x 10-4 39.4 4.03 x 10-4 39.4 4.03 x 10-4 39.4 
4.61 x 10-4 39.3 4.18 x 10-4 39.4 4.18 x 10-4 39.3 
4.87 x 10-4 39.2 4.33 x 10-4 39.3 4.33 x 10-4 39.4 
5.12 x 10-4 39.2 4.47 x 10-4 39.3 4.47 x 10-4 39.4 
5.35 x 10-4 39.3 4.61 x 10-4 39.2 4.61 x 10-4 39.4 
  4.74 x 10-4 39.2 4.74 x 10-4 39.4 
  4.87 x 10-4 39.1 4.87 x 10-4 39.4 
  5.00 x 10-4 39.1 5.00 x 10-4 39.3 
  5.12 x 10-4 39.1 5.12 x 10-4 39.3 
  5.35 x 10-4 39.1 5.23 x 10-4 39.3 
  5.46 x 10-4 39.2 5.35 x 10-4 39.3 
  5.57 x 10-4 39.2   






Table B-9 Surface tension of P84 in water at 25°C 













0.00 72.6 0.00 72.2 4.50 x 10-5 38.7 
1.58 x 10-5 42.4 6.35 x 10-6 42.6 5.60 x 10-5 38.4 
3.16 x 10-5 41.7 7.93 x 10-6 41.9 7.02 x 10-5 38.3 
4.74 x 10-5 41.1 9.52 x 10-6 41.7 8.60 x 10-5 38.0 
6.31 x 10-5 40.7 1.11 x 10-5 41.5 1.10 x 10-4 37.9 
7.87 x 10-5 40.4 1.33 x 10-5 41.1 1.41 x 10-4 37.6 
9.43 x 10-5 40.2 1.65 x 10-5 40.9 1.88 x 10-4 37.3 
1.10 x 10-4 40.0 2.12 x 10-5 40.6 2.50 x 10-4 37.1 
1.41 x 10-4 39.7 2.76 x 10-5 40.3 3.11 x 10-4 36.8 
1.71 x 10-4 39.5 3.55 x 10-5 40.1 4.03 x 10-4 36.6 
2.02 x 10-4 39.2 4.50 x 10-5 39.8 5.24 x 10-4 36.4 
2.62 x 10-4 38.9 5.60 x 10-5 39.6 6.73 x 10-4 36.3 
3.22 x 10-4 38.6 7.02 x 10-5 39.3 8.19 x 10-4 36.2 
3.96 x 10-4 38.4 8.60 x 10-5 39.0 9.64 x 10-4 36.2 
4.68 x 10-4 38.3 1.10 x 10-4 38.7 1.11 x 10-3 36.2 
5.39 x 10-4 38.3 1.41 x 10-4 38.4 1.30 x 10-3 36.2 
6.09 x 10-4 38.1 1.88 x 10-4 38.1 1.52 x 10-3 36.2 
6.78 x 10-4 38.1 2.50 x 10-4 37.8 1.65 x 10-3 36.2 
7.46 x 10-4 38.0 3.11 x 10-4 37.5   
8.13 x 10-4 38.1 4.03 x 10-4 37.2   
8.79 x 10-4 38.1 5.24 x 10-4 37.0   
9.44 x 10-4 38.0 6.73 x 10-4 36.8   
1.01 x 10-3 38.0 8.19 x 10-4 36.7   
1.07 x 10-3 38.1 9.64 x 10-4 36.6   
1.13 x 10-3 38.1 1.11 x 10-3 36.6   
1.19 x 10-3 38.1 1.30 x 10-3 36.5   
1.25 x 10-3 38.1 1.52 x 10-3 36.5   
1.29 x 10-3 38.1 1.65 x 10-3 36.5   
1.33 x 10-3 38.1     






Table B-10 Surface tension of L121 in water at 25°C 













0.00 73.7 0.00 73.8 0.00 72.3 
1.43 x 10-9 73.9 1.43 x 10-9 73.7 1.43 x 10-9 72.4 
2.87 x 10-9 73.9 1.58 x 10-8 72.6 1.58 x 10-8 71.1 
4.30 x 10-9 73.7 4.44 x 10-8 72.5 4.44 x 10-8 68.7 
5.74 x 10-9 73.5 7.29 x 10-8 69.6 7.29 x 10-8 64.1 
7.74 x 10-9 73.0 1.01 x 10-7 64.4 1.01 x 10-7 58.6 
1.06 x 10-8 71.9 1.30 x 10-7 58.9 1.30 x 10-7 54.4 
1.49 x 10-8 70.8 1.58 x 10-7 53.0 1.58 x 10-7 50.4 
4.35 x 10-8 64.3 1.86 x 10-7 49.4 1.86 x 10-7 48.0 
7.20 x 10-8 60.3 2.14 x 10-7 47.0 2.14 x 10-7 46.1 
1.15 x 10-7 54.5 2.56 x 10-7 45.3 2.56 x 10-7 44.7 
1.64 x 10-7 50.6 3.04 x 10-7 43.6 3.04 x 10-7 43.6 
2.20 x 10-7 47.8 3.60 x 10-7 42.8 3.60 x 10-7 42.4 
2.76 x 10-7 46.1 4.15 x 10-7 41.7 4.15 x 10-7 41.4 
3.45 x 10-7 44.6 4.83 x 10-7 40.8 4.83 x 10-7 40.7 
4.27 x 10-7 43.3 5.64 x 10-7 40.0 5.64 x 10-7 40.0 
5.22 x 10-7 42.6 6.57 x 10-7 39.2 6.57 x 10-7 39.4 
6.23 x 10-7 41.8 7.56 x 10-7 38.6 7.56 x 10-7 39.1 
7.29 x 10-7 41.3 8.61 x 10-7 38.2 8.61 x 10-7 38.7 
8.60 x 10-7 41.0 9.89 x 10-7 37.8 9.89 x 10-7 38.6 
1.00 x 10-6 40.8 1.13 x 10-6 37.4 1.13 x 10-6 38.4 
1.15 x 10-6 40.5 1.28 x 10-6 37.0 1.28 x 10-6 38.4 
1.33 x 10-6 40.4 1.45 x 10-6 36.5 1.45 x 10-6 38.5 
1.53 x 10-6 40.6 1.65 x 10-6 36.0 1.65 x 10-6 38.9 
1.76 x 10-6 41.3   2.09 x 10-6 39.2 
1.98 x 10-6 41.8   2.31 x 10-6 39.3 
2.21 x 10-6 42.4     
      
      







Table B-11 Surface tension of F127 in water at 25°C 













0.00 68.6 0.00 68.1 0.00 69.6 
6.61 x 10-9 57.0 6.61 x 10-9 57.6 6.61 x 10-8 48.2 
1.32 x 10-8 53.8 1.32 x 10-8 54.2 1.32 x 10-7 46.3 
2.25 x 10-8 52.1 2.25 x 10-8 53.5 1.98 x 10-7 45.5 
3.57 x 10-8 51.0 3.57 x 10-8 52.7 2.91 x 10-7 44.5 
6.21 x 10-8 49.5 6.21 x 10-8 50.5 4.89 x 10-7 44.0 
9.52 x 10-8 46.5 1.02 x 10-7 48.8 7.53 x 10-7 43.5 
1.41 x 10-7 44.0 1.68 x 10-7 47.8 1.15 x 10-6 43.1 
2.54 x 10-7 43.9 2.66 x 10-7 46.2 1.81 x 10-6 42.7 
3.53 x 10-7 43.0 3.97 x 10-7 45.0 2.79 x 10-6 42.2 
4.85 x 10-7 42.6 5.93 x 10-7 44.0 4.11 x 10-6 41.8 
7.48 x 10-7 42.2 9.82 x 10-7 43.6 6.72 x 10-6 41.4 
1.14 x 10-6 41.9 1.50 x 10-6 42.8 1.06 x 10-5 40.8 
1.67 x 10-6 41.5 2.13 x 10-6 42.2 1.70 x 10-5 40.4 
2.32 x 10-6 41.1 3.05 x 10-6 41.8 2.64 x 10-5 39.9 
3.62 x 10-6 40.6 4.26 x 10-6 41.2 3.85 x 10-5 39.4 
6.20 x 10-6 40.0 6.11 x 10-6 41.2 6.17 x 10-5 38.9 
1.00 x 10-5 39.5 8.29 x 10-6 41.0 9.40 x 10-5 38.4 
1.50 x 10-5 39.0 1.13 x 10-5 40.4 1.42 x 10-4 38.0 
2.10 x 10-5 38.6 1.59 x 10-5 39.9 2.20 x 10-4 37.8 
3.30 x 10-5 38.0 2.13 x 10-5 39.6 3.32 x 10-4 37.8 
4.40 x 10-5 37.5 2.98 x 10-5 39.9 4.36 x 10-4 37.9 
5.92 x 10-5 36.9 3.83 x 10-5 40.2 6.55 x 10-4 37.1 
7.76 x 10-5 36.7 5.74 x 10-5 39.1 1.06 x 10-3 36.3 
9.80 x 10-5 36.5 8.70 x 10-5 38.9   
1.19 x 10-4 36.3 1.14 x 10-4 38.3   
1.40 x 10-4 36.4     






Table B-12 Surface tension of P103 in water at 25°C 













0.00 68.3 0.00 69.2 0.00 69.1 
1.68 x 10-10 67.1 1.68 x 10-9 67.9 1.68 x 10-9 68.0 
3.37 x 10-10 67.2 3.37 x 10-9 67.4 3.37 x 10-9 66.7 
5.05 x 10-10 67.1 5.05 x 10-9 66.3 5.05 x 10-9 64.7 
7.40 x 10-10 67.2 7.40 x 10-9 63.5 7.40 x 10-9 62.9 
1.08 x 10-9 67.4 1.08 x 10-8 59.5 1.08 x 10-8 59.8 
1.41 x 10-8 67.2 1.92 x 10-8 57.1 1.92 x 10-8 57.1 
2.25 x 10-8 64.8 2.76 x 10-8 56.0 2.76 x 10-8 56.1 
3.43 x 10-8 59.5 4.10 x 10-8 53.8 4.10 x 10-8 52.9 
4.77 x 10-8 54.5 5.77 x 10-8 50.7 5.77 x 10-8 50.9 
6.44 x 10-8 50.9 9.12 x 10-8 46.1 9.12 x 10-8 46.1 
9.12 x 10-8 45.4 1.24 x 10-7 43.9 1.24 x 10-7 43.9 
1.21 x 10-7 41.6 1.74 x 10-7 42.4 1.74 x 10-7 42.2 
1.54 x 10-7 40.4 2.57 x 10-7 41.7 2.57 x 10-7 41.6 
2.04 x 10-7 39.4 3.55 x 10-7 41.1 3.55 x 10-7 41.0 
2.70 x 10-7 38.7 4.68 x 10-7 40.5 4.68 x 10-7 40.6 
3.51 x 10-7 38.4 6.27 x 10-7 39.9 6.27 x 10-7 40.3 
4.32 x 10-7 37.9 8.46 x 10-7 39.5 8.46 x 10-7 39.7 
5.92 x 10-7 37.3 1.12 x 10-6 39.1 1.12 x 10-6 39.2 
9.04 x 10-7 36.9 1.42 x 10-6 38.9 1.42 x 10-6 39.2 
1.21 x 10-6 36.2 1.84 x 10-6 38.5 1.84 x 10-6 39.0 
1.50 x 10-6 35.8 2.38 x 10-6 38.4 2.38 x 10-6 38.8 
1.78 x 10-6 35.6 3.01 x 10-6 38.2 3.01 x 10-6 38.6 
2.06 x 10-6 35.4 3.60 x 10-6 37.9 3.25 x 10-6 38.5 
2.19 x 10-6 35.3     
2.33 x 10-6 35.1     
2.46 x 10-6 34.9     





Table B-13 Surface tension of L44 in water at 25°C 













0.00 69.7 0.00 69.3 0.00 67.0 
3.78 x 10-5 46.3 1.89 x 10-6 48.4 1.89 x 10-6 50.4 
7.55 x 10-5 45.6 5.68 x 10-6 48.3 5.68 x 10-6 48.8 
1.13 x 10-4 45.2 2.46 x 10-5 46.7 2.46 x 10-5 47.3 
1.51 x 10-4 45.0 6.23 x 10-5 45.7 6.23 x 10-5 46.1 
2.25 x 10-4 44.4 9.99 x 10-5 45.3 9.99 x 10-5 45.5 
2.99 x 10-4 44.2 1.56 x 10-4 44.9 1.56 x 10-4 44.9 
4.09 x 10-4 43.4 2.68 x 10-4 44.1 2.68 x 10-4 44.1 
7.69 x 10-4 42.7 4.51 x 10-4 43.7 4.51 x 10-4 43.5 
1.12 x 10-3 42.1 7.21 x 10-4 43.0 7.21 x 10-4 42.9 
1.45 x 10-3 41.8 1.07 x 10-3 42.6 1.07 x 10-3 42.5 
2.10 x 10-3 41.4 1.41 x 10-3 42.0 1.41 x 10-3 41.9 
2.70 x 10-3 41.2 1.90 x 10-3 41.6 1.90 x 10-3 41.4 
3.81 x 10-3 40.8 2.51 x 10-3 41.1 2.51 x 10-3 40.8 
4.94 x 10-3 40.6 3.10 x 10-3 40.8 3.10 x 10-3 40.5 
6.00 x 10-3 40.4 3.78 x 10-3 40.6 3.78 x 10-3 40.1 
7.01 x 10-3 40.3 5.26 x 10-3 40.3 4.41 x 10-3 39.8 
7.97 x 10-3 40.1 6.30 x 10-3 40.1 5.49 x 10-3 39.7 
8.89 x 10-3 40.0 7.76 x 10-3 40.0 6.51 x 10-3 39.3 
9.76 x 10-3 40.0 9.54 x 10-3 39.8 7.94 x 10-3 39.3 
1.18 x 10-2 39.6 1.16 x 10-2 39.7 9.70 x 10-3 39.1 
1.25 x 10-2 39.5 1.27 x 10-2 39.3 1.17 x 10-2 38.8 
1.42 x 10-2 39.3   1.28 x 10-2 38.7 
1.58 x 10-2 39.1     
1.77 x 10-2 39.0     
      
      





Ethidium Bromide Fluorescence Data 
Table B-14  Ethidium bromide – plasmid DNA fluorescence (ex./em. = 535 nm/595 nm) following 
addition of 16-3-16 at N+/P- = 10:1 (I1) and Pluronic at varying mole fractions (I2). 
  


















(I2/I0 – I1/I0) 
F87 0.8 54.85 4.28 7.17 0.08 0.13 0.05 
0.6 101.16 17.12 22.80 0.17 0.23 0.06 
0.4 113.42 25.92 32.92 0.23 0.29 0.06 
0.2 115.99 53.99 58.74 0.47 0.51 0.04 
P84 0.8 56.80 5.31 8.88 0.09 0.16 0.06 
0.6 100.41 13.73 21.47 0.14 0.21 0.08 
0.4 119.04 30.92 43.38 0.26 0.36 0.10 
0.2 145.48 47.48 57.39 0.33 0.39 0.07 
L121 0.8 52.16 4.76 18.38 0.09 0.35 0.26 
0.6 85.69 12.82 44.99 0.15 0.53 0.38 
0.4 104.43 24.25 73.11 0.23 0.70 0.47 
0.2 115.60 38.81 109.09 0.34 0.94 0.61 
F127 0.8 30.32 5.39 8.12 0.18 0.27 0.09 
 0.6 54.95 15.11 25.17 0.27 0.46 0.18 
 0.4 78.73 31.31 46.95 0.40 0.60 0.20 
 0.2 93.11 51.15 66.84 0.55 0.72 0.17 
P103 0.8 50.46 3.95 7.68 0.08 0.15 0.07 
0.6 97.73 13.39 24.04 0.14 0.25 0.11 
0.4 130.85 28.48 46.09 0.22 0.35 0.13 
0.2 148.71 47.80 66.35 0.32 0.45 0.12 
L44 0.8 64.09 4.14 5.52 0.06 0.09 0.02 
0.6 115.10 11.76 13.72 0.10 0.12 0.02 
0.4 116.03 19.37 23.12 0.17 0.20 0.03 




Table B-14 (cont’d) Ethidium bromide – plasmid DNA fluorescence (ex./em. = 535 nm/595 nm) 
following addition of 16-3-16 at N+/P- = 10:1 (I1) and Pluronic at varying mole fractions (I2). 


















(I2/I0 – I1/I0) 
F87 0.8 52.15 3.96 7.37 0.08 0.14 0.07 
0.6 101.49 15.05 25.03 0.15 0.25 0.10 
0.4 112.95 38.02 55.73 0.34 0.49 0.16 
0.2 123.67 55.36 74.06 0.45 0.60 0.15 
P84 0.8 55.78 3.63 8.20 0.07 0.15 0.08 
0.6 102.19 12.69 22.93 0.12 0.22 0.10 
0.4 127.89 27.21 45.12 0.21 0.35 0.14 
0.2 147.74 47.90 74.22 0.32 0.50 0.18 
L121 0.8 42.88 4.12 14.62 0.10 0.34 0.24 
0.6 78.48 11.89 44.05 0.15 0.56 0.41 
0.4 101.85 22.02 68.16 0.22 0.67 0.45 
0.2 100.17 30.44 88.85 0.30 0.89 0.58 
F127 0.8 29.44 4.44 8.53 0.15 0.29 0.14 
0.6 60.24 16.89 32.38 0.28 0.54 0.26 
0.4 78.75 29.63 50.91 0.38 0.65 0.27 
0.2 95.43 51.33 74.91 0.54 0.78 0.25 
P103 0.8 54.49 3.54 8.17 0.06 0.15 0.09 
0.6 99.19 14.17 30.09 0.14 0.30 0.16 
0.4 121.13 27.70 48.34 0.23 0.40 0.17 
0.2 140.63 45.52 69.01 0.32 0.49 0.17 
L44 0.8 49.86 3.45 5.46 0.07 0.11 0.04 
0.6 101.25 12.91 19.05 0.13 0.19 0.06 
0.4 123.98 27.79 35.86 0.22 0.29 0.07 






Table B-14 (cont’d) Ethidium bromide – plasmid DNA fluorescence (I0) (ex./em. = 535 nm/595 nm) 
following addition of 16-3-16 at N+/P- = 10:1 (I1) and Pluronic at varying mole fractions (I2). 


















(I2/I0 – I1/I0) 
F87 0.8 57.81 4.24 7.82 0.07 0.14 0.07 
0.6 107.88 19.72 28.62 0.18 0.27 0.09 
0.4 104.78 29.97 43.34 0.29 0.41 0.12 
0.2 146.45 58.72 71.79 0.40 0.49 0.09 
P84 0.8 49.91 3.53 6.91 0.07 0.14 0.07 
0.6 105.49 13.77 23.27 0.13 0.22 0.09 
0.4 133.38 29.45 44.36 0.22 0.33 0.11 
0.2 151.49 48.69 70.94 0.32 0.47 0.15 
L121 0.8 51.83 4.79 15.57 0.09 0.30 0.21 
0.6 70.93 10.53 40.44 0.15 0.57 0.42 
0.4 93.52 19.06 63.97 0.20 0.68 0.48 
0.2 127.78 37.97 112.35 0.30 0.88 0.58 
F127 0.8 31.84 4.84 9.58 0.15 0.30 0.15 
0.6 56.38 15.65 30.57 0.28 0.54 0.26 
0.4 87.52 31.73 50.94 0.36 0.58 0.22 
0.2 107.35 53.46 73.97 0.50 0.69 0.19 
P103 0.8 51.01 3.55 7.45 0.07 0.15 0.08 
0.6 104.14 13.77 29.57 0.13 0.28 0.15 
0.4 132.22 28.07 49.08 0.21 0.37 0.16 
0.2 140.40 44.89 64.31 0.32 0.46 0.14 
L44 0.8 48.03 3.79 5.89 0.08 0.12 0.04 
0.6 93.30 11.92 17.50 0.13 0.19 0.06 
0.4 129.06 29.10 37.80 0.23 0.29 0.06 







Linear Regression Analysis of Interaction Parameter Dependence on EO, PO, 
and Pluronic mole fraction (MF) 
 
Coefficients: 
              Estimate Std. Error t value Pr(>|t|)     
(Intercept) -34.710807   1.493856 -23.236  < 2e-16 *** 
EO           -0.011902   0.005656  -2.105    0.039 *   
PO            0.528727   0.024228  21.823  < 2e-16 *** 
MF           -7.796975   1.678272  -4.646  1.6e-05 *** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 3.184 on 68 degrees of freedom 
Multiple R-squared:  0.882, Adjusted R-squared:  0.8768  







Particle Size Data of Polydisperse Samples 
Table C-1  Intensity statistics for hydrodynamic diameter measurements of 0.2 F87/16-3-16/pDNA, 
























0.2 F87/16-3-16/pDNA 0.2 P84/16-3-16/pDNA 0.2 L44/16-3-16/pDNA 
0.4000 0.0 0.0 0.00 0.00 0.0 0.0 
0.4632 0.0 0.0 0.00 0.00 0.0 0.0 
0.5365 0.0 0.0 0.00 0.00 0.0 0.0 
0.6213 0.0 0.0 0.00 0.00 0.0 0.0 
0.7195 0.0 0.0 0.00 0.00 0.0 0.0 
0.8332 0.0 0.0 0.00 0.00 0.0 0.0 
0.9649 0.0 0.0 0.00 0.00 0.0 0.0 
1.117 0.0 0.0 0.00 0.00 0.0 0.0 
1.294 0.0 0.0 0.00 0.00 0.0 0.0 
1.499 0.0 0.0 0.00 0.00 0.0 0.0 
1.736 0.0 0.0 0.00 0.00 0.0 0.0 
2.010 0.0 0.0 0.00 0.00 0.0 0.0 
2.328 0.0 0.0 0.00 0.00 0.0 0.0 
2.696 0.0 0.0 0.00 0.00 0.0 0.0 
3.122 0.0 0.0 0.00 0.00 0.0 0.0 
3.615 0.0 0.0 0.00 0.00 0.0 0.0 
4.187 0.0 0.0 0.00 0.00 0.0 0.0 
4.849 0.0 0.0 0.00 0.00 0.0 0.0 
5.615 0.0 0.0 0.00 0.00 0.0 0.0 
6.503 0.0 0.0 0.00 0.00 0.0 0.0 
7.531 0.0 0.0 0.00 0.00 0.0 0.0 
8.721 0.0 0.0 0.00 0.00 0.0 0.0 
10.10 0.0 0.0 0.00 0.00 0.0 0.0 
11.70 0.0 0.0 0.00 0.00 0.0 0.0 
13.54 0.0 0.0 0.00 0.00 0.0 0.0 
15.69 0.0 0.0 0.00 0.00 0.0 0.0 
18.17 0.0 0.0 0.00 0.00 0.0 0.0 
21.04 0.0 0.0 0.00 0.00 0.0 0.0 
24.36 0.0 0.0 0.00 0.00 0.0 0.0 
28.21 0.0 0.1 0.00 0.00 0.0 0.1 
32.67 0.0 0.1 0.00 0.00 0.1 0.2 
37.84 0.1 0.2 0.00 0.00 0.1 0.2 




Table C-1 (cont’d) Intensity statistics for hydrodynamic diameter measurements of 0.2 F87/16-3-
























0.2 F87/16-3-16/pDNA 0.2 P84/16-3-16/pDNA 0.2 L44/16-3-16/pDNA 
50.75 0.1 0.2 0.00 0.00 0.1 0.1 
58.77 0.3 0.5 0.00 0.00 0.4 0.5 
68.06 0.7 1.0 0.00 0.10 1.3 1.1 
78.82 1.5 1.7 0.20 0.30 2.8 1.3 
91.28 2.8 2.4 0.70 0.70 4.3 1.9 
105.7 4.2 3.0 1.80 1.00 4.9 2.9 
122.4 5.8 2.6 3.50 0.80 4.8 3.7 
141.8 6.9 2.5 5.00 0.80 4.6 4.5 
164.2 6.9 3.3 6.00 1.40 4.9 5.0 
190.1 6.0 4.0 6.10 1.90 5.4 5.4 
220.2 4.7 4.1 5.80 2.10 5.7 6.0 
255.0 3.5 4.0 5.50 2.30 6.0 5.8 
295.3 3.0 3.3 5.50 2.30 6.6 4.5 
342.0 3.4 2.8 6.00 2.20 7.1 3.9 
396.1 4.7 3.2 6.90 2.30 7.6 5.2 
458.7 6.7 4.4 7.70 2.90 8.0 6.6 
531.2 8.5 5.8 8.10 3.40 7.7 7.2 
615.1 9.2 6.6 7.70 3.50 6.6 6.9 
712.4 8.5 6.5 6.50 3.00 4.7 5.8 
825.0 6.4 5.5 4.80 2.50 2.6 3.9 
955.4 3.7 3.9 3.10 1.90 1.0 1.7 
1106 1.5 2.3 1.90 1.40 0.1 0.3 
1281 0.4 1.1 1.10 1.10 0.0 0.0 
1484 0.1 0.2 0.60 0.90 0.0 0.0 
1718 0.0 0.0 0.40 0.80 0.0 0.0 
1990 0.0 0.0 0.20 0.60 0.0 0.0 
2305 0.0 0.0 0.20 0.50 0.0 0.0 
2669 0.0 0.0 0.20 0.30 0.0 0.0 
3091 0.0 0.0 0.30 0.30 0.0 0.0 
3580 0.0 0.0 0.50 0.60 0.1 0.1 
4145 0.0 0.1 0.80 0.90 0.3 0.5 
4801 0.0 0.1 1.10 1.10 0.6 1.2 
5560 0.3 0.9 1.80 1.10 1.4 1.9 
6439 0.0 0.0 0.00 0.00 0.0 0.0 
7456 0.0 0.0 0.00 0.00 0.0 0.0 
8635 0.0 0.0 0.00 0.00 0.0 0.0 






















Table C-2  Particle size of L121/16-3-16/pDNA nanoparticles measured at 25°C. Mean values ± 
standard deviation for triplicate measurements (n = 3) are reported. 
  
L121 Mole Fraction  Mean hydrodynamic diameter 
(nm) 
Mean PDI 
0.2 148.7 ± 21.3  0.16 ± 0.02 
0.4 152.1 ± 16.5 0.20 ± 0.03 
0.6 158.4 ± 23.6 0.23 ± 0.01 
0.8 156.2 ± 63.7 0.27 ± 0.02 





Transfection Efficiency and Cell Viability Data 
 
 
Figure C-4  Sample image of gating used for flow cytometry analysis of transfection samples. Panel A) 



































Table C-3  eGFP expression and propidium iodide staining results from quadrant gating of 10,000 
events analyzed through flow cytometry events. Average percent of the total events from each 
quadrant ± standard deviation are shown.  
Treatment − GFP, + PI 
(%) 
+ GFP, + PI 
(%) 
+ GFP, − PI 
(%) 
− GFP, − PI 
(%) 
0.2 F87/G/P 3.9 ± 1.1 0.2 ± 0.1 7.6 ± 1.0 88.4 ± 1.3 
0.4 F87/G/P 3.9 ± 0.8 0.2 ± 0.1 8.0 ± 1.2 87.8 ± 1.7 
0.6 F87/G/P 3.6 ± 0.8 0.1 ± 0.0 6.3 ± 0.3 89.9 ± 1.0 
0.8 F87/G/P 4.4 ± 1.6 0.1 ± 0.1 5.5 ± 0.6 89.9 ± 1.4 
F87 only (no G/P) 2.8 ± 0.7 0.0 ± 0.0 0.0 ± 0.0 97.2 ± 0.7 
0.8 F87/G (no P) 3.4 ± 1.4 0.0 ± 0.0 0.0 ± 0.0 96.6 ± 1.4 
0.2 F87/G (no P) 3.0 ± 1.7 0.0 ± 0.0 0.0 ± 0.0 97.0 ± 1.7 
0.8 F87/P (no G) 2.6 ± 0.7 0.0 ± 0.0 0.0 ± 0.0 97.3 ± 0.7 
0.2 F87/P (no G) 2.6 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 97.4 ± 0.5 
0.2 P84/G/P 3.3 ± 0.3 0.2 ± 0.1 8.9 ± 0.7 87.6 ± 0.4 
0.4 P84/G/P 3.8 ± 0.4 0.2 ± 0.1 7.2 ± 1.4 88.9 ± 1.6 
0.6 P84/G/P 3.9 ± 0.2 0.0 ± 0.0 3.9 ± 1.0 92.1 ± 1.1 
0.8 P84/G/P 4.7 ± 1.4 0.0 ± 0.0 1.4 ± 1.0 93.9 ± 1.9 
P84 only (no G/P) 4.0 ± 2.1 0.0 ± 0.0 0.0 ± 0.0 96.0 ± 2.1 
0.8 P84/G (no P) 7.2 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 92.8 ± 1.0 
0.2 P84/G (no P) 5.1 ± 1.8 0.0 ± 0.0 0.0 ± 0.0 94.9 ± 1.8 
0.8 P84/P (no G) 3.9 ± 1.4 0.0 ± 0.0 0.0 ± 0.0 96.1 ± 1.4 
0.2 P84/P (no G) 3.3 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 96.7 ± 0.8 
0.2 L121/G/P 4.4 ± 0.7 0.0 ± 0.0 1.3 ± 0.4 94.3 ± 0.3 
0.4 L121/G/P 4.7 ± 0.5 0.0 ± 0.0 1.0 ± 0.1 94.3 ± 0.4 
0.6 L121/G/P 4.9 ± 0.3 0.1 ± 0.1 3.4 ± 1.4 91.6 ± 1.8 
0.8 L121/G/P 4.5 ± 0.3 0.1 ± 0.2 5.2 ± 2.7 90.1 ± 3.0 
L121 only (no G/P) 3.2 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 96.7 ± 0.5 
0.8 L121/G (no P) 5.2 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 94.8 ± 0.5 
0.2 L121/G (no P) 6.0 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 94.0 ± 0.4 
0.8 L121/P (no G) 3.2 ± 1.3 0.0 ± 0.0 0.1 ± 0.1 96.8 ± 1.2 






Table C-3 (cont’d) eGFP expression and propidium iodide staining results from quadrant gating of 
10,000 events analyzed through flow cytometry events. Average percent of the total events from each 
quadrant ± standard deviation are shown. Average median GFP fluorescence intensity of the live 
transfected cells (+ GFP, − PI) population ± standard deviation is also reported where applicable. 
Treatment − GFP, + PI 
(%) 
+ GFP, + PI 
(%) 
+ GFP, − PI 
(%) 
− GFP, − PI 
(%) 
0.2 F127/G/P 3.1 ± 0.9 0.0 ± 0.0 0.2 ± 0.1 96.7 ± 1.0 
0.4 F127/G/P 3.3 ± 1.0 0.0 ± 0.0 0.1 ± 0.1 96.6 ± 1.0 
0.6 F127/G/P 3.1 ± 0.8 0.0 ± 0.0 0.1 ± 0.0 96.9 ± 0.8 
0.8 F127/G/P 3.5 ± 1.0 0.0 ± 0.0 0.1 ± 0.1 96.4 ± 1.1 
F127 only (no G/P) 2.9 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 97.1 ± 0.3 
0.8 F127/G (no P) 3.5 ± 0.7 0.0 ± 0.0 0.0 ± 0.0 96.5 ± 0.7 
0.2 F127/G (no P) 3.5 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 96.5 ± 0.5 
0.8 F127/P (no G) 3.2 ± 0.6 0.0 ± 0.0 0.0 ± 0.0 96.8 ± 0.6 
0.2 F127/P (no G) 2.7 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 97.3 ± 0.9 
0.2 P103/G/P 5.2 ± 2.1 0.0 ± 0.0 0.8 ± 0.6 94.0 ± 2.7 
0.4 P103/G/P 6.2 ± 3.5 0.0 ± 0.0 0.2 ± 0.1 93.5 ± 3.6 
0.6 P103/G/P 3.6 ± 1.1 0.0 ± 0.0 0.2 ± 0.0 96.2 ± 1.1 
0.8 P103/G/P 5.9 ± 1.7 0.0 ± 0.0 0.1 ± 0.0 94.1 ± 1.7 
P103 only (no G/P) 3.2 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 96.8 ± 0.3 
0.8 P103/G (no P) 7.5 ± 4.0 0.0 ± 0.0 0.0 ± 0.0 92.5 ± 4.0 
0.2 P103/G (no P) 6.4 ± 3.3 0.0 ± 0.0 0.0 ± 0.0 93.6 ± 3.3 
0.8 P103/P (no G) 9.1 ± 6.8 0.0 ± 0.0 0.0 ± 0.0 90.9 ± 6.8 
0.2 P103/P (no G) 5.2 ± 2.9 0.0 ± 0.0 0.0 ± 0.0 94.7 ± 2.9 
0.2 L44/G/P 3.7 ± 0.9 0.2 ± 0.1 9.1 ± 1.0 87.0 ± 1.2 
0.4 L44/G/P 5.7 ± 3.5 0.3 ± 0.1 10.5 ± 1.7 85.2 ± 1.6 
0.6 L44/G/P 3.5 ± 0.8 0.2 ± 0.0 10.8 ± 2.3 85.5 ± 1.6 
0.8 L44/G/P 3.8 ± 0.9 0.3 ± 0.1 12.4 ± 0.5 83.5 ± 1.5 
L44 only (no G/P) 3.2 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 96.8 ± 0.8 
0.8 L44/G (no P) 4.8 ± 1.3 0.0 ± 0.0 0.0 ± 0.0 95.2 ± 1.4 
0.2 L44/G (no P) 3.8 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 96.2 ± 0.8 
0.8 L44/P (no G) 3.1 ± 1.1 0.0 ± 0.0 0.0 ± 0.0 96.9 ± 1.1 
0.2 L44/P (no G) 3.3 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 96.7 ± 0.8 
No Treatment 3.0 ± 0.9 0.0 ± 0.0 0.0 ± 0.0 97.0 ± 0.9 
23 µM 16-3-16 52.1 ± 13.1 0.0 ± 0.0 0.0 ± 0.0 47.9 ± 13.1 
pDNA only 3.0 ± 1.2 0.0 ± 0.0 0.0 ± 0.0 96.9 ± 1.2 
16-3-16 only 4.8 ± 2.2 0.0 ± 0.0 0.0 ± 0.0 95.2 ± 2.2 
16-3-16/pDNA 10:1 4.2 ± 1.5 0.3 ± 0.2 8.8 ± 1.7 86.7 ± 2.2 
Lipofectamine+pDNA 4.3 ± 1.8 0.7 ± 0.5 20.3 ± 4.6 74.7 ± 4.4 
Lipofectamine only 
(no pDNA) 









Table C-4  Comparison of cell viability following treatment with F87 transfection nanoparticles 
determined by two different methods (resuzarin reduction, and propidium iodide staining).    
Treatment 
Cell Viability by Method 
CellTiter Blue (n=3) 
(%, normalized to 
untreated control) 
Propidium Iodide  
(% of total events) 
0.8 F87 96.9 ± 3.0 95.4 ± 1.7 (n = 3) 
0.6 F87 96.0 ± 5.6 96.3 ± 0.9 (n = 3) 
0.4 F87 96.1 ± 7.2 95.9 ± 0.8 (n = 3) 
0.2 F87 94.6 ± 9.0 96.0 ± 1.2 (n = 3) 
1 (F87 only) 96.2 ± 3.2 97.2 ± 0.7 (n = 3) 
0.8 F87 (no 16-3-16) 94.3 ± 3.0 97.3 ± 0.7 (n = 3) 
0.2 F87 (no 16-3-16) 95.2 ± 5.9 97.4 ± 0.5 (n = 3) 
0.8 F87 (no pDNA) 93.8 ± 2.5 96.6 ± 1.4 (n = 3) 
0.2 F87 (no pDNA) 86.8 ± 5.4 97.0 ± 1.7 (n = 3) 
16-3-16 only 97.4 ± 5.7 95.2 ± 2.2 (n = 9) 
16-3-16/pDNA 10:1 (no F87) 93.9 ± 11.2 95.5 ± 1.5 (n = 12) 
Lipofectamine + pDNA 98.0 ± 6.1 95.0 ± 2.2 (n = 12) 
Lipofectamine only 99.2 ± 2.6 - 
Gemini  (conc. = 23µM) 55.8 ± 5.8 47.9 ± 13.1 (n = 12) 
DMSO 1.3 ± 1.7 - 






Results of Dunnett’s test for comparing transfection efficiency of  
Pluronic/16-3-16/pDNA treatments to the 16-3-16/pDNA complex (0GP)  
as a control 
 
 
Dunnett's test for comparing several treatments with a control :   
    95% family-wise confidence level 
 
$`0GP` 
                  diff      lwr.ci     upr.ci    pval     
0.2F127-0GP -8.6233333 -12.9972871 -4.2493795 6.6e-07 *** 
0.2F87-0GP  -1.1600000  -5.5339538  3.2139538  1.0000     
0.2L121-0GP -7.5233333 -11.8972871 -3.1493795 1.7e-05 *** 
0.2L44-0GP   0.2866667  -4.0872871  4.6606205  1.0000     
0.2P103-0GP -7.9866667 -12.3606205 -3.6127129 4.3e-06 *** 
0.2P84-0GP   0.1033333  -4.2706205  4.4772871  1.0000     
0.4F127-0GP -8.6833333 -13.0572871 -4.3093795 5.0e-07 *** 
0.4F87-0GP  -0.7400000  -5.1139538  3.6339538  1.0000     
0.4L121-0GP -7.7666667 -12.1406205 -3.3927129 8.0e-06 *** 
0.4L44-0GP   1.7700000  -2.6039538  6.1439538  0.9876     
0.4P103-0GP -8.5300000 -12.9039538 -4.1560462 8.4e-07 *** 
0.4P84-0GP  -1.6133333  -5.9872871  2.7606205  0.9959     
0.6F127-0GP -8.7140000 -13.0879538 -4.3400462 4.4e-07 *** 
0.6F87-0GP  -2.4333333  -6.8072871  1.9406205  0.8060     
0.6L121-0GP -5.3400000  -9.7139538 -0.9660462  0.0057 **  
0.6L44-0GP   1.9900000  -2.3839538  6.3639538  0.9587     
0.6P103-0GP -8.6133333 -12.9872871 -4.2393795 6.2e-07 *** 
0.6P84-0GP  -4.8666667  -9.2406205 -0.4927129  0.0173 *   
0.8F127-0GP -8.7036667 -13.0776205 -4.3297129 4.9e-07 *** 
0.8F87-0GP  -3.2300000  -7.6039538  1.1439538  0.3631     
0.8L121-0GP -3.5400000  -7.9139538  0.8339538  0.2297     
0.8L44-0GP   3.5900000  -0.7839538  7.9639538  0.2119     
0.8P103-0GP -8.7080000 -13.0819538 -4.3340462 5.6e-07 *** 
0.8P84-0GP  -7.3466667 -11.7206205 -2.9727129 2.7e-05 *** 
LP-0GP      11.5566667   8.7903354 14.3229979 < 2e-16 *** 
 
--- 






Results of Dunnett’s test for comparing transfection efficiency of  
Pluronic/16-3-16/pDNA treatments to that of Lipofectamine/pDNA (LP) 
 
 
Dunnett's test for comparing several treatments with a control :   
    95% family-wise confidence level 
 
$LP 
                 diff    lwr.ci     upr.ci    pval     
0.2F127-LP -20.180000 -24.55395 -15.806046 < 2e-16 *** 
0.2F87-LP  -12.716667 -17.09062  -8.342713 9.3e-13 *** 
0.2L121-LP -19.080000 -23.45395 -14.706046 < 2e-16 *** 
0.2L44-LP  -11.270000 -15.64395  -6.896046 9.8e-11 *** 
0.2P103-LP -19.543333 -23.91729 -15.169380 < 2e-16 *** 
0.2P84-LP  -11.453333 -15.82729  -7.079380 4.6e-11 *** 
0.4F127-LP -20.240000 -24.61395 -15.866046 < 2e-16 *** 
0.4F87-LP  -12.296667 -16.67062  -7.922713 6.1e-12 *** 
0.4L121-LP -19.323333 -23.69729 -14.949380 < 2e-16 *** 
0.4L44-LP   -9.786667 -14.16062  -5.412713 1.4e-08 *** 
0.4P103-LP -20.086667 -24.46062 -15.712713 < 2e-16 *** 
0.4P84-LP  -13.170000 -17.54395  -8.796046 2.1e-13 *** 
0.6F127-LP -20.270667 -24.64462 -15.896713 < 2e-16 *** 
0.6F87-LP  -13.990000 -18.36395  -9.616046 2.9e-14 *** 
0.6L121-LP -16.896667 -21.27062 -12.522713 < 2e-16 *** 
0.6L44-LP   -9.566667 -13.94062  -5.192713 4.5e-08 *** 
0.6P103-LP -20.170000 -24.54395 -15.796046 < 2e-16 *** 
0.6P84-LP  -16.423333 -20.79729 -12.049380 < 2e-16 *** 
0.8F127-LP -20.260333 -24.63429 -15.886380 < 2e-16 *** 
0.8F87-LP  -14.786667 -19.16062 -10.412713 2.1e-15 *** 
0.8L121-LP -15.096667 -19.47062 -10.722713 3.3e-16 *** 
0.8L44-LP   -7.966667 -12.34062  -3.592713 5.0e-06 *** 
0.8P103-LP -20.264667 -24.63862 -15.890713 < 2e-16 *** 
0.8P84-LP  -18.903333 -23.27729 -14.529380 < 2e-16 *** 
0GP-LP     -11.556667 -14.32300  -8.790335 < 2e-16 *** 
 
--- 










Results of Dunnett’s test for comparing cell viability of Pluronic/16-3-16/pDNA 
treatments to the no treatment (NT) control 
 
  Dunnett's test for comparing several treatments with a control :   
    95% family-wise confidence level 
 
$NT 
                   diff     lwr.ci     upr.ci   pval     
0.2F127-NT  -0.13082500  -9.302782   9.041132 1.0000     
0.2F87-NT   -1.03415833 -10.206115   8.137798 1.0000     
0.2L121-NT  -1.46415833 -10.636115   7.707798 1.0000     
0.2L44-NT   -0.95415833 -10.126115   8.217798 1.0000     
0.2P103-NT  -2.22749167 -11.399448   6.944465 1.0000     
0.2P84-NT   -0.50415833  -9.676115   8.667798 1.0000     
0.4F127-NT  -0.35749167  -9.529448   8.814465 1.0000     
0.4F87-NT   -1.14749167 -10.319448   8.024465 1.0000     
0.4L121-NT  -1.70749167 -10.879448   7.464465 1.0000     
0.4L44-NT   -1.27082500 -10.442782   7.901132 1.0000     
0.4P103-NT  -3.27082500 -12.442782   5.901132 0.9987     
0.4P84-NT   -0.92082500 -10.092782   8.251132 1.0000     
0.6F127-NT  -0.08815833  -9.260115   9.083798 1.0000     
0.6F87-NT   -0.74082500  -9.912782   8.431132 1.0000     
0.6L121-NT  -2.01415833 -11.186115   7.157798 1.0000     
0.6L44-NT   -0.75082500  -9.922782   8.421132 1.0000     
0.6P103-NT  -0.65415833  -9.826115   8.517798 1.0000     
0.6P84-NT   -1.00749167 -10.179448   8.164465 1.0000     
0.8F127-NT  -0.51115833  -9.683115   8.660798 1.0000     
0.8F87-NT   -1.57082500 -10.742782   7.601132 1.0000     
0.8L121-NT  -1.68082500 -10.852782   7.491132 1.0000     
0.8L44-NT   -1.15082500 -10.322782   8.021132 1.0000     
0.8P103-NT  -2.88215833 -12.054115   6.289798 0.9998     
0.8P84-NT   -1.72082500 -10.892782   7.451132 1.0000     
0GP-NT      -1.51582500  -7.316680   4.285030 1.0000     
D-NT       -49.15990833 -54.960763 -43.359054 <2e-16 *** 
Gonly-NT    -1.78305389  -8.048693   4.482585 1.0000     
LP-NT       -2.00915833  -7.810013   3.791696 0.9992     
Ponly-NT    -0.06749167  -7.630881   7.495897 1.0000     
 
--- 





Transfection Nanoparticle Composition 
Table C-5  Pluronic mole fraction in mixed micelles (X1) at concentrations used in in vitro 
transfection experiments (c > CMC of the mixture). X1
stock is calculated for c = 0.5 mM, the total 
surfactant concentration within the transfection mixtures, and X1
well is calculated for the total 
surfactant concentration (indicated below for each condition) following dilution with 2 mL of cell 






















0.2 0.642 0.200 9.47 0.211 
0.4 0.028 0.400 12.6 0.401 
0.6 -0.421 0.600 18.9 0.595 
0.8 -0.724 0.800 37.9 0.797 
P84 
0.2 0.273 0.200 9.47 0.205 
0.4 -0.026 0.400 12.6 0.399 
0.6 -0.134 0.600 18.9 0.598 
0.8 -0.309 0.800 37.9 0.799 
L121 
0.2 23.5 0.208 9.47 0.711 
0.4 1.34 0.401 12.6 0.426 
0.6 1.34 0.601 18.9 0.617 
0.8 -0.033 0.800 37.9 0.800 
F127 
0.2 2.44 0.201 9.47 0.248 
0.4 1.19 0.401 12.6 0.423 
0.6 0.09 0.600 18.9 0.601 
0.8 -0.45 0.800 37.9 0.798 
P103 
0.2 2.70 0.201 9.47 0.254 
0.4 1.13 0.401 12.6 0.422 
0.6 2.71 0.601 18.9 0.633 
0.8 0.114 0.800 37.9 0.800 
L44 
0.2 0.243 0.200 9.47 0.204 
0.4 -0.001 0.400 12.6 0.400 
0.6 -0.245 0.600 18.9 0.597 










Figure C-5  Example illustration of random assignment of transfection observations to an interaction 
parameter using a bootstrap method. 
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